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ABSTRACT 
The PAX gene family of transcription factors plays a prominent role during 
embryogenesis however can be aberrantly re-activated during tumorigenesis and 
contributes to the malignant phenotype. 
During embryonic kidney development, PAX2 exerts an anti-apoptotic function however 
its expression typically attenuates during the post-natal period. On the other hand, PAX2 
aberrant expression is observed in the majority of Renal Cell Carcinomas (RCC). RCC is 
resistant to chemotherapy; up-regulation of anti-apoptotic genes is recognized to 
contribute to tumor resistance to chemotherapy. We hypothesized that the anti-apoptotic 
effect of the PAX2 gene that is expressed in RCC cells contributes to RCC and their 
resistance to chemotherapy-induced cell death. 
Human embryonic kidney (HEK293) cells transfected with a PAX2 expression vector and 
exposed to cisplatin, were protected from apoptosis compared to control cells. 
Conversely, murine collecting duct cells stably transfected with PAX2 antisense cDNA 
had twofold increases in cisplatin-induced apoptosis. Similarly, PAX2 knockdown using 
PAX2 siRNA in RCC cells CAKI-1 and ACHN enhances cisplatin-induced apoptosis in 
vitro. 
To test the combination of PAX2 expression silencing and cisplatin teatment in vivo we 
developed a model of renal tumors by injecting ACHN cells as a xenograft under the skin 
of nude mice. I showed that a PAX2 shRNA successfully knocks down PAX2 mRNA and 
protein levels in a RCC cell line (ACHN). ACHN cells stably transfected with shRNAs 
targeted against the PAX2 homeodomain, are more susceptible to cisplatin-induced 
caspase-3 activation than the control ACHN cell line. Furthermore, growth of 
subcutaneous ACHN/shPAX2 xenografts in nude mice is significantly more responsive 
to cisplatin therapy than control of ACHN cell tumors. This work proposes PAX2 as a 
potential therapeutic gene target in metastatic renal cell carcinoma and suggests that 
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adjunctive PAX2 knockdown may enhance the efficacy of chemotherapeutic agents such 
as cisplatin. 
Wilms tumor, the most common pediatric renal cancer, is thought to arise from a 
progenitor cell of the metanephric mesenchyme that fails to complete nephrogenesis. In 
addition to its characteristic triphasic histology, WT can exhibit myogenic differentiation. 
Myogenic programming during muscle development is controlled by a PAX3 transciption 
factor determinant for muscle development; unexpectedly PAX3 transcriptional activity 
has been recently identified in the embryonic mouse kidney. These observations led us to 
hypothesize that PAX3 plays a role during kidney development. Furthermore, we predict 
that if PAX3 expression is verified during renal development, PAX3 may also be 
expressed in Wilms tumor with a myogenic component. 
I showed that PAX3 is expressed in the metanephric mesenchyme and stromal 
compartment of the developing mouse kidney. In a panel of 20 Wilms tumors, PAX3 was 
identified in tumor samples with myogenic histopathology. Furthermore, mutations of 
WT1 were consistently associated with PAX3 expression in Wilms tumors and 
modulation of WT1 expression in HEK293 cells was inversely correlated with the level 
of endogenous PAX3 protein. 
This work supports a novel model of normal renal development in which progenitor cells 
of the metanephric blastema express PAX3 when targeted toward the stromal cell fate. 
Suppression of PAX3 is integral to the mesenchyme-to-epithelium transition, which 
defines the nephrogenic cell fate and may be accomplished, in part, by WT1. Conversely, 
failure to suppress PAX3 may account for the myogenic phenotype in a subset of WT1-
negative Wilms tumors. 
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RESUME 
Les programmes genetiques qui controlent le developpement embryonnaire peuvent etres 
reactives durant l'oncogenese ou ils contribuent a 1'acquisition du cancer. 
PAX2 encode un facteur de transcription essentiel au developpement embryonnaire du 
rein qui a pour fonction de controler l'apoptose ou mort cellulaire programme. Apres 
completion de l'organogenese, la repression transcriptionnelle de ce facteur durant la 
periode postnatale permet la differentiation normale de 1'epithelium renal. Cependant, la 
reactivation aberrante de PAX2 est observee dans la majorite des cas de carcinome renal. 
Les cancers du rein sont extremement resistants aux traitements actuels et aucun agent de 
chimiotherapies n'a, a ce jour, prouve son efficacite contre ce type de cancer. Ainsi il est 
imperatif d'identifier les voies moleculaires impliquees dans la resistance a la 
chimiotherapie des cellules de carcinomes renaux de maniere a definir une nouvelle 
strategie therapeutique efficace. Un des mecanisme notoire qui cause la resistance a la 
mort cellulaire des cellules cancereuses est l'expression de genes anti-apoptotiques. 
En s'appuyant sur la fonction anti-apoptotique de PAX2, nous supposons que 
l'expression de PAX2 dans les adenocarcinomes renaux contribue a leur resistance a la 
mort cellulaire programmee induite par la chimiotherapie. 
Nous montrons que l'expression de PAX2 dans des cellules embryogeniques renales 
leurs confere une protection significative contre l'apoptose induite par Fagent de 
chimiotherapie cisplatin. Reciproquement 1'inhibition de l'expression endogene de gene 
PAX2 dans les cellules d'adenocarcinomes renaux CAKI-1 et ACHN, par siRNA, 
entraine l'apoptose et une susceptibilite des cellules tumorales a la mort cellulaire induite 
par le traitement de cisplatin in vitro. 
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Pour tester in vivo le potentiel de PAX2 comme cible therapeutique, nous avons 
developpe un Model de tumeur renal dans des souris athymiques en les injectant avec 
des xenogreffes des cellules de carcinome renal ACHN en sous-cutanes. Afin d'inhiber 
1' expression de PAX2, nous avons genere des lignees cellulaires de carcinome renal 
stable contenant un vecteur d'expression de PAX2 shRNA. En mesurant la croissance des 
tumeurs +/-PAX2 dans des souris athymiques traites avec du cisplatin (en injection intra-
peritoneale) nous avons pu montrer que l'inhibition de PAX2 dans les tumeurs ACHN-
shPAX2 augmente leur susceptibilite a l'effet therapeutique du cisplatin resultant en une 
reduction significative du volume tumoral. Ce travail met en evidence le role de PAX2 
dans la resistance a la chimiotherapie des cellules de carcinomes renaux et identifie le 
potentiel des strategies therapeutiques visant a moduler l'expression de PAX2. 
La tumeur de Wilms est l'une des plus frequentes des tumeurs solides de l'enfant. Une 
differentiation myogenes est presente dans 5 a 10% des cas. PAX3 est un facteur de 
transcription qui joue un role central dans la myogenese. Recemment et de facon 
inattendue la presence de PAX3 a ete suggeree dans le rein embryonnaire. Nous avons 
emis l'hypothese suivante: si l'expression de PAX3 est confirmee dans le rein 
embryonnaire, il est envisageable que PAX3 soit egalement exprime dans les tumeurs de 
Wilms dans lesquels il est peut etre responsable de la differentiation musculaire parfois 
observee. 
J'ai montre que PAX3 est exprime dans le rein embryonnaire ou il marque la lignee 
stromale. PAX3 est exprime dans les cellules du mesenchyme (MK4) mais pas dans les 
cellules epitheliales (EVICD). 
En sur exprimant PAX3 dans une lignee cellulaire de rein embryonnaire HEK293 j'ai 
montre que la fonction de PAX3 incluse la proliferation et la migration cellulaires. 
Nous avons demontre l'expression de PAX3 dans les tumeurs de Wilms qui ont une 
composante myogenique. Nous avons aussi mis en evidence V association entre 
l'expression de PAX3 dans la composante stromale des tumeurs de Wilms et la presence 
d'une mutation dans le gene WT1. Cette observation fut confirmee in vitro dans des 
cellules de reins embryonnaires, dans lesquels l'inhibition de WT1 via WTl-siRNA 
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resulte en une augmentation de 1'expression de PAX3. Reciproquement la transfection de 
l'isoforme WT(-/+) entraine reduction de l'expression de PAX3. 
L'ensemble de ces observations soutient l'hypothese que WT1 inhibe l'expression de 
PAX3 dans les cellules renales durant le developpement renal normal mais qu'en 
presence d'une mutation dans le gene WT1 acquise lors de la formation d'une tumeur de 
Wilms, PAX3 est exprime de facon anormale. De plus, nous proposons et que 
l'expression de PAX3 est typiquement responsable du potentiel de differentiation 
musculaire des tumeurs de Wilms qui ont une mutation dans WT1 et une histologic 
stromale. 
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CHAPTER I: INTRODUCTION 
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INTRODUCTION 
Foreword: 
Of the many challenges of medicine, rarely a malady has experienced more hard-fought 
progress than the treatment and cure of cancer. According to the World Health 
Organization (WHO), the projections of cancer deaths is rising with an estimated 9 
million people dying from cancer in 2015, and 11.4 million dying in 2030 
(http://www.who.int/cancer/en/). This statistic can be translated into more concrete facts: 
in Canada one person out of four will develop a cancer; we all know someone that has 
been taken by this disease. It has regrettably become a cliche to highlight the need for 
cancer research and the imperative necessity of finding better treatment. 
Kidney cancer is the 7th leading malignant condition among men and the 12th among 
women worldwide, accounting for almost 3% of all cancers worldwide with 200,000 new 
cases and 78,000 deaths annually (Curado. M. P., 2007). In adults, 80 to 85 percent of 
kidney tumors are classified as renal-cell carcinoma, arising from the renal parenchyma 
in adults and 10% are transitional-cell carcinomas from the renal pelvis. Children may 
develop Wilms tumors (nephroblastoma) of the kidney during the first years of life. 
1.1 Renal Cell Carcinoma (RCC) 
Renal-cell carcinoma arises from the renal epithelium and is the most common renal 
malignancy. At the time of diagnosis, a quarter of the patients present with advanced 
metastatic disease. Due to resistance to current therapy, the median 5 year survival rate 
for patients with metastatic RCC is only between five and ten per cent. Understanding 
the kidney cancer molecular pathways underlying RCC resistance to therapy is 
imperative to identify targets for novel drug therapy. 
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1.1.1 Epidemiology 
In Canada in 2006, 4600 patients were diagnosed with renal cancer and 1550 died from 
this disease (Canadian Cancer Statistic 2006, www.cancer.ca). The male to female ratio 
in incidence is 1.6:1 and the median age is in the sixth decade of life. The incidence age 
adjusted for the world population is variable depending on the geographical, location. In 
2002, the incidence rate in Canada was about 11 per 100,000 men and 5.8 per 100,000 
women which is comparable to the incidence rate in the US or Western Europe. Rates are 
generally high in Europe, North America and Scandinavia, intermediate in the Middle 
East and South America and low in Asia and Africa (Fig.1.1) (Scelo & Brennan, 2007). 
During the last two decades, kidney cancer incidence rates have been rising in nearly all 
regions of the world. For example, in Canada the incidence has increased by more than 
50% between 1977 and 1996 (Figl.2) (Perkin et al.). This trend is partly explained by 
improvements in detection and diagnostic but also correlates with an increased 
prevalence of risk factors. In the US, kidney cancer is more frequent in the black 
population (13.3 per 100,000 men and 7.1 per 100,000 women) than in the white 
population (11.1 per 100,000 and 5.6 per 100,000 women). A reason for this difference 
may be explained by the higher frequency of obesity and hypertension among the black 
than in the white population, both recognized as risk factors for RCC (Chow et al, 1999). 
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Figure 1.1 World map of kidney cancer incidence. 
For both male and female, a high incidence of RCC is observed in Europe and North 
America and a low incidence is found in Asia and Africa (Curado. M. P., 2007). (Data 
from Globocan 2002 Cancer Incidence, Mortality and Prevalence Worldwide, IARC 
Cancer Base No. 6, Lyon, IARC Press, 2002) 
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Kidney cancer Age-Standardized incidence rate per 100,000 females 
• < 0.9 • < 1.4 < 2.4 * < 4.0 • < 10.2 
Kidney cancer Age-Standardized incidence rate per 100,000 males 
• < 1.2 • < 2.9 < 3.5 m < 8.1 • < 21.1 
Fig. 1.1 
Figure 1.2 Kidney cancer rate in Canada 1983-1997. 
The kidney cancer rate has steadily increased over time in Canada in both males and 
females for the last two decades (Curado. M. P., 2007). (Graphic built using the data from 
Arkin, D.M., Whelan, S.L., Ferlay, J., and Storm, H. Cancer Incidence in Five 
Continents, Vol. I to VIIIIARC CancerBaseNo. 7, Lyon, 2005). 
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1.1.2 Risk factors 
Overview: 
Cigarette smoking and obesity are the most consistently established causal risk factors 
and estimated to account together for about 60 % of all renal cell cancer cases. 
Hypertension, rather than antihypertensive drugs, appears to influence renal cell cancer 
development. In general, there appears to be a protective effect of fruit and vegetable 
consumption, although no particular component of diet has been clearly implicated. 
There are sporadic reports of occupational exposures such as Polycyclic Aromatic 
Hydrocarbon (PAH) being associated with this cancer but the evidence for association 
with a specific occupation is still inconclusive. 
Cigarette Smoking: 
Several studies have clearly demonstrated that cigarette smoking is a risk factor for 
developing renal cancer. Smokers are at 50% increased risk of developing renal cancer 
compared with non-smokers. This risk has been shown to significantly decrease with 
years of cessation (Hunt et ah, 2005). It is estimated that smoking is responsible for 20-
30% of renal cancer in men and 10-20% in women (McLaughlin et ah, 1995). 
The mechanism by which cigarette smoking increases the risk of kidney cancer is not 
fully understood yet. Cigarette smoke has been shown to cause specific DNA alteration. 
For instance, Korenaga and colleagues found a significant association between smoking 
and allelic imbalance at chromosome 5q22.2-22.3 in RCC (Korenaga et ah, 2005). 
Interestingly, a study conducted in the Netherlands concluded that smoking was not 
associated with VHL specific mutation implying that smoking may cause or promote 
RCC independently of the VHL pathway (van Dijk et ah, 2006). 
Obesity: 
A linear relationship between kidney cancer and increasing weight gain has been 
established in several case-control and cohort studies both in men and women equally. 
A review concludes that the relative risk for RCC is 1.07 per each unit Body Mass Index 
(BMI) increase above the obesity threshold (Bergstrom et ah, 2001). The mechanism by 
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which obesity triggers renal cancer is unclear although hormonal factors such as 
increased levels of estrogen associated with weight gain may be implicated (Calle & 
Kaaks, 2004). In the overall population it is estimated that 25% of all kidney cancer cases 
stem from being overweight and obese. Therefore obesity is designated as major player 
underlying the increase incidence of renal cancer in North America for the last past 20 
years (Calle & Kaaks, 2004) 
Hypertension: 
A history of hypertension has been consistently associated with kidney cancer. 
This association between blood pressure and increased risk cancer seems to occur in a 
dose dependent manner. Since reduction of blood pressure has been shown to reduce 
RCC risk, hypertension appears to have a causal relationship to renal cancer (Scelo & 
Brennan, 2007). About 20-40% of renal cancer can be attributed to hypertension (Scelo 
& Brennan, 2007). 
Diabetes mellitus: 
Diabetes mellitus has been associated with an increased risk of several cancers however 
its relation with RCC risk is controversial. A slight, increased risk was found in patients 
with a history of diabetes mellitus but further studies of this issue are required (Zucchetto 
etal.,2001). 
Use of Analgesics: 
An association between chronic use of phenacetin containing analgesics and cancers of 
the renal pelvis has been clearly established (Scelo & Brennan, 2007). However, the 
effect on development of renal cell carcinoma is less clear. In any event, this is no longer 
a major concern since phenacetin-containing analgesics are currently no longer on the 
market. Extensive studies have been conducted on acetaminophen (the major metabolite 
phenactin) and have concluded that there is no relationship between renal cancer and 
acetaminophen use. Similarly studies have ruled out the use of aspirin as a potential cause 
of increased risk for renal cancer (McCredie et al, 1995). 
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Kidney Transplantation and Dialysis: 
A higher incidence of RCC is observed in patients undergoing long-term renal dialysis. 
RCC seems to arise in those dialysis patients who develop renal cystic disease of the 
native kidneys. Patients with kidney transplants who develop cysts in their native kidneys 
also have increased likelihood of developing RCC. It is estimated that 30-40% of kidney 
transplant patients will develop acquired cystic disease and this confers a 30-fold increase 
in the risk of developing RCC (Stewart et al, 2003). 
Diet: 
A study has concluded that increased intake of both fruits and vegetables possibly reduce 
the risk of kidney cancer (Rashidkhani et al, 2005). However other studies found no 
correlation between fruits and vegetable intake and risk of developing RCC (Weikert et 
al, 2006). Overall, the results of analytical studies indicate that coffee and tea 
consumption does not increase the risk of renal cell cancer (Lee et al, 2006). 
Epidemiologic studies have investigated the association between alcohol consumption 
and the incidence of RCC, with somewhat controversial results. In the past, studies have 
found no relation between alcohol consumption and RCC, however, several recent 
studies have shown a protective effect of ethanol consumption. It was confirmed in a 
pooled analysis of 12 prospective studies that moderate alcohol consumption was 
associated with a lower risk of renal cell cancer among both women and men (Lee et al, 
2007). 
1.1.3 Genetic factors 
Several studies have reported an increased risk of developing renal cancer for individuals 
with a first-degree relative affected by this disease (Chow et al, 2000).Although most 
cases of RCC occur sporadically, an inherited predisposition to renal cancer is estimated 
to account for 1-4% of all cases. Interestingly, these inherited genetic factors can involve 
some of the same genes that cause sporadic renal cancer. Typically, familial renal cancers 
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are characterized by an early onset compared with sporadic cases and frequently 
comprise bilateral and multifocal tumors. So far seven hereditary renal cancer syndromes 
and 5 predisposing genes associated with these have been identified (summarized in table 
1.1). 
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Table 1.1 Inherited syndromes associated with the development of renal neoplasia. 
Von Hippel-Lindau (VHL) disease, associated with clear-cell renal-cell carcinomas and 
multi-organ neoplasia, is caused by germline mutations in the VHL tumor-suppressor 
gene and loss of die wild-type VHL allele; Patients with hereditary papillary renal 
carcinoma (HPRC) harbor germline activating mutations in the MET proto-oncogene, 
which can cause renal cancers with papillary type-1 histology. Papillary type-2 renal 
carcinomas and cutaneous and uterine smooth-muscle tumors are associated with the 
syndrome of hereditary leiomyomatosis and renal-cell cancer (HLRCC), which is caused 
by germline loss-of-function mutations in the Fumarate-Hydratase (FH) gene. The Birt-
Hogg-Dube syndrome (BHD) predisposes to cutaneous nodules (benign tumors of the 
hair follicle), spontaneous pneumothorax and an increased risk for renal cancers such as 
chromophobe renal-cell carcinoma and oncocytic hybrid renal tumor. BHD is caused by 
germline mutations in the tumor-suppressor gene BHD. Hyperparathyroidism-jaw tumor 
syndrome (HPT-JT) is associated with parathyroid adenomas, fibro-osseous tumors of the 
jaw, and unusual renal tumors containing a mixture of epithelial and stromal elements. 
This syndrome is caused by germline mutations in the gene HRPT2 (Pavlovich & 
Schmidt, 2004). 
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Table 1.1 Heritable syndromes associated with renal cancer: 
Syndrome 
Von Hippel-Lindau (VHL) 
Hereditary papillary renal 
cacinoma (HLRCC) 
Hereditary leimyopmatosis renal-
cell cancer (HLRCC) 
Birt-Hogg-Dube (BHD) 
Hyperparathyroidism-jaw tumor 
(HP-JT) 
Constitutional chromosme-3 
translocation 
Gene 
VHL, 3p35 
MET, 7q31 
FH, lq42-43 
BHD, 17pll.2 
HRPTC2, lq25-32 
Unknown gene 
Possibly VHL 
RCC type 
Clear-cell RCC (solid and/or 
cystic, multiple and bilateral) 
Papillary RCC type 1 (solid, 
multiple and bilateral) 
Papillary RCC type 2 
(collecting-duct carcinoma, 
solitary, aggressive) 
Hybrid oncocytic RCC, 
chromophobe RCC, clear-
cell RCC, Oncocytoma 
(multiple, bilateral) 
Mixed epithelial and stromal 
tumor, papillary RCC (cyst) 
Clear-cell RCC (multiple 
bilateral) 
Familial papillary thyroid cancer Unknown gene, Papillary RCC, oncocytoma 
(FPTC) lq21 
1.1.3.1 Familial Clear Cell RCC 
1.1.3.1.1 VHL: Von Hippel-Lindau (VHL) disease 
Von Hippel-Lindau disease (OMIM 19330) is a rare, autosomal dominant, familial 
cancer syndrome consisting chiefly of retinal angiomas, hemangioblastomas of the 
central nervous system (CNS), pheochromocytomas and renal-cell carcinoma of the 
clear-cell type. Kidney cancer develops in 75% of VHL patients by the age of 60 and is 
the leading cause of death in the VHL patient population. Following the classic Knudson 
two hit hypothesis of a hereditary cancer syndrome (Knudson, 1997), one mutated VHL 
allele is inherited and renal cell neoplasia arises when the normal VHL allele is 
inactivated. While Vhl-/- mice are embryonic lethal due to a defect of placental 
vasculogenesis, Vhl+/- mice do not display a significant phenotype. Transgenic mice 
heterozygous for liver targeted deletion of Vhl (generated from the cross between a 
floxed Vhl mouse and a mouse line carrying an albumin-cre driven recombinase), 
develop hemangioblastoma but do not exhibit any of the renal lesions typical of human 
VHL disease (Haase et al., 2001). Nonetheless, it has been recently reported that 
conditional inactivation of VHL in the mouse kidney, using Cre recombinase under the 
control of the phosphoenolpyruvate carboxykinase promoter (active in the renal proximal 
tubule), causes the development of polycythemia and renal cysts (Rankin et al., 2006). 
In humans, the VHL tumor suppressor gene maps to the chromosome 3p24-25 and 
encodes for pVHL protein (or VHL). Demonstrating VHL tumor suppressor functions, 
the reintroduction of VHL protein into VHL -/- carcinoma cell lines has been shown 
sufficient to suppress their growth as renal tumor xenografts in nude mice (Iliopoulos et 
al, 1995). The tumor suppressor function of VHL relates to its ability to target specific 
proteins for destruction. VHL is the substrate recognition component of an E3 ubiquitin 
ligase complex that includes elongin B, elongin C, Cul2, and Rbxl. This complex is 
capable of directing the covalent attachment of polyubiquitin tails to specific proteins, 
which serve as signals for such proteins to be degraded by the proteasome. Several VHL 
targets have been identified, including the members of the hypoxia-inducible factor HBF-
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alpha family (HIF-1 alpha, HIF-2alpha, and HIF-3alpha). Under normal conditions, HIF-
alpha proteins are hydroxylated by members of the EGLN family of enzymes and 
subsequently recognized by pVHL that orchestrates their destruction. When oxygen is 
low or in cells that lack pVHL, HIF-alpha is not tagged for destruction and is free to 
heterodimerize with its constitutively expressed partner HIF-beta. Together, they activate 
the transcription of a panel of genes involved in adaptation to hypoxia. These genes 
include the vascular endothelial growth factor (VEGF) that regulates angiogenesis and 
the transforming growth factor alpha (TGF-alpha that controls cell proliferation) (Kaelin, 
2002). 
Downstream of VHL, HIF-2alpha plays an instrumental role with respect to VHL-/- renal 
carcinogenesis. This is first illustrated by the fact that the elimination of HIF-2alpha, like 
the restoration of pVHL function, is sufficient to suppress VHL-/- tumor growth in vivo 
(Kaelin, 2007; Kondo et al, 2002). In addition, the over-expression of HIF-2alpha in 
VHL-/- renal cancer cells is able to override the reintroduction of pVhl (Kondo et al., 
2003). HIF-1 is also a target of VHL but is not as potent as HIF-2alpha in driving 
tumorigenesis; inhibition of HIF-1 alpha alone in VHL-/- tumor does not suppress 
tumorigeneicity in nude mice. 
VHL disease is clinically divided into two types based on the presence (type 2) or the 
absence (type 1) of pheochromocytoma. Type 2 disease is further subdivided into three 
subtypes: type 2A (low risk of RCC), type 2B (high risk of RCC), and type 2C 
(pheochromocytoma only). VHL disease shows clear genotype-phenotype correlations. 
Type 1 disease is associated with large deletions or protein-truncating mutations that 
directly compromise pVHL's functions, including its ability to regulate HIF-alpha. In 
contrast, type 2 disease is almost always linked to VHL missense mutations. Interestingly, 
both type 2A and type 2B VHL mutations measurably compromise pVHL's ability to 
regulate HIF. Therefore, it is still not fully understood why type 2A and type 2B VHL 
mutations are associated with markedly different risks of developing renal carcinoma. In 
this regard, a number of HIF-independent functions have been ascribed to pVHL, some 
of which might conceivably be linked to renal tumorigenesis. On the other hand, a recent 
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report suggested that type 2A mutants bind to HIF-alpha with higher affinity than do type 
2B mutants. This suggests that quantitative differences between type 2A and type 2B 
mutants, with respect to HIF binding, translate into different risks of renal carcinoma in 
humans (Knauth et al, 2006). Li et al. showed that type 2A mutant is less compromised 
quantitatively with respect to the regulation of HIF2-alpha and HIF target genes, 
compared to type 2B mutants. In addition, the increased levels of HIF2-alpha and its 
downstream targets in cells producing type 2B mutants, correlated with increased tumor 
formation in nude mice. This demonstrates that HIF2-alpha is a critical component in 
VHL-/- renal carcinogenesis (Li et al, 2007). It is important to note that a specific 
germline VHL mutation affecting both alleles, was found to cause a recessive form of 
polycythemia affecting a population living in the Chuvas region of Russia (Ang et al, 
2002) .The occurrence of this cancer-free VHL-/- population clearly suggests that VHL 
mutations alone are not always sufficient to cause renal cancer. 
Functions of VHL that are not related to HIF have also been identified. For instance, 
VHL is clearly involved in assembly of the extracellular fibronectin matrix and has been 
implicated as a regulator of epithelial-cell differentiation and cell-cycle exit, perhaps 
through its ability to downregulate cyclin kinase inhibitors p27 and p21(Mack et al, 
2005). Moreover, VHL is also responsible for suppressing the expression of the 
chemokine receptor CXCR4, which is implicated in the RCC cells capacity to 
metastasize (Staller et al, 2003). Similarly VHL loss of function leads to up-regulation of 
metalloproteases known to play an important role in cancer cell metastasis (Petrella & 
Brinckerhoff, 2006). Furthermore, VHL has been shown to stabilize another tumour 
suppressor, jade-1 that is known to suppress renal cancer cell growth, in part by 
increasing apoptosis (Zhou et al, 2004; Zhou et al, 2002). However, how the function of 
jade-1 is related to the development of VHL-defect associated tumors remains yet to be 
clarified. 
To summarize, VHL disease is the primary cause of hereditary clear cell RCC. It has 
also been very useful to decipher the molecular biology of sporadic RCC as VHL 
mutation is estimated to be present in as much as 80% of clear cell RCC. In addition, the 
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molecular players of the VHL pathway have served successfully as a therapeutic target 
for new agents for the treatment of RCC. 
1.1.3.1.2 Other loci associated with familial clear cell RCC 
Distinct from patients with VHL disease, multifocal bilateral clear-cell RCC has been 
reported in patients with translocation of chromosome 3 at a fragile site (3pl4). Loss of 
the translocated chromosome 3p by non-disjunction probably implicates a VHL gene. The 
remaining allele is typically mutated or silenced by hypermethylation (Chen et al, 2003). 
Few families have been reported worldwide with a hereditary solitary tumor without VHL 
mutation or linkage with chromosome 3p. No other clinical manifestations have been 
detected in these patients; this Familial Clear Cell Renal cancer is associated with 
unknown loci (Teh et al, 1997). 
Three cases of early onset renal call carcinoma have been reported in SDHB-associated 
heritable paraganglioma (OMEVI 18479 & 60573). Hereditary multiple paraganglioma is 
associated with mutation in the mitochondrial enzyme succinate dehydrogenase B located 
at lp36 locus (Vanharanta et al, 2004). Finally, patients affected with tuberous sclerosis 
(OMEVI 191100) have multiple renal angiolipomas and cysts. RCC is also observed in 1-
2% of these cases (Lendvay & Marshall, 2003). 
1.1.3.2 Familial Papillary RCC 
1.1.3.2.1 MET: Hereditary Papillary Renal Cell Carcinoma (HPRCC) 
Hereditary Papillary Renal Cell Carcinoma (OMEVI 605074) is a hereditary cancer 
syndrome, inherited in an autosomal dominant fashion, in which affected individuals are 
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at risk of the development of bilateral, multifocal and type 1 (low grade and favorable 
prognosis) papillary renal carcinoma (Schmidt et al, 1997). Approximately 20 % of 
HPRCC patients develop multiple, bilateral papillary tumors at a later age, than patients 
with VHL disease. M£Tmaps to chromosome7q31, and encodes for Receptor Tyrosinase 
Kinase. Binding of the MET receptor by its ligand, hepatocyte growth factor (HGF) 
induces receptor dimerization and transphosphorylation of the tyrosine kinase domain 
leading to conformational changes and phosphorylation of the docking domain. 
Phosphorylation of the docking domain at Y1349 and Y1356 allows for the recruitment 
and activation of a downstream intracellular pathway resulting in promotion of cell 
proliferation, inhibition of apoptosis and increased motility. Most of the mutation occurs 
in the activation loop of the ATP binding site leading to constitutive MET receptor 
activation. Duplication of chromosome 7 carrying the mutation is generally the second 
event leading to tumorigenesis. MET activating mutation also occurs in 15% of the cases 
of sporadic papillary RCC (Pavlovich & Schmidt, 2004). 
1.1.3.2.2 FH: Hereditary Leimyomatosis Renal Cell Cancer (HLRCC) 
First described by Reed et al in 1973, patients affected with HLRCC (OMIM 605839) 
are prone to develop multiple cutaneous and uterine leimyomas and solitary papillary 
type II RCC (high grade, very aggressive and with a bad prognosis) (Reed et al, 1973). 
Germline mutation in the gene located at locus lq42-43 coding for the Krebs cycle 
enzyme Fumarate Hydratase (FH) predisposes to this dominantly inherited syndrome 
(Tomlinson et al, 2002). It is believed that the FH gene acts as a tumor suppressor gene 
but the exact mechanism leading to tumor development remains to be clarified. One 
proposed mechanism is that impaired mitochondrial function leads to severe energy 
deficits and the formation of oxygen free radicals. This is sensed by the mitochondria as 
hypoxia and leads to stabilization of HIF-la with consequences similar to the one of 
VHL inactivation (Pavlovich & Schmidt, 2004). Depending on the studies, it can be 
estimated that the risk of developing renal cancer in FH carriers ranges anywhere 
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between 1 and 5%. This tumor has a very aggressive course and a total nephrectomy is 
indicated at an early stage. This is unlike the case of VHL patients where nephron-
sparing surgery is the desired treatment (Refae et ah, 2007). 
1.1.3.3 Familial Chromophobe RCC and Oncocytoma 
BHD: Birt-Hogg-Dube syndrome (OMIM 135150): 
BHD syndrome is a genodermatosis that predisposes to benign cutaneous lesions of the 
face and neck, spontaneous pneumothorax and/or lung cysts. In addition, 15-30% of the 
patient carriers of a germlime mutation in the BHD gene (17pll.2) develop RCC with 
diverse histology including chromophobe and mixed chromophobe-oncocytic types at 
various ages. The BHD tumor suppressor gene encodes the protein folliculin (Pavlovich 
& Schmidt, 2004). A recent study suggests Folliculin may be involved in the AMPK and 
mTOR signaling pathways, but further clarification with respect to Folliculin function as 
a tumor suppressor is definitely needed (Baba et ah, 2006). 
1.1.3.4 Diagnosis and management of hereditary renal cancer 
Effective clinical management of hereditary renal cancer syndrome relies on early 
diagnosis. Therefore, early onset, bilateral tumors, familial or personal history of cancer 
should immediately warrant suspicion and clinical investigation for hereditary renal 
cancer. Genetic testing is available for the known causative genes (VHL, MET, FH and 
BHD) and should be performed according to the histological subtype. In clear cell RCC 
cases, the first step is VHL genomic analysis and if normal, a karyotype assessing 
chromosome 3 translocation should be performed. Patients with papillary type I should 
be screened for MET mutation and patients affected with type papillary RCC should be 
checked for FH mutation. In patients presenting with chromophobe and/or oncotyoma, 
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analysis of the BHD gene is wanted. For patients with inherited RCC (multiple, bilateral 
and recurrent tumors), nephrons sparing surgery is the standard treatment. Promising 
results have been obtained with radiofrequency ablation and cryotherapy and therefore 
might be considered for treating small renal tumors (Richard et al, 2004). 
1.1.4 Histopathology 
RCC malignancies are heterogeneous and exhibit several distinct histologies (Figure 
1.3). According to the current WHO classification, there are 4 major histological 
subtypes of renal cell carcinoma: clear cell (>75% of cases), papillary type (15%, 
subdivided into type 1 and type 2), chromophobe tumors (4%) and collecting duct tumors 
(1%). Oncocytoma (4%) is another form of benign renal neoplasm that follows a more 
indolent course. 
Clear cell RCC (75%): 
The classification "Clear Cell" refers to the clear appearance of the cytoplasm under light 
microscopy examination after hematoxylin/eosin (H & E) staining. This is the result of an 
intensive intracytoplasmic accumulation of glycogen, phospholipids and neutral lipids. 
Macroscopically, a clear cell carcinoma typically presents as a multinodular mass with 
yellow-colored surface speckled by gray or white foci (Storkel & van den Berg, 1995). 
Papillary RCC (15%): 
Papillary renal cell carcinomas have a chromophilic appearance on H&E staining under 
the light microscope. The tumor epithelium is either cuboidal (type A papillary RCC) or 
columnar (type B papillary RCC). This is of interest as studies have suggested that type B 
is more advanced at presentation and has a worse prognosis than type A. Generally 
speaking, papillary RCC are of a low nuclear grade although the type B may exhibit 
pleomorphism and significant mitotic activity. Positive staining for cytokeratin 7 is the 
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most useful immunohistochemical marker of papillary renal cell carcinoma, as it is not 
seen in any other renal carcinomas (Fleming & O'Donnell, 2000). 
Chromophobe RCC (5%): 
Macroscopically, the tumour has a uniform soft grey appearance. Under light 
microscopy, chromophobe RCC is weakly stained with eosin (as suggested by the name) 
and the cytoplasm is seen to be composed of pale membrane-bound vesicles with 
perinuclear halo formation. Chromophobe RCCs show an irregular reactivity for 
cytokeratin but are usually vimentin negative. Cytogenetic analysis typically shows 
multiple monosomies but no chromosome 3 loss or trisomies of chromosome 7 and 17. 
Also, mutation in p53 is more common than in other renal tumors and is seen in about 
30% of the cases (Fleming & O'Donnell, 2000). 
Oncocytoma (5%): 
This is a benign renal neoplasm. Oncocytoma usually presents as a well-circumscribed 
and tan colored mass with a central stellate scar. Upon microscopic examination, 
oncocytomas are seen to be composed of cuboidal cells with intensely eosinophilic 
granular cytoplasm. Oncocytomas may occasionally be multifocal and is then referred as 
'oncocytomatosis'. 
Collecting duct RCC (<1)%: 
Collecting duct Carcinomas are usually large tumors located in the medulla of the kidney 
with extension into the perinephric fat and the renal pelvis. The white colored surface is 
interspersed with necroses and presents an irregular border with peri-tumoral cortical 
satellite nodules as a result of severe angio-invasiveness. Regional spread with infiltration 
of the adrenals and lymph-node metastases are common (Storkel & van den Berg, 1995). 
The tumors may have tubular papillary architecture but the most characteristic feature is 
of an infiltrating ductal pattern exciting a desmoplastic stromal response. The infiltrating 
ducts are lined by a single layer of epithelium, often showing extreme pleomorphism with 
mitotic activity and nuclei with prominent nucleoli. In some instances the infiltrating 
33 
ducts form microcysts and this is frequently seen in metastatic collecting duct carcinoma. 
Collecting duct carcinoma appears to occur in a younger age group than most other renal 
carcinomas. In establishing the diagnosis, immunohistochemistry for cytokeratins and for 
lectins may be helpful; collecting duct carcinomas are vimentin negative (Storkel & van 
den Berg, 1995). 
Unclassified RCC: 
It is estimated that 3-5% of renal carcinoma are difficult to classify within this scheme. 
These may be tumors with an unusual mixture of components, tumors with an 
unrecognizable architecture or cytological pattern or sarcomatoid renal carcinomas in 
which the original epithelial element cannot be identified (Storkel & van den Berg, 
1995). 
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Figure 1.3 RCC Histological appearances. 
75% of RCC have clear cell histology; 5% have papillary Type I histology; 10% papillary 
type II; 5% Chromophobe; 5% Oncocytoma and less than 1% are of Collecting Duct type 
histology (Zucchi et al., 2003). 
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1.1.5 Molecular biology of RCC 
1.1.5.1 VHL/HIF pathway 
Between 60% and 80% of sporadic clear cell renal carcinomas are linked to biallelic 
genomic inactivation of the VHL gene. In a number of VHL+/+ clear cell renal 
carcinomas, little or no VHL mRNA is produced as a result of promoter hypermethylation 
(Herman et al, 1994; Kim and Kaelin, 2004). VHL protein, the product of the VHL gene, 
functions as a tumor suppressor, inhibiting growth when reintroduced into cultures of 
renal-cell carcinoma cells. In normal cells, the VHL protein plays a key role in the 
regulation of the hypoxia-inducible factor, which controls the expression of several genes 
in response to hypoxic stress (Latif et al, 1993). Under normoxic conditions (i.e. normal 
oxygen tension), HIF-1 alpha is hydroxylated allowing its ubiquination by the VHL 
protein complex, enabling its proteosomal degradation. Under hypoxic conditions, HIF-
1 alpha is not hydroxylated and cannot be ubiquitinated by the VHL protein complex. 
Similarly, biallelic inactivation of VHL as it occurs in RCC cells, prevents degradation of 
HIF-lalpha (Kamura et al, 2000; Kim and Kaelin, 2004; Latif et al, 1993). 
Once stabilized, HIF-lalpha translocates into the nucleus, where it dimerizes with 
constitutively present HIF-1 beta to form the active transcriptional factor HIF-1 
heterodimer. HIF-1 activates transcription of hypoxia-inducible genes, including 
proangiogenenic factors such as vascular endothelial growth factor (VEGF), cellular 
growth factors such as transforming growth factor alpha (TGFalpha) and its cognate 
receptor, the epidermal growth factor receptor (EGFR). 
When VHL protein function is compromised, these HEF target genes are overexpressed, 
creating a microenvironment favorable for cell transformation. The importance of 
angiogenesis in the biology of renal cancer is well established. RCC must induce the 
formation of novel blood vessels to supply nutrient and oxygen needed for tumor growth 
and malignant progression. VEGF, one of the best-known pro-angigenic factors is 
expressed at high levels in the majority of renal cancer; VEGF overexpression is linked to 
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molecular aberrant activation of the VHL/HIF pathway due to genetic lesions in the VHL 
gene. 
Accumulation of HIF also leads to abnormal production of TGF-alpha. This in 
combination with the overexpression EGF receptor, perhaps via increase of EGFR 
mRNA translation, provides a molecular autocrine mechanism for unregulated growth of 
renal cells (de Paulsen et al, 2001; Franovic et al, 2007; Gunaratnam et al, 2003) 
(Figure 1.5). The importance of the EGFR mitogenic pathway in renal cancer cell is 
confirmed by the fact that inhibition of EGFR expression via RNA interference 
suppresses VHL-/- RCC cells tumorigenicty in nude mice (Smith et al, 2005). However, 
EGFR inhibitors such as Iressa have shown no improvement in overall survival of 
patients with metastatic RCC (Jermann et al. 2006). 
1.1.5.2 MET pathway 
Mutations in the tyrosine kinase domain of the MET gene produced constitutive 
phosphorylation of MET receptor protein. Activating mutation of the MET proto 
oncogene is associated with hereditary papillary RCC. In addition MET is mutated in 
14% of sporadic papillary cancer (Schmidt et al, 1997; Schmidt et al, 1999). More 
recently, it has been shown that in clear cell renal carcinoma, MET can be constitutively 
phosphorylated as a consequence of VHL inactivation, leading to cell growth released 
from contact inhibition and in tumorigenesis (Nakaigawa et al, 2006). HGF and MET 
protein are frequently observed in clear cell RCC and are associated with progression of 
the disease (Miyata et al, 2006). Altogether theses studies validate MET as a major 
pathway implicated in renal cancer biology (Linehan et al, 2004). 
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1.1.5.3 PTEN, Akt and mTOR pathway 
Recent data from a large series of metastatic renal cell carcinoma (RCC) patients have 
identified mTOR pathway activation as an adverse prognostic factor (Lam et al, 2007). 
The mTOR signaling pathway was originally discovered during studies of the 
immunosuppressive agent rapamycin. This highly conserved pathway regulates cell 
proliferation and metabolism in response to environmental factors, linking a cell growth 
factor receptor signaling via phosphoinositide-3-kinase (PI3K) to cell proliferation, and 
angiogenesis. A link of the mTOR pathway to the tumor suppressor PTEN has also been 
established. 
PTEN loss of function through mutation, deletion, or epigenetic silencing results in 
increased activation of Akt and mTOR. This results, downstream, in enhanced activity of 
eukaryotic translation initiation factor 4E binding protein (4EBP1) and the S6K1 kinase. 
The net effect is the stimulation of cellular protein synthesis and entry of cells into the Gl 
phase of the cell cycle. Yet another product of this pathway is an increase in hypoxia 
inducible factor (HIF)l-alpha and HIF2-alpha expression, thus linking the mTOR 
pathway to angiogenesis. Accordingly, akt activation is frequently observed in RCC and 
in combination with a decreased PTEN expression (Hara et al, 2005). 
In addition, activation of mTOR in RCC can be the results of mutations that disrupt the 
tuberous sclerosis complex 1 and 2 genes (TSC1 and TSC2, respectively). Like pVHL, 
the TSC1/TSC2 complex functions to regulate HIF as part of an oxygen sensing pathway 
and its disruption confers a predisposition to renal-cell carcinoma associated with 
increased HIF activity (Kaelin, 2007). 
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Figure 1.4 Molecular pathway in RCC. 
Von Hippel-Lindau (VHL) is mutated in 75% of RCC. VHL normally encodes a protein 
(pVHL) that targets hypoxia-inducible factor (HIF) for proteolysis. As a result of VHL 
inactivation, a defective pVHL is produced and HIF is up-regulated, translocates to the 
nucleus and results in the transcription of several genes involved in angiogenesis and 
tumor growth. These genes include vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), epidermal growth factor (EGF) and the transforming 
growth factor alpha (TGF-a) (Cohen & McGovern, 2005). (Adapted from Cohen et al. 
used with permission of New England Journal of Medicine, 2005 Copyright 
Massacussets Medical Society. All right reserved). 
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1.1.6 Diagnosis staging and prognosis 
RCC is a challenging diagnosis, as it remains clinically silent most of its course. 
The classic presentation of renal-cell carcinoma includes the triad of flank pain, 
hematuria and a palpable abdominal mass (seen in only 10% of cases and is indicative of 
an advanced disease). In fact, 30% of the cases are asymptomatic and are detected 
incidentally as a renal mass on radiographic examination. 
Clinical staging requires radiological assessment to evaluate the extent of the disease. 
Imaging of the chest, abdomen and pelvis should be performed with Computed 
Tomography (CT) or a combination of CT with Magnetic Resonance Imaging (MRI) or 
standard chest radiograph. Staging of RCC is performed worldwide according to the 
tumor-node-metastasis (TNM) classification (Figure 1.5A) (AJCC, 2002; Fuhrman et al, 
1982). To grade tumours, the most widely used system is the Fuhrman scheme (Fuhrman 
et al, 1982) which distinguishes four grades based on nuclear size and shape and the 
prominence of nucleoli of RCC cells when examined under high power (x400 
magnification). 
Several integrated systems have been developed to establish prognosis (Ficarra et al, 
2007). A system that is widely used and has been successfully validated in 400 patients at 
8 international centers is the University of California, Los Angeles (UCLA) Integrating 
Staging System (Figure 1.5C) (Patard et al, 2004a; Zisman et al, 2002). This system 
takes into account TNM staging, the patient's score on the Eastern Cooperative Oncology 
Group (ECOG) performance status (ECOG scale measures functional impairment in 
patients with cancer from 1 to 5: 1 = Fully active, able to carry on all pre-disease 
performance without restriction to 4 = Completely disabled, cannot carry on any selfcare 
and totally confined to bed or chair; 5=dead (Oken et al, 1982), and the Fuhrman nuclear 
grading system which assesses histological grading of the tumor cells. Accordingly, the 
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UISS classifies patients with RCC into 2 categories distinguishing non-metatstatic and 
metastatic. Each of these 2 categories is sub-classified into 3 risk levels: low, medium 
and high. Survival analysis shows a 5 year survival rate of 97% (low), 81% (med) and 
63% (high) for non-metastatic and 39% (low), 17% (med) and 7% (high) for metastatic 
disease (Patard et al, 2004a). (Figure 1.6C) 
Other studies have highlighted the additional prognostic value of a panel of molecular 
markers, which may correlate disease status and response to treatment. The majority of 
clear cell RCC expresses XIAP protein and a significant inverse correlation between 
XIAP levels and tumor aggressiveness. This is indicated by patients' survival, validating 
XIAP as an independent prognostic parameter (Ramp et al, 2004). It is well established 
that deregulation of apoptosis plays an important role in tumor progression and resistance 
to chemotherapy. Therefore it is not suprising that XIAP that is the most potent caspase 
inhibitor of all known IAP (inhibitor of apoptosis) family members is independent 
prognostic marker for RCC. It is important to mention that contrary to previous beliefs, 
Carbonic anhydrase IX has been recently proven not to be an independent predictor of 
outcomes for patients with clear cell renal cell carcinoma (Leibovich et al, 2007). 
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Figure 1.5 Staging and Prognosis of RCC. 
A) Staging of RCC is performed worldwide according to the tumor-node-metastasis 
(TNM) classification (AJCC, 2002). 
B) Visualization of Tumor staging depending on the extend of the disease (adapted from 
Cohen et al. used with permission of New England Journal of Medicine, 2005 Copyright 
Massacussets Medical Society. All right reserved). 
C) The University of California Los Angeles, (UCLA) Integrating Staging System. 
The University of California Los Angeles integrated staging system can predict survival 
in renal cell carcinoma taking into account TNM staging, the patient's score on the 
Eastern Cooperative Oncology Group (ECOG) performance status and the Fuhreman 
nuclear grading (Klatte et al., 2007). 
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2002 TNM Classification of Renal Call Carcinoma 
Primary Tumor (T) 
T1 a Tumor 4 cm or less in greatest dimension, limited to the kidney 
T1 b Tumor more than 4 cm but not more than 7 cm in greatest dimension, 
limited to the kidney 
T2 Tumor more than 7 cm in greatest dimension, limited to the kidney 
T3a Tumor directly invades adrenal gland or perirenal and/or renal sinus fat but 
not beyond Gerota's fascia 
T3b Tumor grossly extends into the renal vein or its segmental (muscle-contaming) 
branches, or the vena cava below the diaphragm 
T3c Tumor grossly extends into the vena cava above the diaphragm or invades the 
wall of the vena cava 
T4 Tumor invades beyond Gerota's fascia 
Regional Lymph Nodes (N) 
NO No regional lymph node metastasis 
N1 Metastasis in a single regional lymph node 
N2 Metastasis in more than 1 regional lymph node 
Distant Metastasis (M) 
MO No distant metastasis 
M1 Distant metastasis 
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1.1.7 Treatment 
Overview: 
Surgery is the treatment of choice for initial presentation of RCC. There is no proven role 
for radiation and there is no standard chemotherapy. Immunotherapy is appropriate for 
selected patients with metastatic disease and research protocol including novel targeted 
therapy, are appropriate for many patients. 
1.1.7.1 Surgical care 
Radical Nephrectomy, which includes removal of the kidney with Gerota's fascia, the 
ipsilateral adrenal gland and regional lymph nodes, has been the standard of care for 
many years. But adrenal involvement can be identified preoperatively by CT scan and 
therefore be reserved for patients with large upper-pole lesions or abnormal appearance 
of the adrenal gland. Resection of the lymph node is limited to prognosis information 
since virtually all patients positive for distance metastasis will relapse later, regardless of 
lymphoadenectomy (Phillips & Messing, 1993). 
Nephron-sparing surgery is the standard of care for small tumors less than 4cm and 
should be performed in patients with a functionally solitary kidney and is indicated in 
hereditary renal cancer, in bilateral tumours and in selected patients with whom the 
contralateral kidney is threatened by an associated disease such as diabetes, mellitus or 
hypertension. 
Partial nephrectomies have excellent survival rates and are accompanied by a low risk of 
local (3.2%) and distant (5.8%) recurrence, with preservation of renal function in 98% of 
cases (Patard et al., 2004). 
Laparoscopic surgery is becoming the standard of care for radical and partial 
nephrectomy. It is a minimally invasive procedure appropriate for most patients with 
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kidney cancer. Long-term oncologic outcomes of laparoscopic surgery and open surgery 
are similar. The benefits of a laparoscopic approach include decreased hemorrhage, 
reduced postoperative pain, shorter hospitalization and better cosmesis (Al-Qudah et al., 
2007). 
Percutaeous thermal ablative therapy is becoming an available option for small tumors. 
The tumor cells are destroyed by radiofrequency, heat ablation or cryoablation. A needle 
probe is advanced through the skin and directed into the tumor using image guidance. 
Studies indicate that radiofrequency ablation can reliably eradicate RCCs smaller than 3.7 
cm. Treatment of larger RCCs will expose the patient at an increased risk of residual 
RCC. Because identification of the RCC type is important, a core biopsy should be 
performed as part of the procedure (Permpongkosol et al, 2006). The rate of 
complication is relatively low but postoperative hemorrhage, urinary leakage and 
damages to adjacent structures have been reported. Altogether, radiofrequency ablation 
seems to be a promising new modality for the minimally invasive treatment of renal cell 
carcinoma (Boss et al, 2007). 
1.1.7.2 Chemotherapy 
Because RCC is often metastatic at the time of diagnosis, medical therapy is usually 
required. However, results of chemotherapy in RCC have been very disappointing with 
response rates less than 10% (Yagoda et al, 1995). RCC is resistant to a variety of 
cytotoxic drugs with diverse structures and different mechanism of action. This 
phenotype has been termed Multi Drug Resistance (Mickisch, 1994). Multi drug 
resistance of the renal carcinoma cells can be caused by expression of the mdrl gene that 
encodes for 179kDa membrane P-glycoprotein. This P-glycoprotein functions as a 
transport channel that extrudes hydrophobic drugs outside of the cells (Pastan & 
Gottesman, 1987). Mdrl is highly expressed in proximal tubule cells— the cells from 
which clear-cell and papillary renal-cell carcinoma may originate. Indeed, mdrl is 
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expressed in 90% of RCC (van Kalken etal, 1991). The MDR resistance associated with 
P-glycprotein expression can be reversed with agents such as Verapamil and 
Cyclosporine, but clinical trials with these agents have not shown an enhanced anti-tumor 
effect of the chemotherapy (Motzer et al, 1995).Another mechanism that contributes to 
renal tumor cell resistance is increased expression of drug metabolizing enzymes such as 
glutathione transferase (Chuang et al, 2005). 
Despite its suboptimal efficacy, chemotherapy is nevertheless of some benefit in renal-
cell carcinomas of the collecting-duct subtype (Gollob et al, 2001; Milowsky et al, 
2002; Peyromaure et al, 2003). In a Phase II study, the combination of carboplatin and 
paclitaxel has shown a clinical response in aggressive collecting duct renal cancer 
(Oudard^a/.,2007). 
Both cisplatin and carboplatin have broad antitumor activity that is attributed primarily to 
their ability to form DNA-platinum adducts resulting in cancer cell apoptosis. Again, 
clinical effectiveness can be limited by up-regulation of anti-apoptotic genes by RCC 
cells. The classical apoptotic pathway consists of activation of the caspase family 
cascade. The effector caspase serves to cleave the cellular protein substrates resulting in 
programmed cell death. The caspase X-linked inhibitor of apoptosis protein (XIAP) has 
the potential to inhibit the activation of caspases enzymes and slows down the process at 
this step. XIAP is expressed in the majority of RCC cells and predicts a worse prognosis; 
Knocking out XIAP expression sensitizes RCC cells to chemotherapy in vitro (Mizutani 
et al, 2005). Similarly Smac/DIABLO expression is downregulated in RCC and 
transfection with Smac/DIABLO sensitized RCC to TRAIL/cisplatin-induced apoptosis 
(Mizutani et al, 2005; Yan et al, 2004). These results suggest that expression of 
antiapoptotic genes in RCC tissue may be markers of chemoresistance. More importantly, 
however, it is conceivable that modulation of the apopototic pathway might render RCCs 
more responsive to standard chemotherapeutic agents. 
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1.1.7.3 Modifiers of biological response 
Overview: 
Renal cancer is one of the few cancers where stabilization and even spontaneous 
regression has been reported in the absence of systematic treatment. One explanation is 
that the host immune response might occasionally control renal tumor growth. 
Immunotherapy function has been proposed to enhance the antigenicity of the tumor and 
enhances host immune surveillance (Oliver et al, 1989). 
Interferon-alpha (INF-alpha): 
Interferon alpha has a direct antiproliferative effect on renal cancer cells and can also 
stimulate host mononuclear cells while enhancing expression of MHC molecules. The 
overall response achieve by interferon alpha treatment is 12% and can be as high as 30% 
in patient with advanced disease (lung metastasis) with prior nephrectomy (Minasian et 
al, 1993). However, IFN-alpha has significant side effects and is rarely considered as a 
single agent for treatment of advanced RCC (Atkins et al, 2007). 
Interleukin 2 (IL-2): 
High dose EL-2 was first approved by the Food and Drug Administration (FDA) for use 
in patients with RCC in 1992 after initial overall response rates of around 15% and 
durable, complete responses were reported. Until 2005, high-dose interleukin-2, was the 
only treatment FDA-approved for metastatic renal cancer (Fyfe et al, 1995). IL-2 acts by 
activating lymphocytes (NK and activator T cells) without affecting cancer cells direcdy. 
IL 2 treatment alone can achieve a response rate of 20% in patients with metastatic RCC 
and a complete remission in 5% of the cases (Rosenberg, 2007). The major toxicities of 
high-dose IL-2 aside from fever and malaise are related to increased vascular 
permeability including hypotension and oliguria. Careful monitoring and fluid 
replacement can control symptoms of this capillary leakage syndrome but has been 
nevertheless implicated in 4% of treatment-related death. As a consequence, IL-2 is often 
not the first choice of treatment of patients with metastatic RCC (Rosenberg, 2007). 
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Tumor Vaccine: 
Tumor vaccine strategy is to enhance the host immunity against the tumor.One of the 
most promising a vaccine has been with autologous or sibling donor dendritic cells (DC) 
transplatation. Dendritic cells are the most potent antigen-presenting cells in activating 
pro-inflammatory tumour specific immune pathways. Immature DC process antigens and 
then migrate to lymphoid organs where they activate specific cytotoxic T-cells targeted 
against tumor antigens (Holtl et al, 2002). However, the overall efficacy of 
immunotherapy for advanced RCC remains modest. 
1.1.7.4 Therapies targeting molecular pathways 
Aberrant VHL/HIF/VEGF pathway activity is seen in the majority of RCCs. This 
provides a strong rational for exploring therapeutic agents that inhibit HIF-regulated 
genes. One phase II study in patients with metastatic RCC showed tumour shrinkage in 
most patients treated with Bevacizumab, a humanized VEGF-neutralizing antibody. The 
treatment was generally well tolerated. In a randomized, placebo-controlled, phase 2 trial 
of bevacizumab in patients with metastatic clear-cell renal-cell carcinoma, partial 
responses were observed in 10% of patients who were given a high dose of the antibody. 
There was a statistically significant improvement in progression-free survival. Although 
overall patient survival was not improved, blockade of VEGF does inhibit tumour growth 
(Yang etai, 2003). 
Sunitinib and Sorenafib are small molecule oral inhibitors of the tyrosinase kinase portion 
of the VEGf and PFGF receptors and are now approved by the FDA for use in advanced 
renal cell carcinoma. A phase II study of Sorenafib in cytokine-refractory RCC patients 
(TARGETS trial) showed significant differences in disease progression-free disease 
compared with placebo. (5.5 vs 2.8 months). A phase II study of Sunitinib showed an 
objective response in 34% of the patients; a phase III study shows a better response rate 
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with Sunitinib than with INF-alpha. Neither Sunitinib nor Sorafenib had a significant 
effect on initial survival, but the final long-term analysis has not yet been reported. An 
important point in evaluating these trials is that both Sunitinib and Sorafenib caused 
clinically significant toxic effects including hypertension. 
Temsirolimus and Everolimus are derivatives of rapamycin and function to inhibit the 
mTOR pathway. Everolimus was shown to be effective in patients with advanced RCC 
and is now being further explored as a single agent and in combination with other 
therapies (Cho et ai, 2007). Temsirolimus showed antitumor activity in Phase II and 
Phase III trials; temsirolimus achieved increased overall survival compared to INF-alpha 
alone (Hudes et ai, 2007). 
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Figure 1.6 Molecular pathways and targeted therapies. 
A) Bevacizumab is a humanized monoclonal antibody that targets VEGF ligand. Both 
Sunitinib and Sorafenib inhibit the VEGF and PDGF(3 pathways, at least in part by acting 
on the VEGF receptor 2 (VEGFR2) and the PDGF receptor p (PDGFRp), which are 
receptor tyrosine kinases. Finally, Temsirolimus and Sirolimus inhibit the mammalian 
target of rapamycin (mTOR) (Brugarolas, 2007). Figure adapted adapted from New 
England Journal of Medicine, 2007 Copyright Massacussets Medical Society. All right 
reserved). 
B) Several targeted drugs are in the pipeline for the treatment of RCC either targeting 
angiogenesis or the mTOR pathways (Larkin et al., 2007) 
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1.1.8 RCC Summary: 
RCC is one of the most resistant tumors to therapy. Only high doses of IL-2 have been 
shown to be able to cause complete remission in patients with advanced renal-cell 
carcinoma and this in only 5% of the cases and along with tricky management of side 
effects. Overall, treatment of RCC is currently moving from the cytokine era to the 
targeted agent era. Small inhibitors targeting the VEGF or mTOR pathway have shown 
significantly improved effects on tumor growth in virtually all patients with RCC. 
Although more patients seem to benefit from this targeted treatment, it is only 
Temsirolimus, which results in an increased overall survival, and this only in limited 
cases. Many questions still remain regarding the efficacy of combination treatments and 
on the best way to achieve complete remission. Nevertheless the promising clinical 
outcome progress of these targeted drugs validates the idea that new treatments can 
emerge from an understanding of the molecular biology of the renal tumors. At the 
moment, the chance of survival for patients afflicted with advanced renal cancer remains 
unacceptably low. Therefore we have to continue further the exploration of the molecular 
pathways implicated in this disease and continue to identify targets for the development 
of novel agents (Larkin et ai, 2007). 
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1.2 Wilms Tumor 
Overview: 
Wilms tumor (WT) is a childhood cancer of the kidney that arises in 1/10,000 children 
from a progenitor cell in the undifferentiated fetal metanephric mesenchyme. WT 
recapitulates in its histology the developmental differentiation process of nephrogenesis. 
The mixture of renal cellular lineages that characterize WT was noticed by Max Wilms 
who first described WT as "die mischgeschwulste der Niere" in 1899 (Wilms, 1899) 
(Wilms, 1899). Since then, WT has remarkably served to define the paradigm of pediatric 
cancer: Knudson and Strong establish the two-hit hypothesis model using WT bimodal 
age distribution. WT was also one of the first cancers in which a tumor suppressor (WT1) 
was mapped by positional cloning and one of the first malignancies described in 
association with epigenetic modification (Willins, 2003). Finally, the multidisciplinary 
management of Wilms tumor has become an example of successful cancer therapy that 
progressed from 30% survival in the 1930s to a more than 85% cure rate today (1991). 
1.2.1 Epidemiology 
In North America, the incidence rate of Wilms tumor is 8.1 cases per million in 
Caucasian children. The incidence rate is about three times higher for blacks in the 
United States and Africa (9-12 cases per millions) than for East Asians (3 cases per 
millions), with rates for white populations in Europe and North America intermediate 
between these extremes (Breslow et al, 1994). The variations in the incidence of Wilms 
tumor vary according to ethnicity; the incidence of Wilms tumor does not exhibit 
geographic variation, suggesting that environmental factors do not play an important role 
(Stiller & Parkin, 1990). The incidence of Wilms tumor over time has been relatively 
constant for the last 20 years (Linet et al, 1999). Although most tumors are sporadic and 
unilateral, bilateral or multifocal tumors account for 10% of the cases (Knudson & 
Strong, 1972). The male-to-female ratio for patients with a unilateral tumor is 0.92 to 
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1.00 and for those with bilateral tumors is 0.60 to 1.00. The mean age at diagnosis for 
those with unilateral tumors is 41.5 months for males and 46.9 months for females, 
compared with 29.5 months for males and 32.6 months for females with bilateral tumors 
(Brcslow etal., 1993). 
1.2.3 Genetic predispositions 
The average age at diagnosis of WT is 42-47 months for children with unilateral tumors 
and 30-33 months for children with bilateral disease (Breslow et al, 1993). An earlier 
age at diagnosis and an increased frequency of bilateral disease is characteristic of 
syndromic WT and in familial WT (Knudson & Strong, 1972). In order to explain this 
bimodal distribution of WT (also observed in Retinoblastoma and Neuroblastoma) 
Knudson and Strong elaborated the 2 hit hypothesis which attempts to model the rate-
limiting events required to initiate tumorigenesis (Knudson & Strong, 1972). They 
hypothesized that WT arises from the occurrence of two sequential genetic events ("hits") 
that inactivate a recessive tumor suppressor gene. Patients born with a germline mutation 
(or first hit) need acquire only a single somatic mutation, inducing a Wilms tumor at an 
early stage and increasing the likelihood of multifocal tumors. In contrast, patients 
without a germline mutation must acquire two de novo hits in a single somatic cell; the 
much lower probability of two independent events occurring in the same cell accounts for 
the later age of onset and unilateral tumors. However, familial forms constitute only 2% 
of Wilms tumors (Diller et al, 1998) and many children exhibit bilateral WT without 
family history. Thus, Knudson's 2-hit model may be an oversimplification. De novo 
events altering the stability of several different Wilms tumor genes has also been 
suggested (Narod & Lenoir, 1991). 
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1.2.4 Genetic syndromes 
Overview: 
Studies of patients affected by genetic syndrome predisposing to Wilms Tumor have been 
fundamental in identifying genetic factors involved in Wilms tumorigenesis (Table 1.2). 
Patients with these syndromes tend to develop multiple tumors. 
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Table 1.2 Genetic syndromes predisposing to Wilms tumor. 
Patients affected by these genetic syndromes tend to develop ealy onset multiple and 
bilateral tumor. The strongest associations are linked to deletions and mutation in the 
gene WT1 in the WAGR syndrome and Denys-Drash Syndrome respectively. The 
Beckwith-Wiedemann syndrome (BWS) locus at l lp l5 has also been associated with 
Wilms tumor due to both germline overexpression of paternally imprinted insulin-like 
growth factor 2 (IGF2). Other rare syndrome caused by mutation in genes not identified 
can also predispose the patients affected by these diseases to the development of Wilms 
tumor. 
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Table 1.2 Heritable syndromes associated with Wilms tumor: 
Syndrome 
WAGR (Wilms tumor, aniridia, 
genitourinary abnormalities and 
menta retardation) 
Denys-Drash 
Frasier 
Beckwith-Wiedemann 
Simpson-Golabi-Behmel 
Sotos 
Perlman 
Familial Wilms Tumor 1 (FWT1) 
Familial Wilms Tumor 2 (FWT2) 
Locus/Gene 
llpl3AVTl:large 
deletion (also 
involving PAX6) 
Ilpl3/WT1 point 
mutation (in the Zn 
finger domain) 
llpl3/WTl:point 
mutations (in the 
KTS splicing donor 
site) 
l lp lS 
(IGF2,H!9,p57) 
Xq26/GPC3 
5q35/NNSDl 
Unknown 
17ql2-21 
19ql3.4 
Renal Phenotype 
30% of the patients develop ilms 
Tumor. 
90% of the patients develop Wilms 
tumor. 
Patients rarely develop Wilms 
tumor. 
5% of patients develop Wilms 
tumor. 
7.5% of the patients develop Wilms 
tumor 
Les than 5% of patients develop 
Wilms tumor 
30% of patients develop Wilms 
tumor 
20% of patients develop Wilms 
tumor 
70% of patients develop Wilms 
tumor 
WAGR (WT is present 30% of the cases): 
Initial insights into the molecular biology of Wilms tumor were derived from the 
observation that patients with Aniridia (absence or malformation of the iris), 
genitourinary malformations, and mental retardation (WAGR syndrome), were at 30% 
risk of developing the tumor. Cytogenetic analysis of individuals with this syndrome 
showed deletions at chromosome l lp l3 , which was later found to be the locus of a 
contiguous set of genes including PAX6, the gene causing aniridia, and WT1, one of the 
Wilms' tumor genes. Reduced dosage of PAX6 gene underlies the defect in ocular 
development while constitutional germline hemizygosity for the WT1 gene is associated 
with the genitourinary malformations. Wilms tumors arise when a renal cell acquires an 
additional somatic point mutation in the remaining WT1 wild-type allele (Call et al, 
1990;Gesslerefa/., 1990). 
Denys Drash (WT present in 90% of the cases): 
The Denys-Drash Syndrome (DDS) (OMEVI number 194080) is characterized by male 
pseudohermaphroditism and progressive glomerular nephropathy leading to end-stage 
renal disease. Normal glomerular development is disturbed and affected patients exhibit 
proteinuira in association with diffuse mesangial sclerosis and severe alterations of the 
podocytes. In addition, DDS patients have 95% chance of developing Wilms tumor 
(Habib et al, 1985). DDS is caused by point mutations in the zinc-finger DNA-binding 
region of the WT1 gene, resulting in loss or alteration of DNA binding ability, as 
demonstrated by in vitro studies (Pelletier et al, 1991a). The most common WT1 lesion is 
a mutation (Arg394Trp) affecting the third zinc finger domain of the WT1 protein 
(Braening et al, 1992). Other point mutations in the second Zinc finger lead to similar 
DDS phenotype (Baird et al, 1992; Sakai et al, 1993). Pelletier has suggested that DDS 
is the result of WT1 mutations, which cause a dominant negative effect on the wildtype 
allele. One mechanism to explain this phenomenon might be that WT1 proteins dimerize 
via their N-Terminal domains (Englert et al, 1995; Moffett et al, 1995; Reddy et al, 
1995). 
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Beckwith-Widemann Syndrome: 
Beckwith-Wiedemann syndrome (BWS) (MIM 130650) is a developmental disorder 
with an incidence of about 1 per 20,0000 births, characterized by somatic overgrowth, 
macroglossia, abdominal wall defects and increased incidence of embryonal tumors. 
Approximately 5% of BWS patients develop Wilms tumors. Although the precise genetic 
mechanism causing Wilms tumor remains undefined, defective expression of imprinted 
genes at locus llpl5.5 have been implicated. Regional genes with aberrant imprinting 
include insulin-like growth factor-2 (IGF2), H19 untranslated RNA, and CDKN1C, 
which encodes a cyclin-dependent kinase inhibitor, p51KSP2. BWS patients often show 
altered DNA methylation of the l l p l5 region associated with decreased expression of 
CDKN1C and increased expression of IGF2. These aberrations in gene expression are 
thought to alter cellular proligferation and may underlie the somatic overgrowth 
phenotype of BWS (Maher & Reik, 2000). 
Hyperparathyroidism-jaw-tumor syndrome: 
Hyperparathyroidism-jaw-tumor syndrome (OMEVI 145001) is a very rare disease that 
predisposes to multiple parathyroid adenomas, a fibro-osseous tumor of the jaw, renal 
cyst, harmatomas and mesoblastic nephroma. In addition, affected individuals have 
hereditary hyperparathyroidism (with consequent nephrolithiasis) and can develop a late 
onset Wilms tumor (Kakinuma et al, 1994). Germline mutation in HRPT2 located at 
lq25-32 has been identified and encoded for the protein parafibromin, which is thought 
to act as a tumor suppressor, but its exact function remains to be determined (Pavlovich 
& Schmidt, 2004). 
Li-Fraumeni syndrome: 
Li-Fraumeni (OMEVI 151623) is a rare syndrome caused by a mutation in the TP53 
tumor-suppressor gene that encodes p53 protein, an important regulator of the cell cycle 
and apoptosis. Patients with Li-Fraumeni syndrome have a strong predisposition to 
develop a variety of cancers and Wilms tumor has been reported in affected individuals 
(Hartleys al, 1993). 
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1.2.5 Familial Wilms Tumor 
Overview: 
Familial WT is relatively rare, occurring in 1-2% of all cases of WT. Typically Wilms 
tumor family pedigrees are small, with only two or three affected relatives, and there is 
usually no associated congenital abnormality or predisposition to other tumor types 
(Ruteshouser & Huff, 2004). 
WT1: 
Germline WT1 mutations are usually de novo mutations identified in WT patients with no 
family history (Pelletier et al., 1991). WT1 mutational analysis of familial cases 
demonstrated that only 2 out of 30 families carried an inherited alteration in WT1 
(McDonald et al, 1998). Thus, germline WT1 mutations are rarely observed in a family 
context, and most individuals with germline WT1 mutations are "sporadic" cases 
(Ruteshouser & Huff, 2004). 
FWT1 and FWT2: 
Genetic linkage studies of WT families have led to the identification of two familial 
predisposition loci at 17ql2-q21 (FWT1) (McDonald et al, 1998; Rahman et al, 1996), 
and 19ql3.4 (FWT2). However, other Wilms tumor families show no linkage to either 
locus, implying the existence of additional familial Wilms tumor susceptibility genes 
(Rapley et al, 2000; Ruteshouser and Huff, 2004). 
1.2.6 Diagnosis and clinical presentation 
Approximately one third of patients present with abdominal pain, anorexia, vomiting, 
malaise, or a combination of these symptoms, but the most common clinical presentation 
of WT is an asymptomatic abdominal mass. About 30% of patients have haematuria, 
10% have a coagulopathy and 25% develop hypertension. Abdominal CT-scan and 
ultrasonography are used to detect abnormal renal mass. X-Ray or CT scan of the chest is 
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recommended to assess lung metastases (Kalapurakal et al, 2004). Wilms tumors may be 
either a solid or cystic mass within the kidney, visibly displacing the collecting system. 
They may be encapsulated and may undergo central necrosis with hemorrhage. The 
tumor extends into the renal vein in 40% of cases. Wilms tumors rarely extend into the 
ureter and bladder. Partially differentiated cystic nephroblastomas (i.e. multilobular cystic 
nephroma) may mimic Wilms tumor appearance, but are considered benign lesions. 
1.2.7 Histology 
Favorable histology: 
The classic untreated Wilms' tumor consists of varying proportions of three (triphasic) 
cell types: blastemal, stromal, and epithelial, commonly recapitulating various stages of 
normal renal development (Figure 1.7). Less commonly, heterologous epithelial or 
stromal components are identified, including mucinous or squamous epithelium, skeletal 
muscle, cartilage, osteoid, or fat elements. A significant number of stromal Wilms tumors 
exhibit skeletal-muscle differentiations, varying from well differentiated 
(rhabdomyomatous) to poorly differentiated (rhabdomyoblastic). 
Anaplastic (Unfavorable histology): 
Anaplastic foci, characterized by greatly enlarged polyploid nuclei, arise within Wilms 
tumors in 5% of cases. Anaplastic tumors are more frequent in African-Americans than in 
Caucasian patients (Bardeesy et al, 1994; Bonadio et al, 1985). They are more resistant 
to chemotherapy and correlate with the presence of secondary p53 mutations (Beckwith, 
1997). 
Blastemal vs Epithelial: 
Blastemal-predominant tumors are often invasive and present at an advanced stage, but 
they respond relatively well to chemotherapy. In contrast, predominantly epithelial or 
myogenic Wilms tumors are often localized at the time of presentation, but tend to be 
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Wilms tumor triphasic histology 
Fig.1.7 
quite resistant to chemotherapy (Anderson et al, 2002). 
1.2.8 Staging/prognosis 
The North American National Wilms Tumor Study Group (NWTSG) has established 
staging system for Wilms tumor. The stage is defined on the basis of tumor size, gross 
anatomy and presence of metastatic disease (Table 1.3) (Kalapurakal et al, 2004). In 
addition, genetic features have been proven useful to predict treatment outcome. Patients 
with loss of heterozygosity (LOH) at chromosomes lp and 16q at 16q are at greater risk 
of relapse and mortality than children without this lesion. This result was confirmed in 
the fifth National Wilms Tumor Study (NWTS-5) that prospectively analyzed LOH in 
primary Wilms tumors. Tumor-specific LOH for both chromosomes lp and 16q occurs in 
5% of patients with a favorable histology and correlates with a significantly increased 
risk of relapse and death (Grundy et al, 2005b). Other prognostic markers are an increase 
in gene copy number at chromosome lq (Hing et al, 2001; Lu et al, 2002). Gene 
expression profiling has demonstrated signature gene expression patterns associated with 
bad prognosis and relapse and may in the future help to identify patients at high risk (Li 
et al, 2005b; Williams et al, 2004). In addition, high telomerase RNA expression in 
Wilms Tumor have been correlated with tumor recurrence (Dome et al, 2005; Dome et 
al, 1999). 
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Table 1.3 Staging of Wilms tumors: 
NWTSG recommends surgical staging in every case and is based on the tumor size, 
lymphe nodes involments and metastasis (1991). 
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Table 1.3 Wilms tumor staging: 
Stage I (43% of patients) 
Tumor is limited to the kidney and is completely resected. 
The renal capsule is intact. 
The tumor is not ruptured or biopsied prior to removal. 
No involvement of renal sinus vessels. 
No evidence of the tumor at or beyond the margins of resection. 
Stage II (23% of patients) 
There is regional extension of the tumor (i.e., penetration of the renal sinus capsule, or extensive 
invasion of the soft tissue of the renal sinus, as discussed below). 
Blood vessels within the nephrectomy specimen outside the renal parenchyma, including those of 
the renal sinus, contain tumor. 
Stage HI (23% of patients) 
Lymph nodes within the abdomen or pelvis are involved by tumor. (Lymph node involvement in 
the thorax, or other extra-abdominal sites is a criterion for Stage IV.) 
The tumor has penetrated through the peritoneal surface. 
Tumor implants are found on the peritoneal surface. 
Gross or microscopic tumor remains postoperatively 
The tumor is not completely resectable because of local infiltration into vital structures. 
Tumor spillage occurs either before or during surgery. 
The tumor was biopsied before removal. 
The tumor is removed in more than one piece 
Stage IV (10% of patients) 
In stage TV Wilms' tumor, hematogenous metastases (lung, liver, bone, brain, etc.), or lymph node 
metastases outside the abdominopelvic region are present. (The presence of tumor within the adrenal gland 
is not interpreted as metastasis and staging depends on all otiier staging parameters present.) 
Stage V (5% of patients) ~ 
In stage V Wilms' tumor, bilateral involvement by tumor is present at diagnosis. An attempt should be 
made to stage each side according to the above criteria on the basis of the extent of disease. The 4-year 
survival is 94% for those patients whose most advanced lesion is stage I or stage II, and 76% for those 
whose most advanced lesion is stage HI. 
Stage I-IV Anaplasia 
Anaplastic histology accounts for about 10% of Wilms' tumors. Children with anaplastic tumors have a 
worse prognosis than children with favorable histology when compared stage to stage. These tumors are 
more resistant to the chemotherapy traditionally used in children with Wilms' tumor (favorable histology). 
1.2.9 Treatment 
1.2.9.1 Overview 
The mainstay of Wilms tumor therapy is a combination of surgery and chemotherapy. 
Radiation therapy is added for patients with advanced disease. The National Wilms 
Tumor Study group, now Children Oncology Group (COG), advocate early nephrectomy 
and then chemotherapy and radiation when indicated. SIOP trials suggest the use of pre-
operative chemotherapy followed by surgery. 
1.2.9.2 Surgery 
The NWTSG has conducted five trials where primary surgical resection of the tumor is 
the initial treatment of most children. As a result, complete nephrectomy is recommended 
in North America. One of the main challenges of WT surgery is to avoid tumor spillage, 
which increases the risk of local abdominal relapse and a subsequent poor outcome 
(Shamberger et al, 1999).Regional lymph nodes should be assessed at the time of 
nephrectomy (Shamberger et al, 1999). It is worth to mention that partial nephrectomy 
is generally not recommended for a unilateral tumor; the rate of renal failure in patients 
with unilateral tumor is less than 1% (Ritchey et al, 1996) 
A retrospective analysis of the NWTS-4 study suggested that patients younger than 2 
years old with favorable histology and a stage I, small tumor, might be treated without 
receiving adjuvant chemoatherapy after nephrectomy, reducing treatment burden. 
However, in the NWTS-5 trial of 75 children with small (<550 g) stage I, favorable 
histology tumors, nephrectomy alone led to relapse by 2 years in 13.5% of subjects and 
the trial was abandoned (Green et al, 2001). Survival was still 98% since relapses were 
successfully treated by chemotherapy, but surgery alone will be restricted to selected 
cases in a future trial planned by the Children Oncology Group (COG) (Grundy et al., 
2005). 
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1.2.9.3 Chemotherapy 
The COG now advocates up-front resection of the primary Wilms tumor before 
chemotherapy. In contrast, Societe international d'oncologie pediatrique (SIOP) 
recommends that chemotherapy be given before surgery. Both approaches yield excellent 
clinical outcomes but the debate about the relative merits of each approach is 
ongoingXGreen, 2007). The NWTSG recommends preoperative chemotherapy for 
specific cases, including bilateral Wilms tumor, tumor in a horseshoe kidney, tumor in a 
solitary kidney, tumor thrombus in the inferior vena cava above the level of the hepatic 
veins and respiratory distress resulting from the presence of an extensive metastatic 
tumor. 
Treatment of WT with favorable histology: 
Overall the NWTS-5 treatment approach is considered a reasonable standard of care for 
Wilms tumor with favorable histological features (Green et al., 1998) (summarized in 
Table 1.4). Treatment of high-risk patients including WT with anaplastic histology, 
bilateral tumor and recurrent Wilms tumor, needs specific considerations. 
62 
Table 1.4 Treatment of favorable histology Wilms tumor: 
The protocols for the treatment favorable histology WTs are summarized here. The 
National Wilms Tumor Study Group (NWRSG), which is now part of the Children's 
Oncology Group (COG), has established standard treatment for Wilms tumor in North 
America which consists of surgery followed by chemotherapy and, in some patients, 
radiation therapy depending on the stage of the tumor (Metzger & Dome, 2005). 
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Treatment of anaplastic WT: 
The NWTS-5 study treated patients with stage I anaplastic Wilms tumor and obtained 
encouraging results using vincristine and dactinomycin. However, preliminary analysis 
showed unexpectedly low survival of 70% and 83% respectively. As a consequence, 
future therapeutic regimen for these patients will include the additional administration of 
Doxorubicin and radiation therapy in COG studies. For patients with stage II, III or IV 
diffuse anaplasia, the treatment regimen includes cyclophosphamide. Such patients 
receive abdominal radiation therapy and a novel chemotherapy regimen consisting of 
vincristine, doxorubicin and cyclophosphamide, alternating with cyclophosphamide and 
etoposide. Survival for this group is 55%. Patients with stage II-TV focal anaplasia are 
treated with abdominal irradiation, vincristine, doxorubicin and dactinomycin. The 
survival estimates for patients with focal anaplasia is 75% (Metzger & Dome, 2005). 
Treatment of recurrent WT: 
Salvage therapy includes multi-agent protocols using cyclophosphamide, ifosfamide, 
cisplatin, carboplatin and etoposide. In particular, the combination (ifosfamide, 
carboplatin and etoposide), has significantly improved survival after relapse with a 50% 
to 60% rate (Metzger & Dome, 2005). 
The role of high dose therapy with autologous stem cell rescue in relapse WT needs 
further clarification. Several studies have shown promising results with overall survival 
between 60 and 75% (Metzger & Dome, 2005). 
Treatment of bilateral WT: 
Synchronous bilateral Wilms tumors account for 6% of all Wilms tumors. The main 
challenge of this stage V tumor is the preservation of the renal function without 
compromising cancer control. This is the only group in which the NWTSG recommends 
pre-treatment with chemotherapy after biopsy confirmation. The role of preoperative 
chemotherapy is to reduce tumor size, thereby facilitating nephron-sparing surgery. Local 
recurrence for these patients is 8.2%. Long-term survival rates for patients with 
synchronous bilateral Wilms tumors are approximately 70%-80% (Metzger & Dome, 
2005). 
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Metachronous bilateral Wilms tumor accounts for approximately 2% of all Wilms 
tumors. The NWTSG has reported lower survival rates for patients with metachronous 
compared to patients with synchronous bilateral tumors. It is estimated that overall 
survival for patients with metachronous bilateral Wilms tumor is about 50%. Children 
younger than 12 months who have perilobar nephrogenic rests are at markedly increased 
risk of contralateral disease and require frequent and regular surveillance for several 
years (Metzger & Dome, 2005). 
1.2.9.4 Treatment long-term sequelae 
Increasing data on the long term side effects of WT treatments have emerged as survival 
has improved. In bilateral Wilms tumor, nephron-sparing surgery is often attempted but 
about 4% of these patients still develop end-stage renal failure when total nephrectomy is 
required or radiation-induced damage compromises residual renal tissue. Congestive 
heart failure is a common complication after anthracyclines and the risk is further 
increased when whole-lung irradiation is given for metastases. Radiotherapy can also 
injure the lung and radiation nephritis is associated with malignant hypertension. Women 
who have received abdominal radiotherapy for Wilms tumor are at higher risk of adverse 
pregnancy outcomes. Finally, there is increased risk of developing a second malignant 
neoplasm (Kalapurakal et al, 2004). 
The treatment of Wilms tumor is one of the great success stories in oncology. Modern 
treatment regimens yield survival rates of 90%. However, there remain some patients for 
whom current treatment is unsatisfactory including those with anaplastic, bilateral or 
recurrent disease with favorable histologic features. This represents about 25% of patients 
who have Wilms tumor and highlight the need for a continued effort to develop novel 
treatment. Thus, therapy for Wilms tumor is not yet optimal and there remains 
considerable motivation to improve on current therapeutic strategies (Kalapurakal et al, 
2004). 
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1.2.10 Pathogenesis of Wilms tumor 
1.2.10.1 WT1 (chromosome l lpl3) 
Only 5% of WT cases involve germline mutations of WT1, but WT1 mutations were 
found in about 20% of 600 sporadic Wilms tumors (Little & Wells, 1997) (updated WT1 
mutational database maintained at http://www.umd.necker.fr). Approximately two-thirds 
of sporadic WT1 mutations are caused by deletion of WT1 or mutations which produce a 
truncated protein with disrupted DNA-binding domain. This is consistent with the view 
that WT1 acts as a recessive tumor suppressor gene. Interestingly, specific missense 
mutations of WT1 may act as dominant-negative properties, as discussed above (Little et 
al, 1993; Pritchard-Jones, 1997). 
Wilms tumours caused by WT1 mutation appear to represent a discrete malignant subtype 
with mesenchymal (stromal) phenotype (Schumacher et al, 1997; Schumacher et al, 
2003). Cells are non-polarized and spindle-shaped, expressing myogenic markers such as 
myogenin and MyoD (Fukuzawa et al, 2004; Miyagawa et al, 1998). WT with stromal-
predominant histology are often associated with CTNNB1 mutations (Fukuzawa et al, 
2004) 
Certain Wilms tumors may lack WT1 immunostaining although no alterations of the 
WT1 coding sequence can be identified (Satoh et al, 2003). It is important, however, to 
mention that WT1 may be inactivated by alterations that might not be detected by 
standard mutational analysis (Huff, 1998). An example of this phenomenon, Malik and 
colleagues showed that an antisense RNA (WT1-AS) transcribed from the WT1 locus, 
can control WT1 protein levels (Malik et al, 2000). The WT1 -AS is imprinted and 
monoallelicaly expressed in the normal kidney. However, loss of imprinting results in 
biallelic expression of the WT1-AS in Wilms tumour tissues. Loss of imprinting is 
apparently due to loss of methylation within a regulatory region that WT1 AS transcription 
(Hancock et al, 2007; Moorwood et al, 1998). 
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1.2.10.2 WT2 (Chromosome llplS) 
A second WT locus (WT2) was mapped to llpl5.5. Loss of heterozygosity (LOH) is 
observed in about 15% of WT cases. The significant bias towards the LOH for 
maternally derived alleles at l i p 15, suggests the involvement of genomic imprinting 
(Williams et al, 1989). The l lp l5 region includes two known imprinted domains, 
IGF2/H19 and CDKN1CKIP2/LIT1 (Mutter et al, 1993; Rump et al, 2005). 
Insulin Growth Factor 2 (IGF2) is paternally expressed (maternal allele is silent) in the 
normal proliferating kidney during nephrogenesis (Hedborg et al, 1994). Since IGF2 is a 
mitogenic growth factor, it is likely that its overexpression will lead to hyperplasia and 
contributes to Wilms tumorigenesis. IGF2 increased expression can be due to LOH of the 
maternal allele subsequently followed by duplication of the paternal. But a more frequent 
cause is the loss of imprinting (LOT) of the maternal allele yielding to biallelic expression 
IGF2 and a resultant increase of its level. One mechanism by which altered methylation 
leads to IGF2 LOI involved a DMR that regulates both IGF2 and HI 9 gene expression. 
IGF2 and HI 9 are located approximately 90 kb apart and separated by the DMR that 
regulates their expression. Normally IGF2 is exclusively expressed from the paternal 
allele, whereas the adjacent paternal H19 allele is silenced (Frevel et al, 1999; Zemel et 
al, 1992). This DMR contains binding sites for the Zinc finger CCCTC-binding factor 
(CTCF), a chromatin insulator (enhancer blocking). The binding of CTCF to the 
unmethylated DMR on the maternal allele prevents IGF2 transcription and enables H19 
transcription (Bell and Felsenfeld, 2000; Hark et al, 2000). On the paternal allele, 
methylation of the DMR prevents CTCF binding, leading to IGF2 transcription and HI 9 
silencing. IGF2 Loss of Imprinting (LOI) correlates with the HI9 DMR hypermethylation 
and occurs in 30-50% of Wilms tumors (Rainier et al, 1993). 
Another imprinted region involves CDKNIC^/LITI. Demethylation of the DMR LIT I, 
a control region of the KIP2/LIT1 domain, occurs in half of all patients with Beckwith-
Wiedemann Syndrome (BWS). The p57KIP2 (KIP2)/CDKN1C gene within the 
KTP2/LIT1 domain, which is expressed predominantly from the maternal allele, encodes 
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a cyclin dependent kinase inhibitor and is a putative tumor suppressor. In several adult 
tumors, KIP2 expression is epigenetically reduced (Kikuchi et al, 2002; Li et al, 2002b; 
Soejima etal, 2004). 
IGF2 LOI must occur as an early event in Wilms tumorigenesis, because somatic 
mosaicism for IGF2 LOI is present in the normal renal kidney tissue adjacent in most 
Wilms tumors with IGF2 LOI (Okamoto et al, 1997). As previously mentioned, a 
significant association between the presence of PLNR and IGF2 LOI in Wilms tumors 
has been described because somatic mosaicism in the tumor bearing kidney occurs more 
frequently for IGF2 LOI than l ip LOH (UPD) (Chao et al, 1993), it is likely that IGF2 
LOI is the predominant mechanism leading to PLNR formation. Presumably increased 
production of IGF2 arising from this epigenetic disturbance could lead to an imbalance in 
metanephric tissue growth and the persistence of these maturation delayed lesions. 
Despite the identification of this imprinted domain, the 1 lp region remains complex. The 
fact that LOH of l i p 15 is also seen in other cancers such as breast, lung and Leukemia, 
which indicates the presence of a tumor suppressor gene with a function that is not 
limited to Wilms tumor and kidney biology (Weston et al, 1989). 
1.2.10.3 CTNNB1 (chromosome 3p21) 
Activating mutations of CTNNB1 coding beta-catenin is a relatively common somatic 
genetic lesion in Wilms tumor. Activating mutations occurs in the exon 3 of the P-catenin 
gene and disrupts its phosphorylation site. Phosphorylation of beta-catenin is regulated by 
CK1 (casein kinase 1) and GSK3 (glycogen synthase kinase 3) and normally facilitate its 
binding to a "destruction complex" containing APC (adenomatous polyposis coli) and 
AXIN (axis inhibition protein). In the absence of phosphorylation, P-catenin is not 
targeted for proteosomal degradation and enters the nucleus where it forms a 
transcriptional complex with TCF/LEF (T-cell specific transcription factor and lymphoid 
68 
enhancer factor) family members mimicking active WNT signaling (Moon et al, 2004). 
Mutations in P-catenin are common in many different types of cancer and have been 
described in 10-15% of Wilms tumors (Koesters et al, 1999). Beta-catenin mutations 
preferentially occurring in exon 3 at codon 45 indicate existence of an underlying 
mechanism causing such a tissue-specific mutational pattern (Kusafuka et al, 2002). 
Remarkably, there is a high degree of overlap between tumors that harbour mutations in 
P-catenin and in WT1 genes; one report describes 19 out of 20 cases in which mutations 
in P-catenin occurred in tumors that also had mutations in WT1 (Maiti et al, 2000). WT1 
inactivation and P-catenin activation might therefore provide cooperative signals that 
drive renal tumorigenesis. It is conceivable that alterations in one pathway might actually 
trigger apoptotic signals that must be overcome by alterations in the second pathway 
before tumor formation can be initiated. 
The sequence of mutational events in the WT1 and CTNNB1 genes have been studied by 
our collaborator in New Zealand who found that in ILNRs adjacent to the tumor with 
both alterations (WT1 and CTNNB1) only WT1 mutation was present suggesting that 
CTNNB1 mutation occurs after the WT1 mutational event (Fukuzawa et al, 2007). 
Even in the absence of mutations in CTNNB1 aberrant activation of the WNT signaling 
pathway can be observed in Wilms tumors (Koesters et al, 2003). The recent 
identification of WTX and its ability to inhibit the beta-catenin pathway provide an 
explanation (Major et al, 2007; Rivera et al, 2007). 
1.2.10.4 WTX (chromosome Xqll . l ) 
Recently Rivera and colleagues investigating the DNA copy-number changes in 51 
primary WT using long-oligonucleotide array comparative genomic hybridization (array 
CGH) identified mutation and/or deletion at locus Xql 1.1. The commonly deleted region 
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was found in about 30% of the tumors and was mapped within a single gene named WTX 
(Rivera etal, 2007). 
WTX protein is presumed to act as a tumor suppressor gene. Accordingly, introduction 
of WTX in Human Embryonic Kidney cells HEK293 significantly decreases colony 
formation in agar plate due to an increase of apoptosis after 48h (Rivera et al, 2007). 
WTX is expressed in the developing kidney. Assessed by RNA in situ hybridization, the 
WTX expression profile closely resembles WT1 in terms of level and localization. Both 
WT1 and WTX are expressed in the condensing metanephric mesenchyme and in early 
epithelial structures that will form the glomerular podocytes (Rivera et al, 2007). 
The function of WTX during kidney development and Wilms tumorigenesis remains to 
be determined. Functional analyses in cultured cells, Xenopus and zebrafish demonstrate 
that WTX promotes beta-catenin ubiquitination and degradation, which antagonizes 
active WNT/beta-catenin signaling. Hence, inactivation of WTX enables beta-catenin 
translocation to the nucleus and subsequent up-regulation of WNT beta-catenin/tcf target 
genes upon WNT stimulation. This provides one possible mechanism for the tumor 
suppressor activity of WTX (Major et al, 2007). 
1.2.10.5 Other loci 
Inactivating mutations in the p53 gene are seen in about 5% of WT and are correlated 
with anaplastic histology (Malkin et al, 1994; Takeuchi et al, 1995). P53 can repress the 
MDRR1 gene, which encodes a pump that prevents accumulation of drugs inside cells. 
Anaplastic cell lines carrying ap53 mutation are resistant to chemotherapy and have been 
shown to overexpress P-glycoprotein, the product of the MDR1 gene (Ramachandran et 
al, 2000; Re et al, 1997). Hence p53 lesions determine chemoresistance in unfavorable 
anaplastic Wilms tumors (Bardeesy et al, 1994; Lahoti et al, 1996). 
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Tumor-specific LOH for both chromosomes lp and 16q identifies a subset of Wilms 
tumor patients who have a significantly increased risk of relapse and death. LOH for 
these chromosomal regions can be used as an independent prognostic factor together with 
the disease stage, to determine intensity of treatment (Grundy et al, 2005b). 
Chromosome 16q LOH has been observed in about 17% of Wilms tumors (Maw et al, 
1992). 
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Figure 1.8 Wilms tumor pathogenesis. 
Wilms tumor pathogenesis can be classifed in 3 main setting: 
1. Loss of WT1 leading to intralobular nephrogenic rest (ILNR) followed by acquisition 
of activating mutation in the CTNNB1 gene and resulting in a stromal histology tumor 
(earlier onset) 
2. LOI of IGF2 leading to perilobular nephrogenic rest (PLNR) followed by other genetic 
lesion causing a blatemal/epitheliela tumor (later onset). 
3. Kidney develops normally and aquire genetic lesion in WT1 and WTX or WTX and 
mutation/deletion or IGF2 LOH that results in a typical triphasic histology Wilms tumor. 
All of these tumors can aquire an anaplastic histology. Mutation in p53 and loss of 
chromosomes lp and 16q are associated with the acquisition of this unfavorable 
histology. 
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1.2.11 Nephrogenic rests 
Wilms tumor is an embryonal tumor that originates from a progenitor cell lineage of the 
developing kidney. "Nephrogenic rests" refer to foci of persistent embryonal remnants 
that may be seen in normal newborns but are often seen in kidneys bearing Wilms 
tumours (Beckwifh et al, 1990). During normal kidney development, signals from the 
ureteric bud induce progenitor cells in the metanephric blastema to undergo 
mesenchyme-to-epithelium (MET) transition and form the epithelium of the nephron. 
Uninduced progenitor cells are committed to the alternative stromal cell fate. The pool of 
nephrogenic progenitor cells (metanephric blastema) is normally sustained throughout 
embryonic life but virtually disappears upon completion of renal development at 36 
weeks of gestation. Nephrogenic rests appear to represent foci of progenitor cells that 
have not been appropriately committed to one differentiation pathway or the other 
(Beckwith e? a/., 1990). 
Beckwith and colleagues identified two distinct precursor lesions that distinguish WT 
subtypes according to pathogenesis; the perilobar Nephrogenic Rest (PLNR) that is 
located at the edge of the renal lobes and the Intralobar Nephrogenic Rest (ILNR) that are 
situated within the lobe. PLNRs, often found in multiplicity, are thought to arise 
relatively late in renal development and are associated with Wilms tumors in the 
Beckwith-Widemann syndrome. In contrast ILNRs are usually solitary, arise earlier and 
are associated with WAGR and DDS syndromes (Beckwith, 1998; Beckwith et al, 
1990). Intriguingly, perilobar nephrogenic rests may be seen in up to 1% of newborns 
otherwise considered clinically normal at postmortem examination but are rarely seen in 
adults, suggesting that PLNRs may involute with age. In contrast, intralobar rests are 
rarely seen in normal infants at postmortem examination. In any case, the presence of 
nephrogenic rests within a kidney resected for a Wilms tumor indicates the need for 
monitoring the contralateral kidney for tumor development, particularly in young infants. 
A recent detailed analysis of 7500 nephrectomy specimens reveals that nephrogenic rests 
of one or the other type is present in the kidney in nearly 40% of the WT patients with 
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unilateral tumors and in virtually all cases associated with predisposition syndrome or 
bilateral tumor (Breslow et al, 2006). In addition, ILNR is frequently associated with 
WT having stromal histology, younger age of onset and genomic WT1 lesions. 
Conversely, WT associated with PLNR exhibits a blastemal/predominant histology and 
older age of onset. After adjusting for age of onset, no statistically significant difference 
in prognosis was found between the nephrogenic rest types associated with the tumor. 
Breslow and colleagues propose a refinement of Wilms tumor classification into three 
types according to nephrogenic rests: A) "ideal type I", accounting for about 20% of all 
WT, is characterized by early age of diagnostic, associated genito-urinary malformations 
and lesions in WT1 and CTNNB1 genes. B) "ideal type II" represents 20% of WT patients 
and is associated with PLNR, later age of onset and LOI at the IGF2 locus 1 lpl5; C) the 
most common group comprises 60% of WT and is not associated with a specific type of 
nephrogenic rest (Breslow et al, 2006). The specific link between Wilms tumor and 
nephrogenic rests remains unknown but underlines the connection between Wilms tumor 
and the pathways of embryonic kidney development. 
1.2.12 Wilms tumor as an aberration of normal nephrogenesis 
WT has long been considered a prototype for deranged cellular differentiation in cancer. 
The theory that WT arises from a pluripotent renal precusor cell is supported by its 
characteristic "triphasic" histology, which includes blastemal, epithelial and stromal 
components. In a triphasic tumor, the blastemal components are similar to the condensing 
nephrogenic mesenchyme; the epithelial components appear to recapitulate the 
mesenchyme-to-epithelium transition leading to nephrogenesis. Finally the stromal 
component of the triphasic tumor resembles the normal stromal renal cells but are 
thought to adopt an aberrant mesenchymal cell fate, giving rise to clusters of myogenic or 
adipose cells. Microarray gene-expression studies have shown that the gene expression 
profile of WT is similar to that of an 8-week human gestation developing kidney (Li et 
al, 2002a; Li et al, 2005a). Genes that are overexpressed in Wilms tumors include 
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PAX2, IGF2 and genes of the WNT canonical pathway. Hence the molecular lesions that 
are involved Wilms tumorigenesis disrupt pathways that are important for renal 
development. For example WT1 (mutated in 10-15% of WT) has a key role in the 
induction of ureteric branching and survival of the metanephric mesenchyme. The WNT 
canonical signalling pathway (aberrantly active in nearly 50% of WT) is critical for the 
induction of epithelial differentiation in the metanephric mesenchyme. Although its role 
remains to be elucidated, WTX (mutated in 30% of WT) is highly expressed in the 
embryonic kidney. 
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1.3 Kidney development 
1.3.1 Overview 
The kidney develops in three distinctive stages: the pronephros (with no known function), 
the mesonephros (the excretory organ of the embryo) and the metanephros (which 
becomes the permanent kidney). The early development of the metanephros is a complex 
process that involves highly regulated interactions between two derivatives of the 
intermediate mesoderm, the Wolffian duct and the metanephric mesenchyme (MM) 
(Figure 1.9). At approximately embryonic day 35-37 in humans (10.5-11 in mice) a 
caudal outgrowth of the Wolffian duct, known as the ureteric bud (UB), invades the 
adjacent metanephric mesenchyme. The mesenchymal cells surrounding the ureteric bud 
(collectively known as the nephrogenic mesenchyme) then condenses to form caps of 
closely associated cells that undergo a mesenchyme-to-epithelium transition (MET) to 
form the anlage of renal tubules, the comma-shaped and S-shaped bodies. These 
transitional structures givre rise to the glomerular podocytes and epithelia of proximal 
tubules, loop of Henle and distal tubules. At its distal end, each nephron fuses to the 
branching ureteric bud which forms the collecting-duct system. Stromal cells arise within 
the nephrogenic zone, but migrate inward to intercalate between tubules. Although many 
different transcription factors orchestrate each stage of kidney embryogenenesis, the 
paired box family PAX2 and PAX8 and the zinc-finger protein, WT1, play a central role 
throughout renal development (Bouchard, 2004; Dziarmaga et al, 2006). In addition, the 
canonical WNT pathway has an important function in nephrogenesis (Iglesias et al, 
2007). 
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1.3.2 PAX2/8 and WT1 in kidney development 
PAX2 and PAX8 are highly expressed by the nephric duct cells during the caudal descent 
of the Wolffian duct (Bouchard et al, 2000; Bouchard et al, 2002). Although 
homozygous Pax2 mutant mice initially form a mesonephric duct, its caudal decent is 
defective and rapidly degenerates and fails to reach the metanephric mesenchyme (Torres 
et al, 1995). As a result, the animals are anephric and lack genital tracts (Favor et al, 
1996; Torres et al, 1995). Pax8 is the earliest known gene expressed during development 
of the pronephros ((Bouchard et al, 2002; Dressier et al, 1990). Interestingly, kidney 
development is unaffected in Pax8 knockout mice, although these mice eventually die 3 
weeks after birth due to thyroid defects (Mansouri et al, 1998). Bouchard et al proved 
that there was significant functional redundancy between PAX2 and PAX8 (Bouchard et 
al, 2002; Narlis et al, 2007). At about 4 weeks fetal age in humans (and at E10.5 in the 
mouse), just before arriving at the cloaca, the nephric duct forms the ureteric bud. It 
grows laterally into the metanephric mesenchyme (MM) where it will induce the 
development of the metanephros by reciprocal interaction between the metanephric 
mesenchyme and the ureteric bud (UB). In the mouse Pax2 and Wtl are essential for the 
invasion of the UB into the MM (Brophy et al, 2001; Ereidberg et al, 1993). Although 
WT1 is not expressed in the nephric duct itself, it is expressed in the intermediate 
mesoderm that surrounds the nephric duct (Armstrong et al, 1993). Wtl knockout mice 
have no UB outgrowth and cells of the metanephric blastema undergo significant 
apoptosis (Kreidberg et al, 1993). Furthermore, these mice do not express PAX2 in the 
metanephric blastema (Kreidberg et al, 1993). 
High levels of WT1 (but not PAX2) are seen in cells of the proximal S-shaped body 
destined to become podocytes; in contrast the distal portion of the S-shaped body 
expresses high level of PAX2 (but not WT1). This part of the S-shaped body gives rise to 
tubular segments of the nephron including proximal and distal convoluted tubules. 
77 
Figure 1.9 Stages of kidney development and nephrogenesis. 
A) The invading UB in the MM, provides inductive signals that cause the mesenchymal 
cells in the proximity to condense around its tip, while others remain uninduced (blue). 
B) The induced comitted cells undergo a mesenchymal to epithelial transition, initially 
forming a renal vesicle. 
C) The renal vesicle progresses into a comma shaped-body. 
D) Progressed form the comma-shaped, the S-shaped body consists of two distinct 
portions, the distal region that express WT1 (but no PAX2) and the proximal regions that 
express PAX2 (but not WT1). The distal portion will fuse to the collecting duct, while the 
proximal portion will form the epithelial portion (podocytes) of the glomerulus. 
E) Tightly regulated proliferation and cellular differentiation continues until the final 
nephron structure is formed (Modified from (Cho EA, 2003). 
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1.3.3 The WNT canonical pathway in kidney development 
The canonical signaling pathway is activated by WNT-family glycoproteins, which bind 
to cognate frizzled receptors. Activated receptors recruit dishevelled protein (Dvl) and 
inhibit degradation of cytoplasmic beta-catenin via the GSK3beta-axin-APC complex. 
When its degradation is blocked, cytoplasmic beta-catenin is available to translocate to 
the nucleus, dimerize with partners belonging to the T-cell factor (TCF) family and 
activate target genes. In general, canonical beta-catenin/TCF signaling is thought to 
activate gene targets involved in cell proliferation (cyclin Dl, c-myc). In the metanephric 
kidney, intense canonical WNT signaling is present in epithelia of the branching ureteric 
bud and in nephrogenic mesenchyme during its transition into renal tubules (Iglesias et 
al, 2007). WNT signaling activity is rapidly downregulated in maturing nephrons and 
becomes undetectable in the postnatal kidney (Iglesias et al, 2007). Thus, it is likely that 
failure of mechanisms that normally suppress WNT signaling (or acquisition of 
constitutive activation of beta-catenin such as CTNNB1 mutation in Wilms tumor) will 
result in incomplete epithelial differentiation and aberrant cellular proliferation. 
1.3.4 Renal stem cells and cancer stem cell 
Typically embryonic progenitor cells have the ability of self-renewal, unlimited 
proliferation and multipotent differenatiation potential. The identification of somatic cells 
with similar "embryonic" properties in adult tissues has established the concept of 
somatic stem cells. In fact, tissue-specific stem cells have been found in many organs, 
including bone marrow, gastrointestinal mucosa, liver, brain, prostate and skin (Blanpain 
et al, 2007). These cells participate in the normal cell turnover of these organs and are a 
potential source of cells after organ injury. With regards to the kidney, stem cells exist in 
the metanephric mesenchyme during kidney development (Herzlinger et al, 1992; Oliver 
et al, 2002). During kidney development these mesenchymal stem/progenitor cells must 
be constantly renewed so that the kidney can continue to grow and induce additional 
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generations of nephrons. Once nephrogenesis is complete the stem cell population is 
significantly reduced and may be restricted to niches of dormant progenitors cells. 
Candidate stem cells have been identified in the adult kidney but the identity of the genes 
and mechanisms required to maintain this mesenchymal stem/progenitor cell population, 
remains to be clarified. 
Putative renal stem cells have been isolated using CD 133 as a surface marker which 
typically identifies progenitor cells in hematopoietic and neural tissues. Bussolati et al. 
reported that CD133-positive cells in the interstitium of the adult human kidney have 
characteristics of stem cells. Interestingly, these putative renal stem cells expressed 
PAX2, as well as several markers typical of bone marrow stromal cells, but were negative 
for hematopoietic cell markers such as CD34 or CD45. By using different culture 
conditions in vitro, the authors indicated that CD 133+ renal cells have the capacity to 
differentiate into either type of tubular cells demonstrating their pluripotency (Bussolati 
et al, 2005) 
Recently the identification of cancer stem cell provides an additional link between 
embryogenesis and tumorigenesis (Reya et al, 2001). Somatic stem cell are normally 
able to maintain their self proliferative capacity for the lifespan of the organism, without 
leading to the development of tumors. This probably might explain why these multipotent 
cells are typically sequestered in niches that to some extent insulate them from 
environmental stress susceptible to subvert their unlimited proliferative capacity towards 
the acquisition of a malignant phenotype (Pardal et al, 2005; Spradling et al, 2001). 
Nevertheless, since normal stem cells and cancer cells share the ability to selfrenew, it 
seems reasonable to predict that malignant growth might arise from the transformation of 
a stem cell (cancer stem cell theory). In is plausible that cancer cells utilize the gene 
machinery for self-renewing cell division that is normally expressed in stem cells. It 
follows that many of the molecular players involved in controlling developmental and 
stem cells self-renewal pathways are implicated in oncogenesis (Reya et al, 2001). 
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PAX genes that are expressed both by embryonic cell during development by tissue-
specific somatic stem in adult tissues; PAX gene aberrant expression have also been 
associated with the development of a variety of tumor thus providing a canonical 
illustration of this phenomenon (Robson etal, 2006). 
1.4 PAX genes in development and cancer 
1.4.1 Overview 
PAX (Paired Box) genes comprise a family of genes well conserved through evolution 
encoding for nine transcription factors that share the DNA binding paired-domain. 
The PAX genes are classified into sub-groups I F / (Table 1.5) according to which 
structural domain they can include (an octapeptide region and a homeodomain). During 
embryonic development, PAX genes expression is organ specific; PAX functions include 
cellular proliferation, cellular differentiation, migration and survival. Disrupting PAX 
gene function during embryonic development, results in abnormal development. 
Once organogenesis is completed PAX gene expression progressively declines and is 
restricted to organ specific progenitor cells in which they confer a self-renewal property. 
On the other hand, aberrant PAX gene expression is observed in a variety of cancers 
(summarized in Table 1.6) in which they have been associated with proliferation, 
resistance to apoptosis, metastasis and angiogenesis recapitulating all of the 
characteristics that define malignant growth (Robson et al, 2006). 
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Table 1.5 PAX genes structure, chromosomal location and human syndromes: 
The nine human PAX genes are organized according to groups (I to IV), based on their 
structural and functional homologies. All of these genes contain the "paired domain", 
while the octapeptide and the homeodomain are particular to specific groups. Both the 
human and mouse chromosomal locations are indicated, as are the human syndromes that 
have been associated with specific PAX gene mutations (Eccles et al, 2002). 
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Table 1.6 PAX genes expression and function in cancer: 
PAX genes, representing subgroups II (PAX2, PAX5 and PAX8) and III (PAX3 and 
PAX7) are frequently expressed in a variety of cancer. Rearrangements implicating, 
PAX3, PAX5, PAX7 and PAX8, are associated with characteristic chromosomal 
translocations that occur in specific tumors. PAX genes in subgroups II and III confer cell 
motility, cell survival and cell proliferation ability, which are often associated with 
tumour progression. On the other hand, PAX genes in subgroups I (PAX1 and PAX9) and 
IV (PAX4 and PAX6) are either less often involved in cancer or their expression is 
indicative of favourable prognosis, as observed for PAX6. (Robson et al, 2006). 
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1.4.2 PAX2 
1.4.2.1 Overview 
PAX2 is a transcription factor of the paired box family expressed throughout embryonic 
development in the central nervous system (CNS), the ear, the eye and the urogenital 
system. Pax2 mouse knockouts have further emphasized the importance of PAX2 
expression within these structures, since homozygous null mutants are lethal and fail to 
develop essential structures within the CNS, the ear and the urogenital system. Pax2+/-
mutant mice exhibit increased apoptosis in various organs, including the kidney. 
Although PAX2 plays a role in differentiation and proliferation, its main function seem as 
an anti-apoptotic molecule. 
1.4.2.2 Human Renal Coloboma Syndrome and the Pax2 mouse 
Renal-Coloboma Syndrome (RCS, OMEVI 120330) is a rare autosomal dominant 
condition, in which patients are affected by renal hypoplasia, ocular colobomas and 
vesico-ureteral reflux (Devriendt et al, 1998; Sanyanusin et al, 1995; Schimmenti et al, 
1997). Kidney hypoplasia is the principal feature of RCS and often leads to end stage 
renal failure, requiring a transplant (Cunliffe et al, 1998; Devriendt et al, 1998; 
Narahara et al, 1997; Schimmenti et al, 1997). RCS is associated with heterozygous 
PAX2 inactivating mutations(Sanyanusin et al, 1995). More than 10 different mutations 
have been identified but the most common mutation is an insertion of an extra guanine 
nucleotide in exon 2, causing a frame-shift and a nonfunctional truncated protein 
(Devriendt <?f al, 1998). 
Interestingly, this identical mutation occurs spontaneously in the (Pax21Neu) mouse (Favor 
et al, 1996). Pax2+/- mice have a 50% reduction of PAX2 protein; this PAX2 deficit 
significantly diminishes branching morphogenesis during fetal kidney development 
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resulting in renal hypoplasia (Porteous et at, 2000). Homozygous inactivation of the 
Pax2 gene is lethal and mice exhibit complete renal agenesis (Favor et at, 1996). 
1.4.2.3 Genomic structure of PAX2 
The PAX family of genes is classified into sub-groups according to homologies and PAX2 
is part of the PAX2/5/8 sub-family (Dahl et al , 1997). In humans, PAX2 is located on 
chromosome 10 within the boundaries of q24 and q25 (Narahara et al., 1997) and in mice 
it resides on chromosome 19. The Human PAX2 gene consists of 12 exons spanning over 
70 Kb of genomic DNA (Sanyanusin et al., 1996). The PAX2 gene encodes a 42k Da 
protein containing a paired domain, which mediates DNA binding, an octapeptide 
domain and a partial homeodomain. The first four exons code for the highly conserved 
paired box domain, while the fifth exon codes for the octapeptide domain (Sanyanusin et 
al., 1996). In humans and in mice, there are three exons that are alternately spliced; exons 
6, 10 and 12 (Sanyanusin et al., 1996), resulting in alternatively spliced PAX2 mRNAs. 
The function or the significance of these spliced isoforms remains to be determined. 
1.4.2.4 PAX2 expression during development 
During kidney development, PAX2 protein is one of the earliest transcription factors 
expressed. It is first seen in the pronephric duct and it is the first epithelial structure to 
form from the intermediate mesoderm. PAX2 expression continues in the mesonephric 
duct and tubules and finally in the Wolffian and Miillerian ducts. PAX2 is highly 
expressed in the metanephric kidney upon induction by the outgrowth and subsequent 
branching of the ureteric bud. Furthermore, PAX2 is expressed in the mesenchymal cells 
as they aggregate around the tips of the ureteric bud and it persists during formation of 
the comma and S-shaped bodies. During nephron formation, PAX2 is restricted to the 
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distal part of the S-shaped body, closest to the point of fusion with the ureteric bud, 
PAX2 is conspicuously absent in maturing WT1(+) podocytes of the glomerulus. Once 
nephrogenesis is complete, PAX2 is progressively attenuated to a relatively low level 
characteristic of adult kidneys (Eccles et al., 1992). 
In the brain, PAX2 is expressed early, starting at embryonic day 7.5, within the 
organizing center at the midbrain-hindbrain boundary (MHB), (Rowitch & McMahon, 
1995). As development proceeds, the PAX2 expression domain becomes restricted to a 
central narrow ring at the MHB (Rowitch & McMahon, 1995). This region specifies the 
posterior midbrain and cerebellum (Rowitch & McMahon, 1995). Absence of PAX2 
results in an absence of the midbrain and cerebellum. 
PAX2 is also expressed in both the developing eye and ear. During the development of 
the inner ear, PAX2 is first expressed in the optic placode and then becomes limited to 
the ventral region of the optic vesicle responsible for generating the structures of the 
saccule, the cochlea and spiral ganglia of the auditory nerve (Puschel et al., 1992) 
Homozygous mutant Pax2 mice do not form any of these structures; massive apoptosis is 
observed in the spiral ganglion cells (Torres et al., 1995). During eye development, 
PAX2 is detected at embryonic day 9 in the optic vesicle. Later PAX2 marks the optic 
cup, the optic fissure and the optic stalk, which subsequently becomes the optic nerve 
(Puschel et al., 1992). In Pax2 mutants, the optic fissure fails to close, resulting in a 
coloboma and there is an extension of the pigmented retina into the optic stalks. 
1.4.2.5 PAX2 function during development 
PAX2 is required for the development of the urogenital system. Although homozygous 
Pax2 mutants initially form a nephric duct, the cells undergo apoptosis and no further 
urogenital structures are formed (Torres et al., 1995). PAX2 has been linked directly to 
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regulation of programmed cell death. Animals with heterozygous Pax2 mutations have 
increased ureteric bud cell death with resultant renal hypoplasia (Porteous et al., 2000). 
Expression of the pro-apoptotic gene Baxa, under control of the Pax2 promoter, 
increased apoptosis in the ureteric tree and markedly inhibited the extent of branching 
morphogenesis, reproducing the kidney phenotype of the Pax2+/- mouse and validating 
apoptosis as a mechanism underlying renal hypoplasia (Dziarmaga et al., 2003) . 
Reciprocally, the renal hypoplasia of the Pax2+/- mouse can be rescued either by 
suppressing apoptosis pharmacologicaslly with the caspase-inhibitor Z-vad-fmk or 
genetically by crossing Pax2+I- mutants with a mouse expressing the anti-apoptotic bcl2 
within the PAX2 expression domain (Clark et a l , 2004; Dziarmaga et al., 2006). Finally, 
NAIP (Neuronal Inhibitor of Apoptosis) has been identified as a direct downstream target 
of PAX2 in developing kidney (Dziarmaga et al., 2006). NAIP belongs to the IAP family 
and is an inhibitor of caspases-3 and 7, the final effectors of the apoptosis process. These 
observations provide one mechanism by which PAX2 exerts its anti-apoptotic function 
(Dziarmaga et al., 2006). 
PAX2 has also been associated with abnormal cellular proliferation and renal cystic 
diseases (Winyard et al., 1996). Constitutive overexpression of Pax2 in transgenic mice, 
leads to renal cyst formation, indicating that attenuation of Pax2 expression is important 
for proper differentiation (Dressier et al., 1993). Reciprocally, in polycystic kidney 
mouse models, reduction of Pax2 gene dosage resulted in a decrease in cyst size (Ostrom 
et al., 2000). 
Although PAX2 is important for the mesenchyme-to-epithelial transtion during 
neophrogenesis, PAX2 must be downregulated for proper podocyte maturation (Wagner 
et al, 2006). Ectopic PAX2 expression in the podocyte of transgenic mice leads to 
abnormal podocyte differentiation and glomerular dysplasia with end-stage renal failure 
soon after birth (Wagner et al, 2006). 
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1.4.2.6 PAX2 expression in cancer 
Expression of PAX2 has been observed in kidney cancer including Wilms Tumor (WT) 
and Renal Cell Carcinoma (RCC) (Daniel et al, 2001; Dressier and Douglass, 1992; 
Eccles et al, 1992; Khoubehi et al, 2001). PAX2 is also expressed in prostate (Khoubehi 
et al, 2001), ovarian (Tong et al, 2007), endometrial and bladder cancers (Muratovska et 
al, 2003; Wu et al, 2005). In addition, breast tumors, (Gibson et al, 2007; Silberstein et 
al, 2002), Kaposi sarcoma (Buttiglieri et al, 2004) and leukemia (Siehl et al, 2003) 
have also been shown to overexpress PAX2. 
PAX2 expression has been detected in at least 25% of tumor samples in a large screening 
of over 400 primary tumors of all types (Muratovska et al, 2003). More specific studies 
have observed expression of PAX2 in 40-53% of lobular or ductal breast carcinomas 
(Silberstein et al, 2002). Similarly, PAX2 is expressed in 52% of primary prostatic 
cancers (Khoubehi et al, 2001), but more strikingly, PAX2 is expressed in all 
histological renal tumor subtypes except transitional cell carcinomas. In particular PAX2 
is expressed in 90% of clear cell RCC, the major histological subtype and virtually all 
papillary RCC. Moreover, PAX2 expression correlates with proliferation index and is 
significantly higher in patients with metastatic disease (Daniel et al, 2001) PAX2 
expression in renal tumors has been verified and validated by several studies as a reliable 
marker of renal neoplasms (Mazal et al, 2005; Memeo et al, 2007; Tong et al, 2006). 
The mechanism by which PAX2 is reactivated in neoplastic tissues is not well 
understood. However, a recent study suggests that mis can occur through 
hypomethylation of the PAX2 promoter (Wu et al, 2005). The PAX2 promoter is 
normally methylated and therefore silenced in normal adult endometrial cells, but loss of 
PAX2 promoter methylation is found in 75% of endometrial carcinomas (Wu et al, 
2005) 
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1.4.2.7 PAX2 function in cancer 
Cell survival: 
Mutatovska et al. used small interfering PAX2 RNAs to silence PAX2 expression in 
bladder and ovarian cancer cells and showed that this caused inhibition of cell 
proliferation and increased apoptosis, confirming the previous finding by Gnarra et al 
(Gnarra and Dressier, 1995; Muratovska et al, 2003). Similarly, inhibition of PAX2 in 
prostate cancer cell lines and Karposi sarcoma results in cancer cell apoptosis. Although 
PAX2 can repress p53 expression the mechanism for PAX2-mediated protection from 
cell death in cancer cells is unknown (Stuart et al, 1995). Inhibition of PAX2 in prostate 
cancer results in apoptosis that is not dependent on p53 (Gibson et al, 2007). 
Apoptosis: 
Transfection of antisense PAX2 into Kaposi sarcoma cells results in enhanced cell death 
following serum deprivation or vincristine treatment (Buttiglieri et al., 2004). PAX2 
expression has been associated with decreased levels of PTEN and increased levels of 
phosphrylated Akt in endothelial cells, but it is unclear whether this mechanism is 
applicable in other cancers (Fonsato et al., 2006). 
Metastasis: 
PAX2 expression correlates with the presence of metastatic disease in RCC (Daniel et al, 
2001). In Karposi sarcoma PAX2 levels correlate with cellular motility and levels of the 
alphaVbeta3 integrin, known to be involved in tumor invasion (Buttiglieri et al, 2004). 
Angiogenesis: Introduction of PAX2 in normal endothelial cells conferred to these cells a 
preinvasive, proangiogenic phenotype similar to that of tumor-derived endothelial cells 
(Fonsato et al, 2006). Conversely, the inhibition of PAX2 in tumor endothelial cells 
results in a decreased apoptosis resistance associated with reduced angiogenesis in vivo 
(Fonsato et al., 2006). The inhibition of PAX2 in tumor-derived endothelial cells 
increased the level of the tumor suppressor PTEN decreased AKT phosphorylation. This 
suggests that angiogenesis is associated with PAX2 expression which antagonizes PTEN, 
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thereby activating the Akt-survival pathway to promote angiogenesis (Fonsato et at, 
2006). 
Tumorigenicity: Transfection of HEK293 cells with PAX2 enabling them to grow in 
xenograft transplants under the skin of nude mice, suggesting a transforming effect of 
PAX2 (Maulbecker & Gruss, 1993). Conversely, PAX2 knockdown in endometrial tumor 
cells result in decreased growth of tumor xenografts in nude mice (Wu et al, 2005). 
Nevertheless, overexpression of PAX2 in transgenic mice results in cystic kidneys but 
not in renal cancer, suggesting that PAX2 by itself is not sufficient to transform renal 
cells. 
1.4.3 PAX3 
1.4.3.1 Overview 
PAX3 is expressed in the developing embryo and is a critical factor for the proper 
formation of the mammalian nervous, cardiovascular and muscular systems. In the 
mouse, a spontaneous heterozygous mutation of Pax3 results in a coat pigmentation 
(splotch) defect; in humans, haploinsufficiency of PAX3 is associated with the 
Wardenburg syndrome (deafness, pigmentation defects, neural crest-related abnormalities 
and variable limb myopathy). In adult tissues, PAX3 expression is restricted to a pool of 
progenitor cells such as satellite muscle cells. Aberrant PAX3 expression can be observed 
in sarcomas and neural crest-derived tumors. Cellular proliferation, migration and 
apoptosis resistance have been attributed to PAX3 but the most well-established role for 
PAX3 involves its function in self-renewal of progenitor cells for myogenic and neural 
crest lineages. 
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1.4.3.2 The Splotch Mouse and the Waardenburg syndrome 
A spontaneous murine Pax3 mutation was first described by Auerbach in 1954 and was 
termed splotch because the mice exhibit a distinctive white belly spot (Goulding et al, 
1993). The Paxil- homozygous splotch mouse dies by day E14.5 due to cardiovascular 
defects. In addition, limb musculature is absent and numerous neural crest derivatives are 
abnormal, including dorsal root ganglia, melanocytes and enteric ganglia (Epstein et al., 
1993; Epstein et al, 2000). Mutations leading to the Splotch phenotype affect the PAX3 
paired homeodomain, resulting in complete loss of PAX3 function (Epstein et al, 1991). 
In humans, PAX3 mutations cause Waardenburg Syndrome (WS) type I and III (OMEVI 
193500 and 148820) (Baldwin et al, 1992; Tassabehji et al, 1992). WS is the most 
common cause of congenital sensorineural deafness and accounts for 2-3% of all 
congenital hearing disorders. First described by the Dutch ophthalmologist, Petrus 
Waardenburg, in 1951, affected patients also exhibit variable degrees of facial 
dysmorphology, myopathy and pigmentary abnormalities (Waardenburg, 1951). Dystopia 
canthorum, a lateral displacement of the eyes, is a feature of type III Waardenburg 
Syndrome and I. In addition, patients with type III WS or Klein-Waardenburg syndrome 
are characterized by muscle hypoplasia. Interestingly, type II Waardenburg Syndrome is 
not caused by PAX3 itself but by a mutation in a PAX3 target gene of the transcription 
factor MITF (Bondurand et al, 2000). Hearing loss, pigmentation defects and 
heterochromia (different colored eyes irises) are related to neural-crest related defects. 
WS is inherited as an autosomal dominant trait. More than 50 different PAX3 mutations 
have been identified in patients with Waardenburg Syndrome including missense, 
nonsense, frameshift, splicing and deletion mutations (Read & Newton, 1997). 
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1.4.3.3 Gene structure 
PAX genes are clustered in sub-groups according to homologies and PAX3 is part of the 
PAX3/7 sub-family (Dahl et al, 1997)]. In humans, PAX3 is located on chromosome 2q 
and in mice it resides on chromosome 1 (Eccles et al, 2002). PAX3 has two DNA 
binding domains, an amino-terminal 120 amino acid "paired" domain (PD) characteristic 
of the PAX family and a "paired-type" homeodomain (HD). In addition, PAX3 has a 
conserved octapeptide and a proline-serine-threonine rich C-terminal trans-activation 
domain, both of which are involved in protein-protein interactions (Apuzzo et al., 2004; 
Apuzzo and Gros, 2006). The paired domain is encoded by exons 2-4, while exons 5 and 
6 encode the octapeptide and homeodomain. Exons 7 and 8 encode a proline-serine-
threonine-rich transactivation domain, while exons 8-10 encode the c-terminal domain. 
(Li et al, 2007; Parker et al, 2004; Wang et al., 2007; Wang et al., 2006; Wang et al., 
1998). 
At least seven isoforms (PAX3a-h) resulting for alternative splicing have been identified 
(Li et al., 2007; Parker et al., 2004; Wang et al., 2007; Wang et al., 2006; Wang et al., 
1998). PAX3a and PAX3b are composed of exons 1 to 4 only and therefore lack the 
homeodomain and the carboxyl-terminal transactivation domain. In terms of distribution, 
PAX3b is almost ubiquitously expressed while most PAX3a expression is restricted to 
the cerebellum and skeletal muscle (Tsukamoto et al, 1994). The PAX3c transcript 
extends to a secondary splice site within intron 8. PAX3d proceeds from the primary 
splice sites from exon 8 to exon 9. The functional DNA binding and transactivation 
properties of PAX3c and PAXd are comparable in vitro (Barber et al, 1999). PAX3e 
contains exons 8, 9 and 10 but lacks introns 8 and 9. PAX3g and PAX3h are truncated 
isoforms of PAX3d and PAX3e, respectively, but also both lack part of the 
transactivation domain encoded by exon 8 (Parker et al, 2004; Wang et al, 2007; Wang 
et al, 2006). Functional analysis further indicated that these isoforms have different 
activities in stably transfected mouse melanocytes in vitro (Wang et al., 2007; Wang et 
al., 2006). 
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There is very strong sequence conservation between mouse Pax3 and human PAX3 
(Goulding et al, 1991). Mouse and human PAX3 protein are 98% homologous (Lalwani 
et al, 1995; Macina et al, 1995). The first cloned murine Pax3 cDNA contained an open 
reading frame of 1437 bp over eight exons and was predicted to encode a protein of 479 
amino acids with a molecular weight of 56 kDa (Pax3c) (Barber et al, 1999; Goulding et 
al, 1991) (Goulding et al 1991 and Barber et al). Alternatively spliced murine Pax3 
isoforms analogous to the human isoforms have been reported. Interestingly, Pritchard et 
al. identified isoform Pax3g (Pax3 A8) in murine myoblasts. PAX3g shows weak 
transcriptionally activity in vitro and inhibits PAX3d (PAX3 -8i) activity in myoblasts, 
presumably by competing for PAX3d binding sites (Pritchard et al, 2003). In addition, 
murine Pax3a and PAX3b differ by die presence or absence of a glutamine residue in the 
linker region between the third and fourth alpha helix of the paired DNA-binding domain 
(Vogan et al, 1996). These two isoforms have distinct DNA-binding properties (Vogan 
& Gros, 1997). 
1.4.3.4 Expression during development 
PAX3 is expressed in the developing hindbrain, mesencephalon and prosencephalon 
where it invariably remains confined to die ventricular zone of die developing central 
nervous system. PAX3 expression becomes restricted to die dorsal neural tube, where 
neural crest cells are specified (Goulding et al, 1991). Neural crest cells represent a 
multipotent population of migratory cells that give rise to die entire peripheral nervous 
system; to melanocytes, enteric ganglia (a subpopulation of vascular smooth muscle), 
bone, cartilage of me face and to various other cell types. In die peripheral nervous 
system development, PAX3 is expressed in the dorsal root and sympathetic ganglia 
(Kioussi et al, 1995). Accordingly the dorsal root ganglia are small or absent in Splotch 
embryos. Pax3-/- mice exhibit malformation of me trigeminal (Vtii cranial nerve), 
superior (IX) and jugular (X) ganglia. (Tremblay et al, 1995). Several reports suggested 
tiiat PAX3 is required for proper neural crest migration(Conway et al., 1997), mis may 
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involve survival of neural crest precursors as they move toward peripheral targets 
(Conway et al, 2000; Epstein et al, 2000). 
Homozygous Splotch embryos display persistent truncus arteriosus. The vessel fails to 
divide into proximal aorta and the pulmonary artery (Conway et al, 1997a).This failure 
of outflow tract septation in Splotch is almost certainly because of a defect in cardiac 
neural crest cell migration. Indeed neural crest cells normally contribute to the outflow 
tract and also differentiate into smooth muscle that contributes to the great vessels 
(Epstein et al, 2000; Kirby et al, 1983). 
PAX3 plays a central role in developing skeletal muscle (Maroto et al, 1997; Tajbakhsh 
et al, 1997). PAX3-deficient embryos exhibit skeletal muscle defects and transgenic 
rescue experiments have demonstrated a requirement for PAX3 in development of the 
diaphragm and limb musculature (Li et al, 1999). PAX3 is initially expressed widely in 
the presomitic mesoderm, but then its expression becomes restricted to the hypaxial 
domain of the somite. Myoblasts migrating from the lateral somites express PAX3 and 
take up residence in the ventral body wall, limbs and diaphragm (Ordahl & Le Douarin, 
1992). As fetal muscles mature, PAX3 expression attenuates in parallel with the 
appearance of myogenic markers such as MYOD (Daston et al, 1996; Tremblay et al, 
1998; Williams and Ordahl, 1994). However, PAX3 expression is maintained in a 
selective population of satellites cells (muscle progenitor cells) residing under a basal 
lamina that forms around the muscle fibers. (Relaix et al, 2006; Relaix et al, 2005). 
1.4.3.4 PAX3 function during development 
Cell survival: 
A striking feature of Pax3-mutant embryos is the loss of the hypaxial dermomyotome, 
which is due to apoptosis (Borycki et al, 1999). In addition, the introduction of dominant 
negative forms of PAX3 into cultured satellite cells increases cell death, demonstrating 
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that PAX3 is required for progenitor cell survival in postnatal muscle (Buckingham and 
Relaix, 2007; Relaix et al, 2006). 
Cell migration: 
In myogenic precursors, PAX3 activates transcription of several target genes, among 
which are MyoD and c-Met (Birchmeier and Brohmann, 2000). The latter codes for a 
cell-surface receptor which mediates delamination of myoblast precursors from the 
epithelial dermomyotome and their migration in the limb bud. This occurs in response to 
hepatocyte growth factor/scatter factor (HGF/SF) ligand (Relaix et al, 2003). 
In neural crest derivatives, PAX3 also activates the c-Ret gene. This gene encodes a 
receptor that interacts with GDNF (glial cell-derived neurotrophic factor), which is 
secreted by mesenchymal cells that surround the enteric ganglia, thus determining their 
location (Lang et al, 2000; Lang and Epstein, 2003; Lang et al, 2005). 
Cell fate: 
PAX3 is required for the proper differentiation of neural crest and myogenic progenitor 
cells (Conway et al, 1997b; Relaix et al, 2004). PAX3 controls myogenic cell fate 
through the myogenic determination factors Myf5 and MyoD; for Myf5, in the embryo, 
this can involve direct transcriptional control (Bajard et al, 2006; Maroto et al, 1997) 
PAX3, when overexpressed in cultured neural tube explants, can induce ectopic MyoD 
expression (Maroto et al, 1997). However, PAX3 protein expression seems to be 
associated with an intermediate precursor cell of the myogenic lineage. After the initial 
increased level of expression, PAX3 protein level is downregulated as the cells become 
committed myoblasts and this decline is necessary for terminal myogenic differentiation. 
This is why introduction of PAX3 can actually inhibit myogenic differentiation of 
myoblast cells (Epstein et al, 1995). 
In the skin, PAX3 is thought to function at a nodal point in melanocyte stem-cell 
differentiation (Lang et al, 2005). PAX3 determines melanocyte stem-cell fate by 
triggering expression of microphthalmia-associated transcription factor (Mitf), essential 
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for initiation of melanogenesis. Meanwhile PAX3 simultaneously represses other 
melanogenic differentiation genes, such as dopachrome tautomerase (Dei), thereby 
maintaining melanoblasts in an early pre-differentiated state (Lang et al, 2005). Similar 
to the process of myogenic stem cell differentiation, PAX3-expressing melanoblasts 
remain undifferentiated until PAX3-mediated repression is relieved by beta-catenin 
signaling that it permits melanocyte differentiation(Lang et al, 2005). 
It is important to emphasize that PAX3 expression is necessary for the initial 
commitment toward differentiation and that PAX3 downregulation is also necessary for 
terminal differentiation. Levels of PAX3 protein are regulated by ubiquitination and 
proteasomal degradation. Remarkably, one amino acid (lysine 475) at the C-terminal 
region of PAX3 appears to be critical, rendering PAX3 susceptible to ubiquitination and 
subsequent proteasomal degradation (Boutet et al, 2007). 
The PAX3 gene has been termed the "Pan" gene (after the Greek god Pan - or the fictional 
character, Peter Pan) because of ability of PAX3 to orchestrate cell fate commitment 
while simultaneously preventing differentiation (Lang et al, 2005). 
PAX3 contributes to stem cell properties: 
Stem cells are defined by both their self-renewal properties and their ability to give rise to 
differentiated progeny. PAX3 expression is characteristic of at least two populations of 
progenitor cells. Skeletal muscle progenitor (satellite) cells have been isolated by flow 
cytometry from Pax3GFP/+ mice (Montarras et al, 2005). Satellite cells are the major 
myogenic progenitor cell population and can efficiently carry out skeletal muscle repair 
and also undergoes self-renewal (Montarras et al, 2005). In addition, PAX3 is expressed 
by putative melanocyte stem cells within the hair follicle. These cells are pluripotent and 
exhibit self-renewal (Real et al, 2006). 
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1.4.3.5 PAX3 expression in cancer 
PAX3 expression has been reported in sarcomas such as embryonal rhabdomyosarcoma 
(ERMS) (Bernasconi et al, 1996), alveolar rhabdomyosarcoma (ARMS)(Barr et al, 
1993), and Ewing sarcoma (Schulte et al, 1997). In addition, PAX3 is expressed in some 
neural-crest-derived tumors including melanomas (Scholl et al, 2001) and 
neuroblastomas (BarretaL, 1999). 
ARMSs are characterized by chromosomal translocations involving juxtaposition of 
PAX3 (or PAX7) and the forkhead transcription factor gene, FKHR. These translocations 
are associated with t(2;13) and yield a chimeric PAX3-FKHR fusion protein in 55-73% 
of cases. However, ERMS may also show increased PAX3 (or PAX7) expression in the 
absence of the PAX3-FKHR chimeric protein (Bernasconi et al, 1996). PAX3 is 
expressed in primary melanomas (Scholl et al, 2001). In addition, PAX3 expression in 
sentinel lymph nodes indicates poor prognosis in patients with melanoma (Takeuchi et 
al, 2004). 
It is important to mention that certain PAX3 isoforms are preferentially expressed in 
certain tumor cell types. For example PAX3c and PAX3d are predominantly expressed in 
melanoma and small-cell lung cancer. PAX3d protein was noted in some melanoma 
patients, indicating that PAX3d is a melanoma-specific isoform while PAX3g and 
PAX3h isoforms predominate in neuroblastomas (Kwang et al, 2002). Incidentally, the 
expression of PAX3a, PAX3b and PAX3e are low or undetectable in these tumors (Wang 
et al, 2007). Overall, the PAX3d protein is the predominant isoform expressed in cancer 
(Wang et al, 2007). 
1.4.3.6 Function in cancer 
Cell survival: 
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Inhibition of PAX3 expression with antisense PAX3 oligonucleotides, triggers apoptosis 
in either ERMS or melanoma cell lines (Bernasconi et al, 1996; Scholl et al, 2001), 
suggesting that PAX3 is required for canc(Wang et al, 2006)er cell survival (He et al, 
2005). PAX3 and PAX3-FKHR proteins activate transcription of the anti-apoptotic gene, 
BCL-XL (Margue et al, 2000). Like PAX2, PAX3 also activates the Akt pathway by 
inhibiting PTEN (Li et al, 2007). In melanocytes, the isoforms PAX3c, PAX3d, PAX3g 
and PAX3h showed a protective effect against basal or etoposide induced apoptosis in 
vitro(Wang et al., 2006). 
Cell proliferation: 
Growth rate is increased growth rate in melanocytes transfected with PAX3c, PAX3d and 
PAX3h compared to control cells (Wang et al, 2006). An interaction between PAX3 and 
the retinoblastoma tumor suppressor Rb have been suggested and could provide a 
molecular link between PAX3 and control of the cell cycle(Wang et al, 2006; Wiggan et 
al, 1998). 
Cell migration: 
PAX3 in sentinel lymphe node has been validated as a bad prognosis factor and 
metastatic disease (Takeuchi et al, 2004). In vitro scratch assays showed that PAX3c, 
PAX3d and PAX3h increased melanocyte migration (Wang et al, 2006). Activation of 
MET receptors by PAX3 may be responsible for increased cellular migration and 
metastasis. 
Tumorigenicty: 
In anchorage-independent growth assays, PAX3c, PAX3d, PAX3g or PAX3h expression 
in melanocytes confer the ability to grow in soft agar, whereas PAX3a-, PAX3b-, 
PAX3e-expressing melanocytes and vector control cells fail to form colonies. This 
suggests that PAX3 expression may transform cells. However, in vivo there is still no 
evidence that PAX3 is sufficient for tumorigenesis. It has been suggested that Pax3 
overexpression might not be responsible tumorigensis itself but instead account for the 
acquisition of characteristics that define malignancy (Robson et al, 2006). 
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1.5 Research aims 
The aim of my doctoral work has been to refine the understanding of PAX gene function 
during kidney development and to test the hypothesis that PAX genes may be used as 
potential therapeutic targets in renal cancer. 
During normal kidney development, PAX2 exerts a powerful anti-apoptotic function in 
epithelial structures but its expression is strongly attenuated during the post-natal period. 
On the other hand, PAX2 expression is observed in all subtypes of renal cell carcinoma 
(RCC). I hypothesized that the anti-apoptotic function of PAX2 is highjacked by renal 
carcinoma cells and contributes to their resistance to chemotherapy. My specific aim is to 
demonstrate that PAX2 overexpression in renal cancer cells confers resistance to 
apoptosis induced by cisplatin and to show that inhibition of PAX2 sensitizes RCC cells 
to cisplatin-induced apoptosis. A second aim is to develop an in vivo model of 
subcutaneous RCC tumours in nude mice to test the proof of principal that PAX2 
knockdown increases the effect of cisplatin therapy. 
Until recendy, PAX2 and PAX8 were considered to be the only PAX genes expressed in 
the developing kidney. However Englenka and colleagues unexpectedly identified 
transcriptional activity of the Pax3 promoter in urogenital derivatives of the embryonic 
mouse. Although these observations suggest that PAX3 is expressed during normal 
kidney development it could also be due to artificial reporter signal in the transgenic 
mice. Hence my third specific aim has been to characterize the pattern of PAX3 
expression in fetal mouse kidney embryo and to determine whether it may be relevant to 
the fate of a specific cell lineage. 
Since PAX3 is known to regulate cell fate of migrating myoblasts during normal muscle 
development, I hypothesized that it might play an important role in Wilms tumor with a 
myogenic phenotype. PAX3 has been implicated in other cancers such as 
rhabomyosarcoma but has never been investigated in Wilms tumors in the past. My final 
specific aim has been to examine PAX3 expression in a panel of Wilms tumor tissues and 
develop insight into how it might contribute to the tumor phenotype. 
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CHAPTER II: PAX2 as a therapeutic target for renal cancer 
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PAX2 as a therapeutic target for renal cancer 
2.1 Overview: 
All major subtypes of Renal Cell Carcinoma (RCC) express PAX2; the level of PAX2 
protein correlates with aggressive tumour behaviour and increased proliferation index. 
For patients with RCC, an effective therapeutic strategy remains elusive due to the 
resistance of this cancer to current chemotherapeutic agents. 
Part I: PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma 
cells. 
The first part of this work demonstrates that PAX2 expression confers apoptosis 
resistance of renal cell carcinoma cells to cisplatin. The central hypothesis is that PAX2 
expression contributes to the resistance of Renal Cell Carcinoma to chemotherapy. We 
show that inhibition of PAX2 in vitro sensitized RCC cells to cisplatin-induced apoptosis. 
These findings have been published in Kidney International in April 2006. 
Part II: In Vivo validation of PAX2 as a target for renal cancer therapy. 
Building on our in vitro finding we demonstrate in vivo that silencing of PAX2 gene 
expression in RCC cells enhances cisplatin-induced apoptosis and inhibits growth of 
subcutaneous RCC xenografts in nude mice. This last part of my work has been 
published in Cancer Letters in April 2008. 
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PAX2 inactivation enhances cisplatin-induced apoptosis in renal 
carcinoma cells 
Pierre-Alain Hueber, Paula Waters, Patsy Clark, Michael Eccles and Paul Goodyer 
Kidney International (2006) 69, 1139-1145 
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2.1.1 ABSTRACT 
Human embryonic kidney 293 cells transfected with a PAX2 expression vector and 
exposed to cisplatin (40 |iM) exhibited 45+/-15% as much caspase-3 cleavage compared 
to control cells. Conversely, murine collecting duct cells stably transfected with PAX2 
antisense cDNA had twofold increase in cisplatin-induced apoptosis. Murine fetal 
(embryonic day 15) kidney explants from Pax21Nm+/- mice exposed to cisplatin (25 |iM 
x24 h) had 50% increased apoptosis (terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling staining). We then show that RCC cells (CAKI-1 (human, 
Caucasian, kidney, carcinoma) and ACHN (human, Caucasian, kidney, adenocarcinoma)) 
express PAX2 protein. PAZ2-small interfering RNA (lOOnM) reduces endogenous PAX2 
protein (10% of baseline) and induces apoptosis (Annexin-V staining). PAX2 knockdown 
sensitized RCC cells to cisplatin-induced apoptosis, killing 50-60% of cisplatin-resistant 
ACHN and CAKI-1 cells. These findings suggest that PAX2 confers resistance to 
cisplatin-induced apoptosis in non-transformed kidney cells and fetal kidney explants. 
Similarly, PAX2 overexpression in RCC cells contributes to cisplatin resistance. 
Conceivably, a therapeutic strategy that inactivates PAX2 in vivo might enhance the 
efficacy of conventional cytotoxic drugs against RCC. 
103 
2.1.2 INTRODUCTION 
It is estimated that over 30,000 people in the United States have renal cell carcinoma 
(RCC); over 10,000 RCC-related deaths occur each year [1]. Only 40% of patients have 
disease confined to the kidney at the time of diagnosis and nearly 25% of patients present 
with symptoms of metastatic lesions. With current therapy, the one-year survival of 
patient with metastatic RCC is less than 50% [2]. This resistance of RCC to conventional 
medical therapy remains the primary obstacle to survival and makes the development of 
new therapeutic strategies imperative. 
Cisplatin is among the most widely used and most effective chemotherapeutic agents for 
many types of human cancer. Cisplatin is thought to act through direct binding to DNA 
causing cisplatin-DNA adducts. If cisplatin-DNA adducts are not efficiently processed by 
the cellular repair mechanism, the pathway of programmed cell death is initiated [3]. 
Molecular mechanisms, which subvert these pro-apoptotic signals, are thought to account 
for resistance of tumours to chemotherapy [4,5]. 
In some malignancies, resistance to apoptosis has been attributed to overexpression of 
genes encoding endogenous inhibitors of apoptosis (IAPs) [6-8], but the specific cause 
for the high resistance of RCC to therapy is unknown. 
During normal kidney development, the transcription factor, PAX2, is expressed both in 
the ureteric bud and mesenchymal cell lineages. We have recently shown that PAX2 
functions to suppress programmed cell death during nephrogenesis; PAX2 gene 
mutations cause increased apoptosis of ureteric bud cells with resultant renal hypoplasia 
[9-12]. Once nephrogenesis is complete, however, renal PAX2 expression is rapidly 
downregulated and is barely detectable in the mature kidney. On the other hand, PAX2 is 
inappropriately re-expressed in a variety of cancers — particularly in renal cell carcinoma 
[13-15]. 
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Thus, the powerful anti-apoptotic function of PAX2 might contribute to the resistance of 
renal cell carcinoma cells to chemotherapy. If so, inhibitors of PAX2 expression might 
enhance programmed cell death in RCC, enhancing the efficacy of chemotherapeutic 
agents such as cisplatin. 
In this report, we demonstrate that transfection of PAX2 cDNA into a human fetal kidney 
cell (HEK293) line confers resistance to cisplatin-induced apoptosis. Conversely, we 
show that inhibition of PAX2 using antisense cDNA enhances cisplatin-induced 
apoptosis of a murine collecting duct cell (IMCD) and that cisplatin-induced apoptosis is 
increased in fetal kidney explants from heterozygous PAX2meu mutant mice. Similarly, 
we show that small interfering RNAs (siRNA) can be used to inhibit PAX2 expression in 
two RCC cell lines (ACHN and Caki-1) derived from clear cell carcinomas and that 
PAX2 siRNA enhances apoptosis and cell death of cisplatin-resistant RCC cells. 
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2.1.3 RESULTS 
2.1.3.1 PAX2 confers resistant to cisplatin-induced apoptosis in non-transformed 
kidney cells 
To evaluate whether PAX2 inhibits cisplatin-induced apoptosis in human fetal kidney 
cells, we stably transfected the HEK293 cell line with an expression vector containing 
full-length human PAX2b cDNA (or empty vector as control). Endogenous PAX2 protein 
was not detectable in HEK293 cells transfected with the empty expression vector or in 
the parental HEK293 cell line. However, as shown in Figure 2.1.1A, PAX2 protein was 
highly expressed in the HEK-293/PAX2 transfectants, providing an opportunity to 
examine the effects of aberrant PAX2 overexpression on cell survival. 
HEK293/PAX2 and control HEK293 cells were exposed to cisplatin (40uM) and assayed 
for activation of caspase-3 at 24 hours. HEK293/PAX2 cells exhibited only 45% as 
much caspase-3 activation as controls in response to cisplatin (Figure 2.1.1B). 
2.1.3.2 Reduced endogenous PAX2 expression increases susceptibility to cisplatin-
induced apoptosis in renal collecting duct cells 
To examine the effect of PAX2 inactivation on susceptibility to apoptosis, we utilized a 
cell line (EVICD) derived from murine renal collecting duct. EVICD cells were chosen 
because the collecting duct lineage is known to express high levels of endogenous PAX2 
protein (Figure 2A). EVICD cells were stably transfected with a CMV-driven expression 
vector containing a full-length antisense hPAX2b cDNA. Stable transfectants 
(EVICD/PAX2-AS) showed significant reduction of Pax2 protein levels (30% of controls) 
(Figure 2.1.2A). These cells were cultured in the presence or absence of 40|nM cisplatin 
and assayed for caspase-3 activation after 24 hours. In preliminary dose-response studies, 
we found that caspase-3 activation (cleavage) at 24 hours climbs with increasing cisplatin 
concentration, peaks at 40uM and then falls off at higher concentrations as cell necrosis 
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ensues (data not shown). In the absence of cisplatin, low basal levels of apoptosis were 
equivalent in IMCD/PAX2-AS and control IMCD cells. However, in the presence of 
cisplatin (40uM), activation (cleavage) of caspase-3 was twofold higher in EVICD/PAX2-
AS transfectants compared to control EVICD cells (Figure 2.1.2B). 
2.1.3.3 Reduced PAX2 expression in heterozygous mutant (Pax eu) mice increases 
susceptibility of fetal kidney explants to cisplatin 
To demonstrate that genetically reduced Pax2 expression increases apoptosis induced by 
cisplatin, whole fetal kidneys (El5) were isolated from wildtype and heterozygous 
mutant PAX21Neu mice and placed in explant culture as previously described [12]. 
Following exposure to cisplatin (25|0.M) for 24h, explants were processed for TUNEL 
immunohistochemistry. Untreated apoptosis in wildtype explants was only slightly lower 
than El5 Pax21Neu kidney explants (Figure 2.1.3). However, in the presence of cisplatin, 
the intensity of TUNEL staining per unit cross-sectional area was increased 9-fold above 
the untreated baseline in mutant explants, compared to an increase above baseline of only 
5-fold in wildtype explants (p<0.01, mutant vs wildtype) (Figure 2.1.3). 
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Figure 2.1.1.PAX2 expression confers resistance to cisplatin-induced apoptosis. 
Human embryonic kidney cells (HEK293) lacking endogenous PAX2 were stably 
transfected with hPAX2 cDNA to generate the HEK293/PAX2 cell line with elevated 
PAX2 protein expression (A). HEK293 control and HEK293/PAX2 cell lines were 
exposed to cisplatin (40)J,M) and assessed for caspase-3 activation (cleavage) at 24h (B). 
Bar graphs represent the mean and SD of three experiments (each experiment was 
performed in triplicate); HEK293/PAX2 versus HEK293 control, * p< 0.01. 
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Figure 2.1.2. Reduced PAX2 expression sensitizes IMCD cells to cisplatin. 
1MCD cells were stably transfected with a vector containing a full-length antisense 
hPAX2b cDNA. Stable transfectants (EVICD/PAX2-AS) (third lane) had reduced levels 
of PAX2 protein compared to untransfected IMCD cells (first lane) or EvlCD/empty 
vector cells (second lane) by Western immunoblotting (A). The cells were treated with 
cisplatin (40(xM). The sensitivity to cisplatin-induced apoptosis was assessed by assay of 
caspase-3 activation (cleavage) at 24h (B). The bar graph represents the mean and SD of 
three experiments (each experiment was performed in triplicate); HVICD/PAX2-AS 
versus IMCD control, *p< 0.01. 
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Figure 2.1.3. Genetic reduction of PAX2 increases susceptibility to cisplatin-induced 
apoptosis. 
Whole fetal kidneys were microdissected from E15 Pax21Neu mutant (N=18 kidneys) and 
wildtype (N=10 kidneys) mice and cultured at 37°C for 30h. Half of the explants from 
each group were treated with cisplatin (25jiM) in the culture medium for 24h. Apoptosis 
was measured by TUNEL-staining and quantified using Northern Eclipse software 
(staining intensity per mm2). Cisplatin caused a 9-fold increase in apoptosis in the 
Pax21Neu explants, but only a 5-fold increase in wildtype explants (*p<0.01). 
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2.1.3.4 SiRNA-inactivation of endogenous PAX2 induces apoptosis in RCC cells 
To demonstrate endogenous PAX2 expression in RCC cells, we assessed the 43-kDa 
PAX2 protein band intensity on Western immunoblots of ACHN and CAKi-1 cell lines 
derived from human clear cell carcinomas. Both cell lines exhibited high levels of 
endogenous PAX2 protein (Figure 2.1.4A/B). 
In order to inhibit endogenous PAX2 protein expression, the cells were exposed to a pool 
of four PAX2 siRNAs (25nM each) for 24h or 48h. PAX2 protein levels fell 
progressively with increased exposure time and by 48 hours were nearly undetectable in 
CAKI-1 cells and reduced to 15% of baseline in ACHN cells. (Fig.4A/B) 
To assess whether PAX2 suppression induces apoptosis in RCC cells, ACHN and CAKI-
1 cells were exposed to lOOnM siRNAs or control medium for 24 hours and 48h. Cells 
undergoing apoptosis were then detected by fluorescent annexin-V staining in situ 24h 
and 48h post transfection (Figure 2.1.5/6). For CAKI-1 cells, exposure to PAX2 siRNAs 
resulted in 20.5 % and 38.6% annexin (+) cells after 48 hours compared to 6.8% 
annexin(+) cells exposed to nonspecific control siRNAs. Similarly, ACHN cells exposed 
to PAX2 siRNAs showed 15% and 31.7% annexin(+) cells at 24 and 48 hours 
respectively vs 5% annexin(+) cells with nonspecific control-siRNAs (p<0.001) (Figure 
2.1.5/6).The effect of PAX2 siRNAs was specific to cells expressing endogenous PAX2 
since the siRNAs had no effect on survival of HEK-293 cells (data not shown). 
2.1.3.5 Effect of PAX2 siRNA and cisplatin on RCC cell survival and apoptosis is 
additive 
We examined whether PAX2 inactivation might add to the cell death caused by cisplatin 
exposure in vitro. CAKI-1 and ACHN cells were treated with PAX2 siRNAs or control-
siRNAs for 24h, followed by exposure to various doses of cisplatin (10-160 fimol/L) for 
a further 24h. The effect of combined treatment on cell viability was assessed at 48h as 
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above and expressed as a percent of untreated cells. Addition of PAX2 siRNAs to 
cisplatin-treated cells significantly reduced survival of CAKI-1 cells compared to control 
siRNA-treated cells: 62.2% v.s 37% (cisplatin = 10|0,mol/L); 42.21 v.s 26.8% (cisplatin = 
20|imol/L); 25.2% v.s 15.5% (cisplatin = 40|imol/L), respectively (Fig 7). Similarly, 
exposure of ACHN cells to PAX2 siRNAs killed 80% vs 42.8% (cisplatin = 10umol/L); 
61.4 v.s 34.7% (cisplatin = 20|J,m/L) and 45% v.s 22% (cisplatin = 40[tmol/L) of 
cisplatin-resistant cells, respectively (Figure 2.1.7A/B). The level of apoptosis of RCC 
cells in response to the combined treatment was analyzed by annexin V staining in situ. 
Treatment with cisplatin (10-40uM) plus PAX2 siRNAs (25nM each) resulted in a 
percentage of cells undergoing apoptosis equivalent to the sum of the individual 
treatments (Figure 2.1.7C/D). 
2.1.3.6 Therapeutic cell death of the combined treatment with PAX2-siRNA and 
cisplatin is caspases dependent 
To demonstrate that the effects of iMZ2-siRNA and cisplatin on RCC cell survival are 
mediated by the caspase pathways of programmed cell death, we analyzed the effect of a 
broad caspase (caspase 3,5,7) inhibitor (Z-VAD-fmk). The combined cytotoxicity of 
cisplatin and PAX2-siRNAs was >90% inhibited by concurrent exposure to 25|J,mol/L Z-
VAD-fmk (Figure 2.1.8). 
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Figure 2.1.4. Endogenous PAX2 protein expression by CAKI-1 and ACHN renal 
carcinoma cells is suppressed by PAX2-siRNA. 
Endogenous expression of 42kDa PAX2 protein was confirmed by Western 
immunoblotting for both CAKi-1 (A) and ACHN (B) RCC cell lines from the NCI60 
panel. Cells were seeded at 105 cells/ml in 24-well plates and exposed to PAX2 siRNAs 
or control siRNAs (lOOnM) added to media with lipofectamine-2000 according to the 
manufacturer's protocol. PAX2 protein level was assessed by Western immunoblotting 
after 24h and 48h treatment. 
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Figure 2.1.5. Inhibition of PAX2 induces apoptosis of Renal Cell Carcinoma cell 
lines. 
CAKI-1 and ACHN cells were treated with lOOnM PAX2 siRNA or control siRNA 
(Dharmacon). Apoptosis was measured by counting the percentage of cells which were 
annexin-V positive after 24h and 48h. The bar graph represents the mean and SD for 
three experiments (each experiment was performed in triplicate); PAX2-siRNA versus 
siRNA-control, *p<0.01. 
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Figure 2.1.6. Annexin V staining. 
Immunocytochemical staining for annexin V in PAX2-siRNA treated cells vs Control-
siRNA treated cells after 24h. ACHN (A) and CAKI-1 (B) were stained with anti-annexin 
V fluorescent (green) antibody, and with 4',6-diamidinophenylindole (DAPI) (blue). 
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Figure 2.1.7. RCC cell death caused by PAX2 siRNA and cisplatin are additive. 
The viability of CAKI-1 (A/C) and ACHN (B/D) cells was assessed after 24h of cisplatin 
exposure and 24h pre-treatment with PAX2 siRNAs or control-siRNAs. Cell survival was 
measured by colorimetric assay of cellular dehydrogenase activity and expressed as a 
percentage of that in untreated cells. PAX2-siRNA versus siRNA-control, *p< 0.01. 
116 
A 
CAKI-1 
-^-Control siRNA 
-A-PAX2 siRNA 
Lipofectamine 
20 40 80 
Cisplatin uM 
B 
„120% 
| 100% 
I 80% 
I 60% 'H 
> 40% -! 
_ 20% 1 
o 
0% 
10 20 40 
Cisplatin uM 
-•-Control siRNA 
-A-PAX2 SiRNA 
Lipofectamine 
80 160 
CAKI-1 
80% 
£ 60% 
> 40% 
c 
< 20% H 
•control-siRNA 
DPAX2-siRNA 
0% 
rh 
10 20 
Cisplatin uM 
40 
D 
ACHN 
•Control siRNA 
80%H DPAX2 siRNA 
»• 60% 
I 
> 40% 
< 20% 
0% 
10 20 
Cisplatin uM 
m 
40 
Figure 2.1.8. Combined killing induced by PAX2 inhibition plus cisplatin is caspase-
dependent. 
CAKI-1 and ACHN cells were treated with 25^iM Z-VAD-fmk, a broad caspase 
inhibitor. After 4h, PAX2 siRNAs or Control siRNAs were added to the media. At 24h, 
cells were exposed to cisplatin 30fxmol/L. The effect of Z-VAD-fmk on the combined 
cytotoxicity of cisplatin and PAX2-siRNAs was measured by colorimetric assay of 
cellular dehydrogenase activity at 48h. For each cell line, PAX2-siRNA plus cisplatin 
significantly lowered cell survival versus siRNA-control (*p< 0.01) but cell survival was 
fully restored to control levels in the presence of Z-VAD-fmk (**p<0.01). 
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2.1.4 DISCUSSION 
We have recently shown that PAX2 suppresses apoptosis in the ureteric bud lineage 
during nephrogenesis [10]. By suppressing programmed cell death, PAX2 facilitates 
efficient branching of the ureteric bud and optimizes the final nephron number [9,12]. 
However, once nephrogenesis is complete, renal PAX2 expression is rapidly 
downregulated and is barely detectable in mature kidney [Cohen J T et al. Pediatric 
Academic Societies, annual meeting San-Francisco CA, abstract 3276, 2004]. In a variety 
of cancers - particularly in renal cell carcinomas - there is inappropriate re-expression of 
PAX2 [12,14,17]. 
Since PAX2 normally exerts a powerful anti-apoptotic function during development, we 
reasoned that it might have the same (but undesirable) effect on renal carcinoma cells, 
contributing to their relative resistance to chemotherapy (RCC). 
Cisplatin has been used as an anticancer therapy for many years and its cytotoxic mode of 
action is primarily mediated by its interaction with DNA to form platinum-DNA adducts 
[5]. Cisplatin interaction with DNA induces several signal transduction pathways, 
including those involving p53, p73, caspases, cyclins, CDKs, pRb, PKC, MAPK and 
PI3K/Akt, and eventually results in the activation of apoptosis [3]. Possible mechanisms 
of resistance to cisplatin include reduced intracellular accumulation of cisplatin, 
enhanced drug inactivation and increased repair activity of DNA damage. However, since 
cisplatin cytotoxicity is mediated through the pathways of programmed cell death, 
mechanisms which block these pathways might also contribute to cisplatin resistance [3]. 
While PAX2 clearly suppresses basal apoptosis in developing kidney, the molecular 
mechanism underlying this phenomenon is not yet known. To determine whether the 
developmental effects of PAX2 can be generalized to cisplatin-induced apoptosis, we 
transfected human fetal kidney cells with a PAX2 expression vector in the presence or 
absence of cisplatin. PAX2 was as effective in suppressing apoptosis associated with 
cisplatin exposure as it is in other settings [10]. Similarly, we were able to show a 
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protective effect of PAX2 on cisplatin-induced apoptosis in normal murine fetal kidney 
explants. Other investigators have reported that PAX2 enhances resistance of endothelial 
cells to vincristine-induced apoptosis [18]. Taken together, these observations suggest 
that PAX2 influences core components of the programmed cell death pathway in normal 
cells, independent of the pro-apoptotic stimulus. 
We identified significant levels of Pax2 protein in RCC cell lines (CAKI-1 and ACHN). 
Initial efforts to inhibit PAX2 with antisense oligonucleotides were met with limited 
success. However, we found that PAX2 RNAi powerfully inhibited Pax2 protein 
expression and significantly increased basal apoptosis in RCC cells. Furthermore, 1/3 of 
RCC cells resistant to cisplatin were killed by exposure to the PAX2 siRNA. Our results 
extend previous observations suggesting that PAX2 affects basal RCC cell survival in 
vitro [17]. 
Recently, direct infusion of siRNA into the tail vein of mice selectively inhibited renal 
Fas protein and mRNA expression and Fas-mediated apoptosis following ischemic injury 
to the kidney [19]. Similarly it has been shown that injection of siRNA into the jugular 
vein could functionally silence vasopressin V2 receptors in the mouse kidney [20]. It is 
conceivable, therefore, that a PAX2 siRNA could be delivered successfully into the 
kidney in vivo. Although PAX2 function is critical during embryogenesis, PAX2 levels 
fall to nearly undetectable levels in normal adult kidney. Thus, PAX2 inhibition should 
preferentially affect cancer cell viability with minimal or no effect on normal adult tissue. 
RCC cells are relatively resistant to programmed cell death but the molecular mechanism 
is not well understood. Recent studies indicate that neither Bcl-2 nor Bax-cc expression 
influence progression of RCC. On the other hand, the level of an endogenous caspase 
inhibitor, XIAP, correlates with decreased patient survival of patients with clear cell 
carcinoma, suggesting a possible role for this family of molecules [21-26]. Interestingly, 
preliminary observations by Dziarmaga et al suggest that PAX2 may activate 
transcription of another IAP, the neural apoptosis-inhibitory protein (NAIP) [Dziarmaga 
A et al. Proceedings, International Pediatric Nephrology Association Workshop, 
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Adelaide, p64, 2004], but the importance of NAIP in regulation of renal cell apoptosis 
has not been established. 
PAX2 expression is aberrantly re-expressed in a variety of cancers including prostate, 
breast, leukemia and Wilms tumor [27-32]. In adults, all major subtypes of renal cell 
carcinoma express PAX2 and the level of PAX2 protein correlates with aggressive 
tumour behaviour and increased proliferation index [3,15]. This observation suggests 
PAX2 could also serve as a prominent tumor marker for patient with renal cell carcinoma 
and as a potential candidate for targeted molecular therapy for a variety of non-renal 
cancers. 
For patients with renal cell carcinoma, an effective therapeutic strategy remains elusive. 
The overall response rate of RCC patients to current anticancer agents (including 
cisplatin) is only 10-20% [5]. Our findings suggest that strategies to inactivate aberrant 
PAX2 expression in tumour tissue might be used in combination with standard anticancer 
drugs to enhance therapy of RCC. 
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2.1.5 METHODS 
Cell culture 
The two human RCC cell lines (ACHN and CAKI-1 cells) selected from the NCI-60 
cancer cell panel, were obtained from the American Type Culture Collection (Rockville, 
MD) and maintained as adherent monolayer cultures in RPMI culture medium (Life 
Technologies,Carlsbad CA), supplemented with 10% fetal bovine serum (Life 
Technologies). 
SiRNA mediated inactivation of PAX2 
RCC cells were transfected with a commercially available pool of 4 double-stranded 
small interfering RNAs (siRNAs) targeting PAX2 (siPAX2smart po01 Dharmacon cat # M-
003307-00-05) mRNA (Accession NM_000278) or a pool of control siRNAs (siControl 
Dharmacon cat # D-001206-13-20).AU siRNAs were duplexed, desalted, 2' deprotected 
and purified (>80%) by Dharmacon Inc. (Dharmacon, CO, USA). Cells were seeded at 
105 cells/ml in 24-well plates. PAX2 siRNAs or the control siRNAs (lOOnM) were added 
to media using a lipophilic transfection reagent according to the manufacturer's protocol 
(Lipofectamine 2000, Invitrogen Inc., Carlsbad, CA, USA). 
Western Immunoblotting 
A total of 30 ng of protein extracted from each transfected cell population was resolved 
on 10% sodium dodecyl sulfate-polyacrylamide gels 100V for 1.5 h at 4°C, and then 
transferred over 1 hour at 100V (4°C) onto polyvinylidene difluoride membranes (Bio-
Rad,Mississauga ON). Blots were probed with polyclonal anti-PAX2 antibody (Zymed, 
San Francisco, CA) followed by anti-rabbit IgG secondary antibody and detected with an 
enhanced chemiluminescence detection system (Amersham, Piscataway, NJ). Membranes 
probed for PAX2 were reprobed for 6-actin (Oncogene Research Products, San Diego, 
CA) to normalize for loading differences and to allow comparisons between transfected 
and untransfected cell populations. Band intensities were quantified using an image 
acquisition system (Imaging Research, St. Catharines ON). 
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Stably transfected cell lines 
HEK293/hPAX2 cells were stably co-transfected with a neomycin resistance vector and a 
CMV-driven expression plasmid containing the full-length human PAX2b cDNA as 
previously described [16]. IMCD cells, derived from the murine collecting duct lineage, 
were co-transfected with a neomycin resistance vector and a CMV-driven expression 
vector containing a full-length antisense human PAX2b cDNA. Stably transfected clones 
were selected in media containing neomycin. 
Culture of whole fetal kidney explants 
Kidneys were microdissected from wildtype and heterozygous mutant PAX21Neu El5 
embryos and cultured at 37°C as previously described [9,12]. These mice express about 
half the normal amount of Pax2 protein in fetal kidney [9,12]. At the end of the 30 hours 
culture period, explants were fixed in 4% formaldehyde for 1 hour and then transferred to 
60% ethanol. 
TUNEL staining 
The in situ cell death detection POD kit (Roche Diagnostics, Laval, QC) was used to 
detect apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick-end 
labelling (TUNEL) in serial sagital sections of paraffin-embedded wild-type and 
PAX2lNen mutant kidneys as previously described [12]. TUNEL-stained sections of fetal 
mouse kidney were examined by light microscopy and Spot Advanced digital imaging 
software. The images obtained (magnification 40x) were analyzed using Northern Eclipse 
software to generate a value representing the percent of TUNEL (+) cells per cross-
sectional surface area (mm2) covered by a user-defined threshold of TUNEL staining 
intensity. All quantification of apoptosis was done blindly and without knowledge of the 
genotype or treatment status. 
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Caspase-3 assay 
The caspase-3 substrate Ac-DEVD-AFC (BD Pharmingen San Jose, CA) was used in 
caspase-3 assays according to the manufacturer's instructions. 100 [ig of cell lysate was 
added to the reaction buffer (20 mM HEPES, pH 7.4, 100 raM NaCl, 10 mM 
dithiothreitol, 0.1% CHAPS, 10% sucrose) containing 125 u.M of Ac-DEVD-AFC in a 
lml cuvette. Fluorescence of the cleavage product was measured using a Luminescence 
Spectrometer LS50 (Perkin Elmer Fremont, CA). 
Annexin-V staining 
The percentage of cells undergoing programmed cell death was measured by double 
staining with fluorescein-conjugated annexin V and DAPI. Cells were washed and 
exposed to a solution containing 20 \i\ of Annexin-V-Fluos (Roche Diagnostic Systems, 
Mannheim Germany) according to the manufacturer's protocol. The cells were then 
washed and exposed to DAPI (lug/ml) (Roche Diagnostic Systems, Mannheim, 
Germany) for 15 minutes at 37°C. The percentage of annexin(+) cells were determined 
with a fluorescence microscope (Axioscope; Zeiss, Jena, Germany). 
Cell viability assay 
The cell viability kit (CCK-8, Dojindo Molecular Technologies Inc, Gaithersburg, MD) 
was used according to the manufacturer's protocol. Z-VAD-fmk was obtained from 
Calbiochem (Darmstadt, Germany). 
Statistical analysis 
Each experiment has been repeated 3 times. Means and SD have been calculated for all 
the independent experiments. In each experiment, differences in means were tested for 
significance using the Student t-test. 
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2.2.1 ABSTRACT 
PAX genes are frequently overexpressed in human cancer tissue and appear to contribute 
to the tumor phenotype, suggesting that they may be potential targets for cancer therapy. 
In particular, aberrant PAX2 expression has been reported in a high proportion of primary 
tumors, including the majority of Renal Cell Carcinomas (RCC). We recently 
demonstrated that PAX2 suppresses cisplatin-induced apoptosis in cultured RCC cells. 
We hypothesized that silencing of PAX2 expression might partially overcome the 
notorious resistance of renal cell carcinomas to chemotherapy in vivo. In this report, we 
show that a PAX2 shRNA successfully knocks down PAX2 mRNA and protein levels in 
an RCC cell line (ACHN). ACHN cells stably transfected with shRNAs targeted against 
the PAX2 homeodomain are 3-6-fold more susceptible to cisplatin-induced caspase-3 
activation than control ACHN cells line. Furthermore, growth of subcutaneous 
ACHN/shPAX2 xenografts in nude mice is significantly more responsive to cisplatin 
therapy than control ACHN cell tumors. Our observations validate PAX2 as a potential 
therapeutic gene target in renal cancer and suggest that adjunctive PAX2 knockdown may 
enhance the efficacy of other chemotherapeutic agents. 
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2.2.2 INTRODUCTION 
Paired box (PAX) transcription factors are critical regulators of normal embryogenesis 
but generally exhibit oncogenic properties when aberrantly expressed in adult tissues. 
The aberrant re-expression of PAX proteins is observed in a variety of cancers including 
leukemia, breast, prostate, kidney and bladder carcinoma [2, 3]. As a result, PAX proteins 
have become a hallmark of malignant cells, suggesting that they might be potential 
therapeutic targets for cancer gene therapy. 
During normal kidney development PAX2 is highly expressed in cells of both the 
condensing mesenchyme and the ureteric bud lineages but expression is sharply 
suppressed in the perinatal period as new nephron formation comes to an end [4]. 
Heterozygous PAX2+I- mutations cause renal hypoplasia (Renal-Coloboma Syndrome) 
and increased apoptosis of the ureteric bud, suggesting an anti-apoptotic function of 
PAX2 during nephrogenesis [5]. PAX2 expression is observed in 90% of clear cell Renal 
Cell Carcinomas (RCC); this is the most common subtype of RCC and PAX2 expression 
is associated with a metastatic phenotype [6-8]. 
RCC accounts for approximately 3% of all cancer cases worldwide [9]. Metastatic 
disease is present at the time of diagnosis in one third of patients and, since RCC cells are 
notoriously resistant to chemotherapy, the prognosis is poor. The one-year survival in 
patients with advanced metastatic RCC is less than 50%[9]. Thus, the development of 
novel therapeutic strategies bypassing resistance is imperative. 
We have recently shown that the anti-apoptotic function of PAX2 contributes to the 
resistance of RCC cells to chemotherapy in vitro; inhibition of PAX2 expression by small 
interfering RNAs (siRNAs) in cultured RCC cells enhances programmed cell death 
induced by cisplatin [10]. In this report, we provide in vivo proof of principle that PAX2 
knockdown sensitizes RCC tumours to cisplatin. RCC cells, stably transfected with an 
shRNA expression vector targeting PAX2, were tested in a nude mouse xenograft model. 
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2.2.3 RESULTS 
2.2.3.1 Stable knockdown of PAX2 mRNA and protein in ACHN cells 
Knockdown of PAX2 expression in ACHN cells was achieved using a vector-based small 
hairpin RNA (shRNA) strategy. shRNA constructs targeted against PAX2 mRNA were 
inserted into pRNATin-H1.2 expression vector bearing a GFP marker (Figure 2.2.1A/B). 
shRNA constructs were stably transfected into ACHN cells and selected with neomycin 
for 4 weeks. Individual neomycin-resistant, GFP-positive clones were expanded for 
characterization. Out of 5 constructs that were initially screened, two PAX2 shRNA 
constructs (shPAX2-l and shPAX2-2) were able to inhibit PAX2 expression efficiently 
(Figure 2.2.1A/B). 
To identify clones with efficient PAX2 knockdown, the PAX2 transcript was measured by 
QRT/PCR in pooled clones generated from each construct (Figure 2.2.2A). 
ACHN/shPAX2 clones expressing shPAX2-l and shPAZ2-2 reduced PAX2 mRNA levels 
to 40% and 20%, respectively, in comparison to control ACHN cells stably transfected 
with empty vector (ACHN/shvector) (Figure 2.2.2A). None of the control clones derived 
from the ACHN cell line (ACHN/shvector) differed from the parental cell line in terms of 
PAX2 mRNA expression level (Figure 2.2.2B). 
To confirm that PAX2 mRNA knockdown correlates with reduced PAX2 protein levels, 
Western immunoblotting was performed on the individual clones derived from each 
construct. Control (ACHN/shvector) clones showed no reduction of PAX2 protein 
compared to the parental ACHN cell line. Individual clones transfected with either 
shPAX2-l or shPAX2-2 showed a significant reduction in PAX2 protein (Figure 2.2.2 
C/D). In half (3/6) of the ACHN/shPAX2-l clones, PAX2 protein levels were reduced to 
<20% of controls (Figure 2.2.2C). More than 70% (5/7) of the clones generated with the 
shPAX2-2 construct showed nearly complete knockdown of PAX2 protein. The 
remaining 2 clones showed an intermediate but significant decrease of PAX2 protein 
levels. 
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Figure 2.2.1 Diagram of Pax2 shRNA construct. 
A) Pax2 shRNA sequences targeting the human Pax2 mRNA (Accession number 
NM_00278) were selected using GeneScript software; B) two shRNAs were inserted into 
pRNATin-H1.2 plasmids. 
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A 
PAX2 shRNA insert 
sequence sense loop antisense 
shPAX2-1 TCATTGGAGGCGCTGGAAACA TTGATATCCG TGTTTCCAGCGCCTCCAATGA 
shPAX2-2 TAACCAGGCAGAGTGGTGCTC TTGATATCCG GAGCACCACTCTGCCTGGTTA 
B 
PAX2 shRNA 
c G F P \ \ 
pRNATin-H1.2/neo 
6127 bp 
Figure 2.2.2 Stable knockdown of PAX2 mRNA and protein in ACHN cells 
expressing shRNA constructs. 
A) Quantitative RT-PCR demonstrates that clones expressing shPAX2-l and shPAX2-2 
reduced mRNA level to 40% and 20% respectively of control ACHN cells stably 
transfected with empty vector, respectively. B) Western immunoblots show no reduction 
of PAX2 protein compared to parental cell line in ACHN cells stably transfected with 
empty vector. C/D) Individual clones transfected with shPAX2-l or shPAX2-2 show 
significant reduction in PAX2 protein 
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2.2.3.2 Stable knockdown of PAX2 sensitizes ACHN cells to cisplatin-induced 
caspase-3 activation. 
To determine whether PAX2 inhibition confers increased susceptibility to cisplatin-
induced apoptosis, two ACHN/shPAX2 clones (shPAX2-23 and shPAX2-2.1) with 
reduced PAX2 expression (Figure 2.2.2C/D) were selected. PAX2 mRNA knockdown 
was confirmed in these two clones by RT-PCR (Figure 2.2.3A). Apoptosis was measured 
by assessing caspase-3 activation compared to control ACHN shvector and ACHN 
parental cell lines. After exposure to cisplatin (50uM) for 24 hours, the shPAX2-2.3 and 
shPAX2-2.1 clones exhibited 3-6 fold greater activation of caspase-3 compared to control 
cell lines (Figure 2.2.3B). 
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Figure 2.2.3: Stable knockdown of PAX2 sensitizes ACHN cells to Caspase-3 
induced by treatment with cisplatin. 
A) Two ACHN clones (shPAX2-2.3 and shPAX2-2.1), selected after Western 
immunoblot screening, were analyzed by RT-PCR to confirm significant PAX2 mRNA 
knockdown. B) After exposure to cisplatin (50uM for 24 hours), these clones exhibited 3-
6 fold greater activation of caspase-3 compared to control cell lines. 
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2.2.3.3 PAX2 knockdown in ACHN tumor xenografts enhances the anti-tumor 
growth effect of cisplatin in nude mice. 
To validate PAX2 as a potential therapeutic target in vivo, we examined subcutaneous 
tumor growth of ACHN/shPAX2 xenografts in a nude mouse model. Nude mice were 
injected subcutaneously with control (ACHN/shvector) or ACHN/shPAX2-2.1 clones (5 
million cells) and monitored for external tumor volume every 2 days (Figure 2.2.4A). 
Measurable tumors appeared after a lag period of 15 days. At 21 days, ACHN/sliPAX2 
and ACHN/shvector tumor volumes were not significantly different (p > 0.05). Similarly, 
ACHN/shvector tumor growth was comparable to tumours arising from ACHN parental 
cell lines (data not shown). On day 21, mice were injected intra-peritoneally (i.p.) with 
PBS or cisplatin (2 mg/kg). This cisplatin dose was determined in preliminary studies to 
achieve a measurable effect on tumor volume. 
Over the subsequent week, untreated tumors arising from ACHN/shPAX2 cells and 
control ACHN/shvector cells grew rapidly and, by day 27, were not significantly 
different in size (tumor volume = + 200% and 186% of baseline at day 21, respectively) 
(p>0.05) (Figure 2.2.4A). Cisplatin treatment of control ACHN/shvector tumors slowed 
growth rate somewhat from day 21 to 27 compared to the untreated mice (tumor volume 
= 140% of baseline), but did not induce tumor regression. In contrast, cisplatin treatment 
of mice with ACHN/shPAX2-2.1 tumors showed a striking reduction in tumor growth 
rate; tumor volume fell by 10% from day 21 to 25 (Figure 2.2.4A). The effect of 
cisplatin treatment was also expressed as a ratio of treated (T) to untreated (C) tumor 
volumes (%) (Figure 2.2.4B). The therapeutic effect of cisplatin measured by T/C was 
significantly enhanced in shPAX2-2.1 cells compared to empty shvector controls 
(p=0.008, paired t-test), suggesting a synergistic effect of PAX2 inhibition and cisplatin 
chemotherapy. 
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Figure 2.2.4 Effect of PAX2 knockdown on the growth of ACHN tumor xenografts 
in nude mice treated with cisplatin. 
A) Nude mice were injected subcutaneously with control (empty vector) or shPAX2-2.1 
ACHN clones (5 million cells) and monitored for external tumour volume every 2 days. 
Each point represents the mean tumor volume (+/- standard deviation) in each 
experimental group (n=6 mice). Measurable tumour appeared after a lag period of 15 
days. On day 21, mice were injected with cisplatin (2 mg/kg). Over the subsequent week, 
tumours from the ACHN shPAX2-2.1 clone showed a significant reduction in growth (-
10% of baseline) compared to tumours arising from control ACHN cells transfected with 
empty shvector (+ 180% of baseline) or compared to untreated tumours. 
B) Effect of cisplatin was also expressed as the ratio of treated (T) to untreated (C) 
tumour volume (%). The therapeutic effect of cisplatin was significantly enhanced in 
shPAX2-2.1 cells compared to empty shvector controls (p=0.008, paired t-test). 
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2.2.4 DISCUSSION 
Renal cell carcinoma (RCC) is the most common cancer of the kidney. Recurrent 
tumours develop in almost 50% of patients treated for localized disease. The striking 
resistance of RCC to chemotherapy is, to a large extent, attributable to suppression of 
programmed cell death pathways normally activated by chemotherapeutic agents [9]. 
Renal cancer cells escape apoptosis by a number of mechanisms including the 
overexpression of anti-apoptotic genes such as XIAP [12-14]. Thus, adjunctive therapies, 
which inactivate the anti-apoptotic responses of tumour cells, might enhance the efficacy 
of primary chemotherapeutic agents. 
Over 90% of RCC cells express the developmental transcription factor PAX2. We 
previously reported that knockdown of PAX2 in RCC cells by transient transfection of 
pooled siRNAs enhances basal and cisplatin-induced apoptosis in vitro. In this study, we 
developed shRNAs to achieve stable knockdown of PAX2 in subcutaneous tumours 
derived from RCC cells. Our aim was to provide in vivo proof of principle that this 
strategy sensitizes RCC tumours to chemotherapeutic agents such as cisplatin. In initial 
experiments, we screened a panel of potential shRNA sequences for efficient PAX2 
knockdown; two shRNAs targeting the PAX2 homeodomain were found to reduce PAX2 
mRNA and protein significantly when stably transfected into RCC cells. Since the 
ACHN/shiMX2.1 clone showed the greatest reduction of PAX2 mRNA and increased 
both basal and cisplatin-induced apoptosis, it was chosen for our in vivo studies. 
Interestingly, RCC cells transfected with shPAX2.l were able to form subcutaneous 
tumours in nude mice, despite substantial knockdown of PAX2. This contrasts somewhat 
with the observation that PAX2 overexpression promotes tumorigenicity of endometrial 
cancer cells in nude mice compared to the parental ECC-1 cell line that was unable to 
form subcutaneous tumors [15]. Conceivably, PAX2 is necessary to permit the initial 
oncogenic program in endometrial cancer, but once transformation has occurred, its 
suppression does not restore the normal phenotype. However, the primary transforming 
event in renal cell carcinoma is likely to be independent of PAX2. Indeed, loss of the VHL 
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gene function is evident in about 50-70% of sporadic cases of RCC [16]. VHL encodes 
an E3 ligase that promotes ubiquitination of hypoxia-inducible transcription factors HIF1, 
HIF2 and HIF3, leading to their degradation [16]. Unregulated expression of HIF is 
sufficient to drive the primary transforming event in this large subset of renal cell 
carcinomas [17, 18]. The VHL gene is intact in some renal cell carcinomas and this is the 
case in the ACHN cell line. The primary transforming event in ACHN tumors might be 
loss of the tumor repressor, JADE-1, barely detectable in ACHN cells. However, The 
effect of JADE-1 on ACHN cell tumorigenicity has not been demonstrated directly [19]. 
Nevertheless, it seems that molecular pathways independent of PAX2 drive primary 
oncogenic transformation of renal tubular cells in renal cell carcinoma. 
It is conceivable that the widespread expression of PAX2 in renal cell carcinomas may 
represent a characteristic response of renal cells to stress. We have shown that renal 
PAX2 expression is normally down-regulated in the postnatal period but is re-activated to 
fetal levels in response to urinary tract obstruction [4]. Reappearance of PAX2 in the 
obstructed kidney is associated with partial protection from apoptosis [4]. Similarly, 
others have shown that PAX2 expression is induced by osmotic stress and protects renal 
medullary cell from apoptosis following exposure to high salt concentrations in vitro 
[20]. Also, PAX2 directly interacts with a BRCT-domain protein (PAX2 Interacting 
Protein, PTIP), which is activated by cellular stress and promotes resistance to ionizing 
radiation [21-23]. 
During normal kidney development, PAX2 exerts a powerful anti-apoptotic effect in cells 
of the collecting duct lineage through direct transcriptional activation of the neural 
apoptosis inhibitory protein (NAIP) gene [11]. NAIP was originally identified as an 
endogenous suppressor of caspase-3 and caspase-7 activities in neuronal cells. We 
identified NAIP expression in the normal fetal kidney and showed that NAIP suppresses 
the apoptotic pathway in renal tubular cells[ll]. However, the resistance of RCC cells to 
programmed cell death is likely to be more complex. At least one other member of the 
inhibitor of apopotosis (IAP) gene family, XIAP, is overexpressed in renal cell 
carcinomas [24] and high XIAP expression is associated with a worse clinical prognosis 
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[13, 24]. The relationship between PAX2 and other members of the IAP gene family 
remains to be clarified. Additionally, there is evidence mat PAX2 may inhibit 
programmed cell death by regulating BID/BAD (in prostate cancer) or PTEN/AKT (in 
renal endothelial cells), though these pathways may be context specific [1, 25]. 
Cisplatin binds to DNA causing chromosomal damage, which may be repaired or may 
activate the apoptotic pathway [26]. In this study, we found that shRNA knockdown of 
PAX2 expression increased susceptibility to cisplatin-induced caspase activation in vitro 
and enhanced the effect of cisplatin on subcutaneous tumor growth in nude mice. PAX2 
has also been implicated in resistance to chemotherapy of prostate cancer cells and 
Kaposi's sarcoma [25] [1]. While growth of ACHN/shPAX2.1 tumors was sharply 
suppressed by cisplatin, tumor growth recovered once the effect of the single cisplatin 
dose had worn off after 5-6 days. It should be noted that our ACHN/shPAX2 transfectants 
were initially selected in culture medium with neomycin, possibly selecting for additional 
resistance mechanisms that could compensate for loss of anti-apoptotic effects of PAX2. 
For example, PAX2 may be partially compensated for by PAX8, which is commonly 
expressed in RCC cells. Heterozygous inactivation of Pax8 in Pax2+I~ mutant mice 
increases ureteric bud cell apoptosis during branching morphogenesis of the kidney and 
causes exaggerated renal hypoplasia [27]. Thus, an shRNA targeting conserved domains 
of both PAX genes might heighten the response to cisplatin compared to PAX2 
knockdown alone. 
Following intravenous injection in mice, siRNA accumulates spontaneously in the kidney 
and has been shown to selectively suppress gene function in the proximal tubules [28]. 
Most renal cell carcinomas are thought to arise from the renal proximal tubule, raising the 
possibility that PAX2 siRNAs might be used as adjunctive therapy for chemotherapy of 
RCC. In preliminary studies, nanoparticles have been used to deliver modified siRNAs 
safely to monkey tissues [29] and tumor-targeted nanoparticles have been shown to 
deliver siRNA to metastatic tumors in a murine pancreatic cancer model [30]. Although 
protracted PAX2 knockdown is not expected from a synthetic siRNA, the effect might be 
sustained long enough to enhance bolus cisplatin therapy, as in our subcutaneous RCC 
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tumor model. PAX2 is expressed at high levels in fetal brain, kidney and retina during 
development, but is sharply down-regulated in mature adult organs [2, 4]. Thus, PAX2 
siRNAs are expected to enhance cytotoxicity of chemotherapeutic drugs in renal tumours 
rather than in normal tissues. While the delivery systems for siRNAs in vivo are not yet 
fully developed, our observations suggest that reagents to silence PAX2 warrant 
consideration as adjunctive therapy for renal cell carcinoma. 
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2.2.5 METHODS 
Vector construction 
ShRNA constructs targeting PAX2 mRNA (NM_NM_000278) were designed using 
Genescript software guidelines (Genescript, Piscataway, NT, USA). The two 21-base 
oligonucleotides (sense and antisense) linked by a loop sequence were cloned into the 
pRNATin-H1.2 vector. Stably expressing cell lines were selected using lmg/ml 
neomycin. After 4 weeks, resistant clones that were positive for GFP expression by 
fluorescent microscopy were chosen and amplified. 
Cell culture 
A human RCC cell line (ACHN) was selected from the NCI-60 cancer cell panel and 
obtained from the American Type Culture Collection (Rockville, MD, USA). ACHN 
cells were maintained as adherent monolayer cultures in MEM culture medium 
(Invitrogen, Burlington, Ontario, Canada) supplemented with 10% fetal bovine serum. 
Quantatitative RT-PCR 
RNA was isolated from cells with RNeasy® Plus columns (Qiagen Laboratories, 
Valencia, CA, USA) according o the manufacturer's directions. Quantitative real-time 
reverse transcription/polymerase chain reaction (RT-PCR) was carried out using the 
Qiagen QuantiTect SYBR® Green RT-PCR method (Qiagen Laboratories, Valencia, 
CA). Each 25[xl PCR reaction contained lOOng RNA, forward and reverses primers, and 
the passive reference dye (ROX) to normalize the SYBR Green/double-stranded DNA 
complex signal during analysis to correct for well-to-well variations. Triplicate reactions 
were performed for each template amount. As a control, DNA standard template was 
replaced with water. Primers were as follows: 
PAX2 Forward primer: 5'-CCCAGCGTCTCTTCCATCA-3' 
PAX2 Reverse primer: 5'-GGCGTTGGGTGGAAAGG-3', 
B2M Forward primer: 5'-AGATGAGTATGCCTGCCGTGT-3' 
B2M Reverse primer: 5'-GCTTACATGTCTCGATCCCACTTA-3'. 
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PCR cycling conditions (N=40 cycles) were as follows: initial denaturation at 95°C for 
15 min, followed by annealing for 30 seconds at 55 °C and 30 seconds/kb extension at 
72°C. We performed simulatenous real-time RT-PCR with beta-2-microglobulin (B2M) 
and all resulting values were normalized with this houskeeping gene. These conditions 
yielded a single-band amplicon by agarose gel electrophoresis; the identity of the PCR 
product was confirmed by melting curve analysis on the Mx4000 (Stratagene, Cedar 
Creek, TX, USA). Estimates of PAX2/B2M transcript levels were quantified by the CT 
method as previously described[ 11 ]. 
Western immunoblotting 
A total of 50ug of protein extracted from each cell population was resolved on 10% 
sodium dodecyl sulphate-polyacrylamide gels at 100V for 1.5 h at 4°C, and then 
transferred over 1 h at 100 V (4°C) onto polyvinylidene difluoride membranes (Bio-Rad, 
Mississauga, ON, Canada). Blots were probed with polyclonal anti-PAX2 antibody 
(Zymed, San Francisco, CA, USA), followed by anti-rabbit IgG secondary antibody and 
detected with an enhanced chemiluminescence detection system (Amersham, Piscataway, 
NJ, USA). Membranes probed for PAX2 were reprobed for Calnexin (Calbiochem, EMD 
Chemicals Inc, San Diego, CA, USA) to normalize for loading differences. Antibody was 
detected by a chemiluminescence system (ECL Plus) Amersham Biosciences, NJ USA). 
Analysis was performed using ImageQuant TL on a Storm® phospholmager (Amersham 
Biosciences, NJ, USA) 
Caspase-3 assay 
The caspase-3 substrate A^-acetyl-Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin 
(BD Pharmingen San Jose, CA, USA) was used in caspase-3 assays according to the 
manufacturer's instructions. Cell lysate (100u,g) was added to the reaction buffer (20 mM 
A^-2-hydroxyethylpiperazine-iV-2-ethanesulphonic acid, pH 7.4, 100 mM sodium 
chloride, 10 mM dithiothreitol, 0.1% 3-[(3-cholamydopropyl)-dimethylammonio]-2-
hydroxy-1-propanesulphonic acid, 10% sucrose) containing 125 uM of N-acetyl-Asp-
Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin in a 1 ml cuvette. Fluorescence of the 
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cleavage product was measured using a Luminescence Spectrometer LS50 (Perkin-
Elmer, Fremont, CA, USA). 
Subcutaneous xenograft in nude mice 
ACHN cells were trypsinized, washed twice with PBS, pelleted and resuspended in PBS; 
the viability of collected cells was confirmed by staining with trypan blue. To establish 
ACHN tumor xenografts in mice, 6-week-old SCID mice were injected subcutaneously in 
the right flank with 5 million ACHN cells in 200 jxl of PBS. When tumor volume reached 
150mm3, mice were randomized for therapy in two experimental groups (+/- cisplatin). 
Tumor volume was determined every 2 days by external measurements with a caliper and 
calculated as V=Lx l2 x 0.5, where L and 1 represent the larger and the smaller tumor 
diameters. Animal care was provided according to institutional guidelines. Cisplatin was 
injected intra-peritoneally (i.p.) at day 21. 
Statistical analysis 
Each experiment was repeated three times. Means and standard deviations have been 
calculated for each independent experiment. In each experiment, differences in means 
were tested for significance using the Student's Mest. Statistical significance was defined 
as p <0.05. 
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Connecting Chapter II and III: 
The work presented in chapter II illustrates the proof of principle that therapeutic 
strategies which suppress PAX2 have potential as adjunctive agents in treatment of renal 
cancer. Most importantly, our findings establish the connection between normal kidney 
development and renal cancer. 
Wilms' tumor (WT) is the most common pediatric kidney cancer and is thought to arise 
from multipotent embryonic renal precursors of the metanephric blastema, which fail to 
terminally differentiate and continue to proliferate. Accordinly the Wilms tumors 
typically include blastemal, epithelial and stromal cells (triphasic histology). 
Furthermore, the presence of heterologous elements such as muscle, cartilage and fat 
reflects the pluripotential ability of the renal progenitor cells from which the tumor 
originates. Due to its embryonic features, Wilms Tumor has served as canonical model to 
study developmental pathways leading to cancer. 
During normal kidney development, renal progenitor cells of the metanephric blastema 
can give rise to all the cell types of the nephron. A dichotomy that delineates two main 
distinct cellular programs of differentiation can be established: The nephrogenic program 
gives rise to the epithelial cell lineages while the mesenchymal program produce the 
stromal cell lineages. Upon inductive signal from the invading UB, metanephric 
progenitor cells adjacent to the UB tip will condense and form a cap. This cap of induced 
mesenchyme undergoes mesenchymal to epithelial transition to form the polarized 
epithelial cells lining the lumen of an S-shaped tubular structure that will give rise to the 
all epithelials cells of the nephron including the renal tubule and the podocytes. While 
inductive signals from the ureteric bud drives contiguous mesenchymal cells toward a 
nephrogenic fate, the remaining satellite mesenchymal cells are induced to adopt an 
alternative differentiation program marked by the expression of a different set of 
transcription factors. These cells retain a non-polarized mesenchymal phenotype, migrate 
between the emerging tubules and form a stromal component of the renal medulla. 
149 
PAX2 is initially expressed in the nephric duct epithelium and high levels of PAX2 
protein are seen throughout the branching ureteric bud as well as in the distal portion of 
the S-shaped body. In the S-shaped body it activates WNT4 expression and genes 
involved in the mesenchyme to epithelial transition. In the previous chapter we showed 
that aberrant PAX2 expression in renal cell carcinoma, may account for the characteristic 
resistance of tumor cells to apoptosis induced by chemotherapeutic agents (Hueber et ah, 
2006). Aberrant PAX2 expression is seen in a subset of triphasic Wilms tumors, but 
PAX2 is conspicuously absent in Wilms tumours with a prominent stromal phenotype. 
Until recently, PAX2 and PAX8 were the only members of the PAX gene family 
described to be expressed in the fetal kidney (Dziarmaga et al., 2006). However, recent 
studies characterizing PAX3 expression in a transgenic mouse expressing P-galactosidase 
induced by Cre recombinase under the control of a 6.4kb region located upstream the 
PAX3 genomic found beta-galactosidase activity in the urogenital derivative of the 
mouse embryo indirectly suggesting the potential presence of PAX3+ cells in the kidney 
(Engleka et ah, 2005). Here, I show for the first time, that PAX3 is expressed in 
developing kidney and in Wilms tumors. 
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CHAPTER III: PAX3: from kidney development to Wilms tumor 
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PAX3 is expressed in the stromal developing kidney and in Wilms tumor 
with myogenic phenotype. 
Pierre-Alain Hueber, Ryuji Fukuzawa, LeeLee Chu, Reyhan Elkares, Shu-Jie He, 
Matthew Anaka, Anthony Reeve, Michael Eccles Myriam Blumentkrantz, Nada Jabado, 
Diana Iglesias and Paul Goodyer. 
Manuscript submitted to Pediatric Developmental Pathology. 
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3.1 ABSTRACT 
Wilms tumour (WT) is the most frequent renal neoplasm of childhood; a myogenic 
component is observed in 5-10% of tumours. We demonstrate for the first time that 
myogenic Wilms tumors are associated with expression of PAX3, a transcription factor 
known to specify myoblast cell fate during muscle development. In a panel of 20 Wilms 
tumors, PAX3 was identified in 13/13 tumour samples with myogenic histopathology, 
but was absent in 7/7 tumours lacking a myogenic component. Furthermore, we show 
that PAX3 is expressed in the metanephric mesenchyme and stromal compartment of 
developing mouse kidney; a specific pattern of Pax3 isoforms was identified in fetal vs 
adult kidney. Modulation of endogenous PAX3 expression in human embryonic kidney 
(HEK293) cells influenced cell migration in in vitro assays. 
Mutations of WT1 were consistently associated with PAX3 expression in Wilms tumors 
and modulation of WT1 expression in HEK293 cells was inversely correlated with the 
level of endogenous PAX3 protein. We demonstrate abundant PAX3 and absence of 
PAX2 expression in a novel cell line (WitP3) isolated from the stromal portion of a 
Wilms tumor, bearing a homozygous deletion of the WT1 gene. In contrast, PAX2 was 
strongly expressed and PAX3 was absent in a Wilms tumor cell line (Wit49) with 
epithelial phenotype and intact WT1 gene. 
We hypothesize that PAX3 sets stromal cell fate in developing kidney but is normally 
suppressed by WT1 during the mesenchyme-to-epithelium transition leading to 
nephrogenesis. Loss of WT1 permits aberrant PAX3 expression in a subset of Wilms 
tumors with myogenic phenotype. 
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3.2 INTRODUCTION 
Wilms Tumor (WT) is the most common pediatric solid tumor, arising in 1/10000 
children. This malignancy was first described by Max Wilms in 1899, as a 
"mischgeschwulste der niere"; composed of mixed stromal, epithelial and 
undifferentiated mesenchymal cells. This triphasic histology is thought to reflect the 
derivation of Wilms tumor from stem cells of the metanephric mesenchyme, capable of 
differentiating toward either a stromal or an epithelial cell fate (1). It follows that genes 
controlling the divergence of these cell lineages from a pluripotent precursor must be 
central to the pathogenesis of WT (2, 3). 
During normal kidney development, signals from each branch of the arborizing ureteric 
bud induce adjacent mesenchymal cells to cluster and express specific transcription 
factors, including the paired box gene, PAX2. This cap of induced mesenchyme is 
rapidly transformed into polarized epithelial cells lining the lumen of an S-shaped tubular 
structure. At its distal end, PAX2-positive cells of the S-shaped body generate the various 
segments of the renal tubule and fuse to the arborizing ureteric bud. At its proximal end, 
PAX2 expression is suppressed as cells undergo further differentiation into podocytes 
and elicit the ingrowth of capillaries to form the glomerulus of each nephron. 
While inductive signals from the ureteric bud propel many mesenchymal cells toward a 
nephrogenic fate, other mesenchymal cells are induced to express alternative 
transcription factors, such as retinoic acid receptor-P (4). These cells retain a non-
polarized mesenchymal phenotype, migrate between the emerging tubules and form a 
substantial component of the renal medulla (5). 
Until recently, it was generally agreed that, of the nine PAX family members, only PAX2 
and PAX8 are expressed in mammalian fetal kidney. However, in the course of their 
studies of neuromuscular development, Engleka et al. created a novel murine PAX3 allele 
by inserting Cre downstream of the Pax3 promoter (6). In Cre-dependent R26R reporter 
mice, the allele was used to track Pax3 promoter activity during development. Beta-
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galactosidase reporter activity was noted in expected sites such as dorsal neural tube, 
somites and cardiac neural crest cells, but was unexpectedly seen in mesenchymal 
compartments of newborn mouse kidney (6). This observation suggests that PAX3 could 
be involved in renal development. 
In this study we demonstrate that PAX3 is expressed in metanephric mesenchyme and 
stromal cells of normal embryonic mouse kidney but is progressively down-regulated in 
the perinatal period. Aberrant PAX3 expression was seen in a subset of Wilms tumor 
with myogenic phenotype and loss of WT1. PAX3 was noted in a novel Wilms tumor cell 
line bearing a homozygous deletion of WT1 but not in a Wilms tumor cell line with intact 
WT1. Our observations suggest a new model of Wilms tumor pathogenesis in which loss 
of WT1 permits PAX3 expression, accounting for the myogenic phenotype. 
3.3 RESULTS 
3.3.1 PAX3 mRNA and protein is detected in the mouse embryonic kidney and in 
renal cell lines 
To determine whether PAX3 is expressed in the developing mouse kidney, we first 
isolated RNA from E15 and El8 and adult kidneys and amplified a portion of the Pax3 
transcript (RT-PCR), which allowed us to distinguish three known murine Pax3 isoforms. 
These are formed by alternative splicing of the eighth exon and/or intron (7). The primary 
Pax3c transcript (lacking intron 8) was evident at all stages (Fig.3.1A). However, fetal 
kidney samples also exhibited expression of the Pax3d (+ intron 8), lacking in the adult 
(Fig 1A). At E18, the putative inhibitory transcript, Pax3g, was also identified. PAX3 
protein was also detected by Western immunoblotting at various stages. The 56kDa 
PAX3 protein was detectable at E12.5, peaked between E15-E18 and was down-
regulated thereafter to relatively low levels in adult kidney (Fig.3.1B). 
To clarify whether Pax3 expression is characteristic of mesenchymal vs ureteric bud 
lineage, we assessed PAX3 protein and mRNA in an established mouse embryonic 
155 
mesenchymal (MK4) cell line (8) and in an epithelial cell line (IMCD) derived from 
murine collecting duct (9). As seen in Figure 3.1C/1D, both PAX3 mRNA and protein 
are detected in MK4 cells but are undetectable in the IMCD line (Fig.3.1C&D). MK4 
cells express both the Pax3c (-8i) and Pax3g (A8e) transcript identified in whole El8 
mouse kidney (Fig.3.1). 
3.3.2 PAX3 protein expression is restricted to the mesenchymal compartment of 
embryonic kidney 
We performed PAX3 immunohistochemistry on fetal and adult mice. As the ureteric bud 
emerges from the nephric duct at E l l , PAX3 protein is evident in the somites (Som), 
brain and the neural tube (NT) (Fig.3.2), but is absent from the uninduced metanephric 
mesenchyme. As the ureteric bud arborizes and initiates nephrogenesis, strong PAX3 
nuclear staining appears in cells of stromal compartment and metanephric blastema (MB) 
(Fig.3.2). Between E14 and E18, this pattern of PAX3 expression intensifies, but fades as 
committed cells undergo the mesenchyme-to-epithelium transition to form the S-shaped 
body (S). PAX3 is faindy seen in maturing proximal tubules (PT) at PI, but is absent in 
epithelium of mature glomeruli (G) and collecting duct (CD) (Fig.3.2). From El8 
onward, PAX3 expression progressively declines, to reach relatively low adult level by 3-
weeks of age. Control E17 kidney stained without primary antibody is negative for PAX3 
staining (Fig.3.2). 
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Figure 3.1. PAX3 mRNA and PAX3 protein are expressed in mouse embryonic 
kidney and in renal cell lines. 
A) Whole murine kidney RNA was amplified by RT-PCR with primers spanning exons 
8-9. Three Pax3 isoforms were detected: Pax3(+8i) containing exon 8 and intron 8 
(1007bp); Pax3 (-8i) with exon 8 but intron 8 deleted (516bp); and Pcvc3(A8c), the 
inactive form of Pax3, with both intron 8 and exon 8 deleted (267bp). 
B) Renal PAX3 protein was assessed by Western immunoblotting normalized for beta-
actin. Each bar represents the mean of three independent experiments at embryonic day 
E12.5 through 6 weeks postnatal age (adult). Insert shows representative Western 
immunoblot. C) PAX3(+8i) and Pax3(-8i) transcripts were identified by RT-PCR in MK4 
cells derived from induced metanephric mesenchyme but not in EV1CD cells derived from 
the inner medullary collecting duct. (D) PAX3 protein was identified by Western 
immunoblotting in MK4 but not mEVICD cells. 
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Figure 3.2 PAX3 protein localizes in the stromal and the mesenchymal 
compartments of developing mouse kidney. 
PAX3 immunostaining at various stages of development. At E l l , PAX3 is not detected 
in the ureteric bud (UB) or uninduced metanephric mesenchyme, but a strong signal is 
seen in the neural tube (NT), somites (Som), mandibule (M), lateral and medial nasal 
process (mnp & lnp); PAX3 is absent from the gut (G), heart (H) and liver (L). From 
El2.5 onward, PAX3 immunostaining appears in the stromal (Str) and the mesenchymal 
lineage of the kidney, but is absent from epithelial cells of the S-shaped body (S), 
glomerulus (G) and collecting duct (CD). From El 8 to 6 weeks of age, PAX3 staining is 
progressively attenuated to a relatively low level in mature kidney. 
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3.3.3 PAX3 is expressed in a subset of myogenic Wilms Tumor 
Since Wilms tumors (WT) are thought to arise from progenitor cells of the metanephric 
blastema, we considered the possibility that PAX3 might be sustained in tumor tissue, 
contributing to its phenotype. In preliminary studies, we observed that PAX3 staining 
was associated with the stromal component of myogenic Wilms tumors; this was 
especially evident in tumors bearing WT1 mutations (Fig.3.3 A/B). Since PAX3 has a 
well-known role in setting myoblast fate during normal muscle differentiation, we 
systematically examined PAX3 mRNA (qRT-PCR) and PAX3 protein 
(immunohistochemistry) in a panel of twenty primary Wilms tumors, chosen to include 
13 tumors with myogenic characteristics (based on histopathology and gene expression 
array studies) and 7 tumors without evidence of myogenic markers (21 and unpublished). 
Nuclear PAX3 mRNA and protein were identified in all myogenic WT (Fig.3.3C). In 
contrast, PAX3 expression was absent in Wilms tumors devoid of myogenic 
differentiation (Fig.3.3 B/C). The correlation between myogenic phenotype and PAX3 
expression was confirmed by PAX3 RT-PCR whenever RNA was available (Fig 3.3C). 
Interestingly, many (8/13) of the myogenic tumors had previously been shown to have 
WT1 coding mutations (Fig.3.3 C) 
3.3.4 PAX3 is regulated by WT1(-/+KTS) in human embryonic kidney (HEK293) 
cells 
Since WT1 mutations were identified in many of the PAX3-expressing myogenic Wilms' 
tumors gene, we investigated whether one of the WT1 isoforms could suppress PAX3 
expression in vitro. First, we tested this hypothesis by overexpressing the four WT1 
isoforms in HEK293 cells; PAX3 band intensity was quantified relative to calnexin by 
Western immunoblotting and compared to the endogenous level in untransfected 
HEK293 cells. At 48 hours, WT1(+ KTS) suppressed PAX3 protein level to 60% of 
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baseline (Fig.3.4 A). The other WT1 isoforms had no significant effect on PAX3 protein 
level (Fig.3.4 A). 
Since HEK293 cells express endogenous WT1 protein, we also examined the effect of 
WT1 inactivation, in transient transfection assays with a WT1 siRNA. By 48 hours WT1 
protein level was reduced to 25-50% of baseline 48 hours after siRNA transfection; 
PAX3/calnexin band intensity rose to about 200% of baseline (Fig.3.4 C). 
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Figure 3.3 PAX3 mRNA transcript and protein is up regulated in a panel of Wilms 
Tumor with myogenesis. 
A) PAX3 immunostaining of triphasic Wilms tumor tissues. Strong PAX3 expression 
(arrow) is seen in the stromal component but not in epithelial cells (epith) or blastemal 
cells (blast). Note that, in the left hand panel, a nest of PAX3(+) stromal cells underlies 
an area of PAX3(-) cells undergoing myogenic differentiation (Myo). 
B) PAX3 immunostaining (arrow) in a stromal-predominant Wilms tumor with proven 
WT1 mutation. PAX3(-) blastemal cells (blast) lie adjacent to a region of PAX3(+) 
stromal cells (Str); an epithelial component to the tumor is typically lacking. 
C) Summary of the PAX3 immunohistochemistry results in a panel of 13 Wilms tumors 
with myogenic components and 7 Wilms tumors lacking myogenic features. PAX3 
expression was characterized by quantitative RT-PCR and immunostaining. The coding 
sequence for WT1 and CTNNB1 genes were analyzed by RT-PCR amplification of each 
exon followed by direct sequencing. 
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Figure 3.4 WT1 inhibits PAX3 promoter transcriptional activity in human 
embryonic kidney (HEK293) cells. 
A) Representative Western immunoblot showing endogenous PAX3 protein expression 
in HEK293 cells transiently transfected with various WT1 isoforms. PAX3 band intensity 
was normalized for calnexin and expressed as a percent of empty vector control. Each bar 
represents the mean of 3 experiments +/- s.d. *p <0.01. 
B) Representative Western immunoblot showing endogenous PAX3 protein expression in 
HEK293 cells after transient transfection with an siRNA targeting WT1. WT1 and PAX3 
band intensities were normalized for calnexin; each bar represents the mean and s.d. as a 
percentage of standard siRNA control. * p<0.05. 
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3.3.5 PAX3 enhances proliferation and migration of HEK293 cells 
Aberrant PAX3 gene expression has been observed in a variety of cancers, enhancing cell 
survival by suppressing apoptosis and stimulating cell migration (10). We examined the 
effect of PAX3 overexpression on the phenotype of HEK293 cells. This human 
embryonic kidney cell line is derived from the metanephric mesenchyme, expressing low 
levels of WT1 and PAX2 (13). HEK293 cells were stably transfected with the full-length 
PAX3 cDNA and isolated in neomycin selection medium. A clone with high PAX3 
protein expression and the parental cell line were used for further study (Fig. 3.5A). 
In previous work, we identified a strong anti-apoptotic effect of PAX2 during kidney 
development (12, 13). To determine whether PAX3 also suppresses apoptosis, we 
measured caspase-3 activity in the parental HEK293 cell line and the HEK293/PAX3 
cells 24 hours after exposure to cisplatin (50uM). There was no protective effect of PAX3 
on cisplatin-induced caspase-3 activation (data not shown). In the absence of cisplatin, 
PAX3 had no effect on proliferation/survival of subconfluent HEK293 cells (assessed by 
change in total lactate dehydrogenase activity in the monolayer) after 24 hours but a 
modest but significant increase was noticed after 72h (Fig. 3.5B). 
During embryonic development, Pax3 is expressed in myoblasts as they migrate toward 
the limb bud (14). In a scratch assay, we compared the migration of HEK293 cells after 
suppression or enhancement of endogenous PAX3 expression. Twenty-four hours after 
transient transfection with a PAX3 expression vector or empty vector control (about 75% 
transfection efficiency), the monolayer was scratched; change in scratch width measured 
from baseline to 48 hours was used as an index of cell migration. PAX3 overexpression 
had no apparent effect on cell migration (FIG 3.5E). On the other hand, when we used a 
PAX3 siPvNA to knock down PAX3 expression after 48 hours (Fig. 3.5D), cell migration 
was significantly reduced (65% of empty vector controls) compared to control cells 
transfected with a standard siRNA (95% of empty vector controls) (Fig 3.5C). 
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3.3.6 PAX3 is expressed in a primary cell line derived from the stromal portion of a 
triphasic Wilms tumor 
To further assess the relationship between WT1 and expression of PAX3 or PAX2, we 
compared a WTl(-) Wilms tumor cell line cell line (WiTP3) to a previously described 
WT1(+) Wilms tumor cell line (Wit49) {Alami, 2003 #54}. We isolated the novel WitP3 
from a stromal nodule protruding through the renal capsule in a triphasic Wilms tumour 
from a 5-month-old boy (Fig. 6A). WT1 genomic status was assessed by RT-PCR and 
direct sequencing. WiTP3 cells exhibited a de novo homozygous deletion of the WT1 
gene and WT1 protein was undetectable (Fig. 6B/C). Conversely, WT1 sequence was 
intact in Wit49 cells (data not shown) and WT1 protein was easily detected (Fig. 6C). 
PAX3 protein was abundant in WiTP3 cells as assessed by Western immunoblotting, but 
PAX2 protein was undetectable (Fig. 6C). In contrast, Wit49 cells expressed high levels 
of PAX2 protein but no endogenous PAX3 (Fig. 6C). 
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Figure 3.5 Function of PAX3 in HEK293 cells. 
A) Western immunoblot showing low endogenous PAX3 expression in parental HEK293 
cells and high PAX3 expression in HEK293 cells stably transfected with PAX3 cDNA 
expression vector. 
B) Proliferation of HEK293/PAX3 cells compared to parental cell line HEK293 in 
culture (MTT assay). Bars represent mean cell number of three independent experiments 
+/- standard deviation (SD). 
C) Western immunoblot showing PAX3 knockdown in HEK293 transfected with PAX3 
siRNA compared to siRNA control. 
D) Effects of PAX3 overexpression or knockdown on HEK293 cell migration as assessed 
by scratch wound assay. Cell movement into the wound is shown 48 hours after 
scratching. Bars represent mean migratory distance normalized to empty vector controls 
in three independent experiments +/- SD. 
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Figure 3,6 Characterization of a primary Wilms tumor cell line (WiTP3). 
A) H&E staining and WT1 immunostaining (left panels) of a triphasic Wilms tumor 
showing a WTl(-) nodule (Str nod) protruding through the renal capsule. The right-hand 
panel shows the stromal phenotype of WiTP3 cells in monolayer culture. 
B) PCR of WT1 exons demonstrates homozygous deletion of spanning exons 3-9 in 
WiTP3 cells; DNA extracted from the patient's peripheral leukocytes shows an intact 
WT1 coding sequence. 
C) Western immunoblot showing strong PAX3 (but weak PAX2 and absent WT1) 
expression in WiTP3 cells (lane 2). Conversely, WiT49 cells show strong PAX2 and 
WT1 protein bands but no PAX3 (lane 3). All three proteins are detected at low levels in 
control human embryonic kidney HEK293 cells (lane 1). 
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Figure 3.7 Development model of Wilms tumor molecular pathogenesis. 
During normal kidney development, signals from the ureteric bud commit progenitor 
cells in the metanephric mesenchyme to differentiate toward the nephrogenic lineage 
(transition to the epithelial phenotype of cells which will form renal tubules) vs the 
stromal lineage (non-polarized cells which migrate to peritubular zones). Loss of WT1 
prevents mesenchyme-to-epithelium transition (MET), sustaining PAX3 expression and 
stromal phenotype; second genetic hits (eg activating mutations of CTNNB1) are 
required for Wilms tumorigenesis. When WT1 is intact, progenitor cells can undergo 
MET, lose PAX3 expression and commit toward nephrogenesis; genetic lesions such as 
loss of WTX cause Wilms tumors exhibiting triphasic histology with partially-committed 
blastemal cells that may progress toward PAX2(+) epithelium or regress toward the 
PAX3(+) stromal phenotype. 
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3.4 DISCUSSION 
In embryonic kidney, the transcriptions factors PAX2 and PAX8 cooperate in setting cell 
fate of nephric duct epithelia and in regulation of nephrogenesis. However, no other 
members of the PAX family were suspected to play a role in renal development until 
Engleka reported that a 5' flanking sequence of Pax3 was able to target gene expression 
to the renal mesenchyme (6). The expression pattern of reporter genes targeted by 
isolated promoter fragments do not always mirror events in vivo, but here, we 
demonstrate that robust PAX3 protein is evident in metanephric mesenchyme and 
throughout the stromal compartment of fetal kidney. Renal PAX3 expression is 
significantly down-regulated after El 8 to the relatively low levels characteristic of adult 
mice. Accordingly, PAX3 is expressed in the MK4 cell line derived from metanephric 
mesenchyme, but not in EVICD cells derived from epithelial cells of the renal collecting 
duct. These observations strongly suggest a developmental role for PAX3 in the renal 
stromal lineage during organogenesis. 
Interestingly, we identified the well-described primary Pax3 (Si) transcript in murine 
kidney and in the MK4 cell line (derived from metanephric mesenchyme). According to 
Pritchard et al this isoform is abundant in myoblasts of developing muscle and exerts the 
most powerful transcriptional effect on a Pax3-responsive reporter gene in vitro (7). 
However, in both (E15 and E18) fetal mouse kidney samples, we also noted the presence 
of the Pax3 (+8i) transcript. The human homolog of this isoform (PAX3D) has been 
identified in melanoma cells and appears to have similar effect on transcriptional activity 
of target genes when compared to the human homolog (PAX3C) of murine Pax3(-Si) 
(16). However, since the Pax3(+Si) isoform is restricted to fetal kidney, it is conceivable 
that there is a need for specific fetal regulation of Pax3 during development involving 
sequence information within the eighth Pax3 intron. 
At El8 (and in MK4 cells) we noted a third Pax3 transcript, Pax3(-8e). Pritchard 
previously showed that this isoform is present in fetal myoblasts and has very weak 
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capacity to activate transcriptional activity of a Pax3-responsive reporter in vitro (7). This 
suggests that expression of the PAX3(A8e) isoform, lacking exon 8, might normally 
attenuate the transcriptional activity of the predominant PAX3 isoform. In developing 
kidney, PAX3 protein begins to fall at El 8. Conceivably, the transient appearance of an 
inhibitory isoform could reflect the need to downregulate PAX3 function at that stage. 
During normal muscle development, PAX3 is thought to determine cell fate in myoblasts 
and neural crest cells as they migrate toward peripheral sites within the embryo (14). 
PAX3 activates a set of genes critical for the myogenic pathway, but PAX3 is 
downregulated in myoblasts as they take up residence in the limb buds and undergo 
terminal differentiation (14). During kidney development, signals from the ureteric bud 
induce adjacent metanephric progenitor cells to undergo mesenchyme to epithelial 
transition and form the epithelial component of individual nephrons. A second subset of 
the metanephric progenitor cells acquires markers of the stromal lineage such as RARP 
and FOXB (17, 18). These cells migrate inward from the nephrogenic zone to form the 
stromal compartment surrounding renal glomeruli and tubules. Our "scratch" assays 
showed that PAX3 knockdown blunts migration of human embryonic kidney (HEK293) 
cells in vitro. It is therefore plausible that PAX3 regulates molecular pathways involved 
in stromal cell movement during normal kidney development. 
Although many Wilms tumors show "triphasic" histology, comprised of mixed blastemal, 
epithelial and stromal components (23), a discrete subset of tumors (5-10%) exhibit a 
predominandy "stromal" phenotype with elements showing myogenic differentiation (19-
22). This subset of Wilms tumors is further defined by genomic lesions of WT1 and 
associated missense mutations of the beta-catenin gene (CTNNB1) exon 3, causing 
constitutive activation of the canonical WNT signaling pathway (21, 23, 24). Since, we 
identified strong PAX3 expression in stromal cells of the developing kidney, we 
hypothesized that PAX3 might be characteristic of Wilms tumors with predominance of 
mesenchymal cells. We used a panel of myogenic (N=13) vs non-myogenic (N=7) Wilms 
tumors to determine whether aberrant PAX3 expression was associated with the 
myogenic phenotype (2). We noted that PAX3 mRNA and protein was expressed in all 
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myogenic tumor samples, but were never seen among the non-myogenic tumors. This 
observation strongly suggests that PAX3 expression underlies the myogenic phenotype of 
this Wilms tumor subset. Interestingly, gene rearrangements which fuse the PAX3 DNA 
binding domain to a truncated 3' portion of the forkhead gene (FKHR) cause aggressive 
rhabdomyosarcomas in humans (25) 
Since aberrant PAX3 expression was highly associated with WT1 mutations in our Wilms 
tumor panel, we examined the effect of WT1 on PAX3 expression in HEK293 cells in 
vitro. When the cells were transiently transfected with WT1 (-/+ KTS), PAX3 protein 
levels were reduced to 60% of control after 48 hours. Conversely, when siRNAs were 
used to knock down endogenous WT1 expression to about 50% of control, we observed a 
corresponding increase in PAX3 protein of about 30%. Taken together, these studies 
support the hypothesis that PAX3 is normally regulated by WT1 during renal 
development. This idea is consistent with our observation that PAX3 is excluded from 
WT1-expressing cells such as the glomerular podocyte and with the report that transient 
transfection of WT1 into murine C2C12 myoblasts inhibits the myogenic program (3) 
However, we noted Pax3 expression in three myogenic tumors apparently lacking a 
mutation of the WT1 coding sequence. Furthermore, the effects of WT1 on in vitro 
expression of PAX3 were modest, suggesting that other factors may be important for 
PAX3 regulation. Alternatively, WT1 could affect PAX3 in an indirect manner, simply 
by promoting the mesenchyme-to-epithelium transition of progenitor cells. 
We isolated a primary stromal cell line (WiTP3) from a patient with a large stromal 
nodule arising within a triphasic Wilms Tumor. Although WT1 immunostaining was 
strong in blastemal and epithelial compartments of the tumor, the stromal nodule lacked 
WT1 immunostaining and the stromal cell line was found to have deletion of both WT1 
alleles. Relatively high levels of PAX3 mRNA and protein were evident in WiTP3 cells, 
whereas PAX2 protein was barely detectable. This contrasts with the WT1-positive 
WiT49 Wilms tumor cell line isolated by Alami et al., (15) which expresses abundant 
PAX2 but no PAX3. The contrasting gene expression patterns in these two cell lines 
170 
further support the dichotomy between the PAX3-positive and PAX3-negative subtypes 
of Wilms tumors. 
We propose a model of normal renal development in which progenitor cells of the 
metanephric blastema express PAX3 when targeted toward the stromal cell fate. PAX3 
expression may contribute to the phenotype of migrating stromal cells, but does not 
appear to have a major influence on cell division or control of apoptotic pathways. 
Suppression of PAX3 is integral to the mesenchyme-to-epithelium transition, which 
defines the nephrogenic cell fate and may be accomplished, in part, by WT1. Conversely, 
failure to suppress PAX3 may account for the myogenic phenotype in a subset of WT1-
negative Wilms tumors. 
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3.5 METHODS 
Western Immunoblotting 
Cells or embryonic kidney were lysed in radioimmunoprecipitation assay (RIPA) buffer 
[50 mmol/L Tris-Cl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate, 
0.1% SDS, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L sodium orthovanadate]. 
Subsequently, protein concentrations were determined using the protein assay reagent kit 
(Pierce, Rockford, IL) with bovine serum albumin as a standard. Equivalent amounts of 
protein were loaded in each lane of a 10% SDS polyacrylamide gel and electrophoresed 
followed by blotting onto a polyvinylidene difluoride membrane. After blocking with 5% 
(w/v) fat-free milk powder, 0.1% Tween 20 in PBS, the membrane was incubated for 1 
hour at room temperature with anti-PAX3 antibody (1:1000) (Hybridoma bank. 
University of Iowa), anti-WTl antibody (Santa-Cruz, CA); anti-PAX2 1/250 antibody 
(Zymed, Santa-Cruz, CA) or anti-actin antibody (Sigma, St. Louis, MO) diluted into 3% 
(w/v) fat-free milk powder, 0.1% Tween 20 in PBS, washed and incubated with 
secondary antibody (Sigma). The membrane was then washed and incubated with 
ECLplus reagents according to the manufacturer's directions (Amersham, GE Healthcare 
Buckinghamshire UK). The signals were then detected using a Phosphoimager 
(Amersham, GE Healthcare Buckinghamshire UK) 
Immunohistochemistry on embryonic mouse kidney 
PAX3 staining was carried out as previously described. Briefly, sections were 
deparaffinized and re-hydrated using xylene and graded alcohol series, then rinsed in tap 
water. Microwave antigen retrieval using 0.01 M citrate buffer (pH 7.0 and pH 2.0, 
respectively) was performed twice for 30 min. Sections were incubated with primary 
mouse monoclonal anti-quail PAX3 antibody (Hybridoma bank, Iowa, USA) (1:100) 
overnight at 4°C. Slides were then incubated with secondary biotinylated horse anti-
mouse IgG at room temperature for 30 min, followed by avidin-biotinylated horseradish 
peroxidase (HRP) for 30 min according to the manufacturer's instructions (Vector 
Laboratories). Peroxidase activity was developed for 2 min at RT using 
172 
diaminobenzidene tetrachloride (DAB; Zymed) as die chromogen, witii hematoxylin as 
the counterstain, and then rinsed in Scott's water for 5 minutes. 
Patient samples 
20 Wilms tumors samples were selected from a collection of tumors obtained with 
informed consent from North Health Ethics Committee Auckland, New Zealand. For all 
tumors, each WT1 exon was amplified by PCR and sequenced {Fukuzawa, 2004 #2}. 
The cell line W1TP3 was obtained with informed consent from a Wilms tumor ressected 
at the Montreal Children's Hospital under a Children Oncology Group (COG) protocol, 
approved by the Institutional Review Board. 
Immunohistochemistry on Wilms Tumor tissue 
WT1 (6F-H2, DAKO, CA, USA), PAX3 (Hybridoma bank, Iowa, USA) were used as 
primary antibodies, and the DAKO Envision horseradish peroxidase system (K4001, 
DAKO Cytomation, CA, USA) was used to detect the primary antibodies 
RNA Extraction 
RNA was extracted from cells using RNeasy plus kit (Qiagen, Valencia, CA) as per 
manufacturer's recommendations. RNA quantities and quality were assessed by 
spectrophotometry. (NanoDrop ND-1000, Wilmington, DE, USA 
PAX3 RT-PCR 
Mouse Pax3 transcripts were amplified from RNA isolated from whole embryonic 
kidney using the primers spanning exon 7-9 as described by Pritchard and colleagues 
{Pritchard,2003#49} 
5' GTGTCAGATCCCAGTAGCACCG 3' 
5' TCCAAGTGGACAGTTCACTTATGC 3'. 
Quantitative PAX3 RT-PCR 
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PAX3 mRNA expression was quantified in relationship to the mRNA level for a 
housekeeping gene, ubiquitin-conjugating enzyme E2G2 according to the formula: 
P A Y ^ / F O P O—fP ~\ ACTPax3 (mean control - mean sample); / p % ACTE2g 2(mean control- mean sample) 
using Relative Expression Software Tool (REST© - Pffafl et al, 2002) and average 
efficiencies calculated by LinRegPCR. 
Human PAX3 primers were as follows: 
Forward primer (exon2): 5' TCCATACGTCCTGGTGCCAT 3' 
Reverse primer (exon3): 5'TTCTCCACGTCAGGCGTTG 3' 
WT1 PCR 
Primers for each WT1 exon are summarized below (annealing temperature = 58°C) 
WTl 
exon 
exon 1A 
exon IB 
exon 2 
exon 3 
exon 4 
exon 5 
exon 6 
exon 7 
exon 8 
exon 9 
exon 10 
Forward primers 5'-3' 
CAGCAAATGGGCTCCGACGTG 
CCGGTGCTGGACTTTGCG 
GTGGCTGGTTCAGACCCA 
CAGCCTCGCACCCCGAGC 
TGTGGAGGCTTGCACTTTC 
CCATGCATGCTCC 
GATAAGCATTTCCAAATGGCG 
CAAGACCTACGTGAATGTTC 
AGGAGAGGTTGCCTTTAATGA 
GGCCGAGGCTAGACCTTC 
GACTTCACTCGGGCCTTG 
Reverse primer 5'-3' 
CGGGCGCTTCGGCTTAC 
CCTGAATTCCCGGCCTACTTACCC 
GAGGATAGCACGGAAGAAG 
CAAGGACCCAGACGCAGA 
TCTTCATAAGTTCTAAGCACC 
AGTCCTAACTCCTGCATTGC 
GCTGGGGCCTGTCTGTG 
TGTTTGCCCAAGACTGGAC 
AAGAGAATCATGAAATCAACCC 
TCCATCCCTCTCATCACAAT 
GCCTGGGACACTGAACGG 
amplicon 
(bp) 
150 
351 
250 
199 
271 
179 
185 
249 
230 
211 
236 
Cell lines 
HEK293 cells were purchased from ATCC and grown in DMEM media (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal calf serum and 10% Pen/Strep 
(Invitrogen, Carlsbad, CA, USA). The WiT49 cell line (derived from a primary lung 
metastasis of an aggressive Wilms tumor) {Alami, 2003 #54} was generously provided 
by Dr H Yeger (The Hospital for Sick Children, Toronto, Canada). WiT49 cells were 
maintained in 1:1 high glucose DMEM:F12 Nutrient Mix, 10% fetal calf serum, 100 
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U/ml penicillin, 100 ug/ml streptomycin. The HEK293/PAX3 cell line was generated by 
transfecting HEK293 with a PAX3 cDNA expression vector; stably transfected clones 
were selected and maintained in media containing neomycin. PAX3 expression was 
confirmed by Western immunoblotting. Primary WiTP3 cells were isolated from a 
stromal nodule arising from within a triphasic Wilms tumor resected from a 5 month-old 
patient at the Montreal Children's Hospital. A sample of the stromal nodule was 
microdissected and cultured in DMEM (Invitrogen, Carlsbad, CA, USA) with 10% fetal 
calf serum. 
RNA interference 
Short interfering RNA (siRNA) duplexes specific for human WT1 were obtained from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The PAX3 silencer, pre-designed 
human PAX3 siRNA ID# 215907, and a standard negative siRNA control were obtained 
from Ambion (Austin, TX, USA). HEK293 cells were transfected with lOnM of siRNA 
using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer's protocol. 
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CHAPTER IV: DISCUSSION AND FUTURE DIRECTIONS 
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4.1 DISCUSSION 
4.1.1 Paradigm 
Embryonic and tumor cells share similar features as they both have potential for rapid 
proliferation, migration and dedifferentiation. Accordingly the same genetic programs 
that are active during embryogenesis are often re-activated during tumorigenesis (Monk 
& Holding, 2001). Furthermore embryonic genes expressed in human tumors are 
typically not expressed in normal adult tissues and thereby have the potential of being 
specific targets for cancer therapy (Dressier and Woolf, 1999; Monk and Holding, 2001). 
The transcription factor PAX2 is essential and abundantly expressed during normal 
kidney development but is downregulated once organogenesis is completed. On the other 
hand, PAX2 is estimated to be aberrantly expressed in 25% of cancers, including breast, 
brain, lymphoma and ovarian (Muratovska et al, 2003). In particular PAX2 expression is 
considered a reliable and specific marker for renal cell carcinoma (RCC) tumors; about 
90% of clear cell carcinomas exhibits nuclear PAX2-postive immunostaining (Daniel et 
al, 2001; Mazal et al, 2005). 
During normal kidney development PAX2 functions as an anti-apoptotic gene 
(Dziarmaga et al, 2006a; Torban et al, 2000). Apoptosis is a genetically controlled 
process that plays an important role in both embryonic development and adult tissues 
homeostasis, by which cells can initiate their own death in response to specific stimuli 
(Kerr et al, 1972). Cells undergoing apoptosis or programmed cell death are typically 
(Kerr et al, 1972) characterized by the activation of the caspase-enzyme family. 
Apoptosis can be triggered by chemotherapeutic drugs and is considered an important 
mechanism by which chemotherapy exerts its anti-tumoral merapeutic effect. For 
example, platinum-compounds such as cisplatin used in clinical oncology for more than 
30 years, control tumor growth by causing cellular DNA damage resulting in cancer cells 
apoptosis (Kelland, 2007). On the other hand, apoptosis resistance can hamper the 
sensitivity of cancer cells to chemotherapy; renal cancer has a notorious resistance to 
chemotherapy, which is thought to be the primary cause of its poor prognosis (Motzer et 
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ah, 1997). Various mechanisms can underlie the resistance of cancer cells to cisplatin-
induced apoptosis among which is the overexpression of anti-apoptotic genes (Kelland, 
2007). 
Building on the well-established anti-apoptotic function of PAX2 in development we 
hypothesize that PAX2 expression in RCC contributes to its resistance to cisplatin-
induced cell death. Hence targeted inhibition of PAX2 should selectively sensitize RCC 
cells to cisplatin therapy whereas it should have minimal influence on normal tissues in 
which PAX2 has been appropriately downregulated. Thus the first objective was to 
determine whether the anti-apoptotic function of PAX2 played a significant role in the 
response to chemotherapy. 
4.1.2 PAX2 confers resistance to cisplatin-induced apoptosis 
Our first aim was to show that the role of PAX2 in protecting embryonic cells from 
apoptosis could be extended to normal kidney cells that are challenged with a pro-
apoptotic agent such as a chemotherapeutic drug. To address this issue we generated cell 
lines expressing different levels of PAX2 and examined their susceptibility to apoptosis 
when treated with cisplatin. The human embryonic kidney (HEK293) cell line was 
chosen as a model of a human renal cell lineage; aberrant PAX2 expression in this cell 
line was produced by stable transfection with a PAX2 expression vector. We chose 
cisplatin as a representative of the chemotherapeutic drugs that typically causes cancer 
cell death via induction of apoptosis (Eastman, 1990; Lee et ah, 2001; Park et ah, 2002). 
Cisplatin induces apoptosis of renal cells; indeed this accounts for the well-known 
nephrotoxicity of cisplatin. Cisplatin is effective in other tumors of the genitourinary tract 
might be a useful agent in RCC if the resistance to apoptosis could be overcome (Servais 
etal.,2001). 
Activation of the apoptotic pathway by chemotherapy eventually converges on caspase-3, 
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leading to the morphological changes associated with programmed cell death. Since 
caspase-3 is considered the central effector of apoptosis, we assessed caspase-3 activity 
as a measure of apoptosis pathway activity. We showed that cisplatin treatment activates 
capase-3 in HEK293 cells but that PAX2 overexpression diminishes cisplatin-induced 
caspase-3 activation. Conversely suppressing endogenous PAX2 in a murine inner 
medullary collecting duct cell line sensitizes the cells to caspase-3 activation following 
cisplatin treatment. 
These experiments establish that PAX2 expression in normal cells is protective against 
cisplatin treatment and suggests that the PAX2 level in renal cells correlates with their 
susceptibility to cisplatin-induced apoptosis. Our findings are consistent with other 
studies which have shown that the level of PAX2 protein in endothelial cells is correlated 
with sensitivity to vincristine-induced apoptosis (Fonsato et al, 2006). 
4.1.3 Suppression of PAX2 enhances cisplatin-induced apoptosis in RCC cells 
We predicted that the role of PAX2 in protecting normal embryonic cells from apoptosis 
could be extended to renal tumor cells that express endogenous PAX2 and exhibit a 
chemoresistant phenotype. We supposed that by inhibiting PAX2 the cellular apoptotic 
machinery balance would be shifted towards cell death and enhance sensitivity to 
chemotherapy. 
Although PAX2 expression is well established in primary renal tumors, we had to find a 
PAX2 expressing renal cancer cell line that could serve as an in vitro model. We screened 
all the renal cancer cell lines of the NCI-60 panel which includes 60 human cancer cell 
lines used by the Developmental Therapeutic Program of the National Cancer Institute 
(NCI) to screen compounds for anticancer activity (Grever et al, 1992; Weinstein et al, 
1997). Using Western immunoblotting to measure PAX2 protein expression we found 
that A498, CAKI-1 and ACHN cells express significant levels of PAX2 protein. On the 
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other hand, some other renal cancer cell lines such as 786-0 did not express PAX2 
protein. CAKI-1 and ACHN are both cell lines derived from metastatic clear cell 
carcinoma found in the pleural effusion of patients and therefore are representative of 
chemo-resistant metastatic aggressive RCC tumors. 
In order to inhibit PAX2 expression, we initially used PAX2 oligonucelotide antisenses 
(AS-ODN). We had mixed success with AS-ODNs because of nonspecific toxicity and 
this led us to an alternative approach using small inhibitory RNAs (siRNA). These 
molecules had just emerged as the state-of-the-art strategy for targeted knockdown of 
genes in mammalian cell lines (Couzin, 2002). Treatment with PAX2-siRNA successfully 
inhibited the expression of PAX2 protein in RCC cells ACHN and CAKI-1. 
The reduction of PAX2 expression in RCC cells results in an increase in the level of basal 
apoptosis. In addition, RCC cells with reduced levels of PAX2 were more sensitive to the 
therapeutic effect of cisplatin treatment both in terms of apoptosis measured by annexin 
V and cell survival measured by a dehydrogenase enzymatic assay. Although PAX2 has 
been previously shown to be important for RCC cell survival (Gnarra & Dressier, 1995), 
our studies demonstrate for the first time that inhibition of PAX2 results in caspases-
dependent apoptosis in RCC cells. This was conclusively shown by the observation that 
pre-treatment of of RCC cells witfi the drug Z-Vad-Fmk (a pan caspases inhibitor) was 
able to prevent the cell death induced by the combined effect of PAX2 inhibition and 
cisplatin treatment. 
Since the publication of our results, several studies have shown that PAX2 inhibition 
causes apoptosis in a variety of cancer cell types including ovarian, prostate carcinoma 
and Karposi sarcoma (KS). Our collaborator from the Eccles group in New Zealand 
showed that PAX2 expression is required for ovarian cancer cell survival; PAX2-siRNA 
treatment causes a 50% decrease in cell survival (Muratovska et al, 2003). In KS cells, 
Buttiglieri and colleagues observed that inhibition of PAX2, using stable transfection of 
PAX2 antisense, significantly increased the number of apoptotic KS cells measured by 
TUNNEL assay under basal conditions. It also enhanced the sensitivity of KS cells to 
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apoptosis induced by serum deprivation or vincristine treatment (Buttiglieri et al, 2004). 
Similarly, inhibition of PAX2 using PAX2-siRNA in prostate cancer cells results in 
significant cellular death (Gibson et al, 2007). Thus, our observations have been 
broadened by other to additional forms of cancer and have clearly established a role for 
PAX2 in setting susceptibility of cancer cell to apoptosis. 
However, the molecular mechanism by which PAX2 acts on the apoptosis pathway 
remains rather unclear. In endothelial cells, PAX2 expression was associated with a 
reduction of expression of the tumor suppressor gene PTEN and concomitant activation 
of the AKT-survival pathway. Interestingly the PTEN/AKT pathway is often deregulated 
in RCC (Hara et al, 2005) and its aberrant activation has been demonstrated as a 
molecular mechanism of cisplatin resistance (Stewart, 2007). In addition, AKT 
expression significandy decreases in p53 wildtype LNCaP and DU145 prostate cancer 
cells following PAX2 knockdown. Yet the AKT levels were unchanged in p53 mutant 
PC3 cells (Gibson et al, 2007). These observations suggest that PAX2 perhaps interacts 
with the AKT pathway at least when p53 is intact. 
P53 acts on the apoptotic pathway via activation of mitochondrial pro-apoptotic genes 
including BAX and PUMA (Jiang et al, 2006) and is involved in cisplatin-induced 
apoptosis of renal cells (Wei et al, 2007a; Wei et al, 2007b). Furthermore p53 can 
contribute to resistance of cancer cells to cisplatin (Lin and Howell, 2006), and has been 
suggested as a PAX2 target gene (Stuart et al, 1995). However studies in prostate cancer 
show that apoptosis induced by PAX2 knockdown is independent of p53 function 
(Gibson et al, 2007). This latter observation is consistent with our results in which PAX2 
inhibition causes apoptosis both in an RCC cell line (ACHN) with wild-type p53 and in a 
RCC cell line (CAKI) with a null mutation of p53. 
The anti-apoptotic function of PAX2 was first discovered in normal embryonic mouse 
kidney cells. This anti-apoptotic activity appears to involve activation of NAIP (Neuronal 
Inhibitor of Apoptosis), a gene belonging to the "inhibitor of apoptosis" (IAP) family. 
IAP proteins are major regulators of apoptosis primarily due to their ability to inhibit 
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cellular caspases enzymes (Deveraux et al, 1998; Deveraux et al, 1999). NAIP was 
shown to be downstream target gene of PAX2 in normal embryonic kidney. The NAIP 
anti-apoptotic function was confirmed in renal collecting duct cells, in which inhibition 
of NAIP enhances caspases activation upon apoptotic stimulus induced by transfection 
with the mitochondrial pro-apoptotic 5AX-a(Dziarmaga et al, 2006a). 
Nevertheless when we looked for differences in NAIP expression in ACHN cells with 
PAX2 knockdown compared to ACHN parental cells, the NAIP protein levels were not 
affected, suggesting that PAX2 suppresses apoptosis in RCC cells via some other 
mechanism. 
Although expression of the eight members of the IAP family have been described in 
cancer cells, XIAP is considered to be the most potent member in terms of its ability to 
inhibit caspase activity. Interestingly high levels of XIAP expression are observed in 
RCC tumors (Mizutani et al, 2005; Ramp et al, 2004; Yan et al, 2004) and correlates 
with a bad prognosis. Moreover inhibition of XIAP expression with siRNA induced 
apoptosis and sensitized renal cancer cells to TRAIL-induced apoptosis (Chawla-Sarkar 
et al, 2004). However, XIAP mRNA level was unchanged in cisplatin-resistant 
HEK293/PAX2 cells compared to cisplatin-sensitive HEK293 cells as assessed in an 
expression gene array (Dziarmaga et al, 2006a). To date there is no evidence that PAX2 
interacts with XIAP in renal cells. 
In summary, although the molecular mechanism by which PAX2 interacts with the 
apoptotic pathway appears complex and perhaps context-specific, our studies clearly 
demonstrate that PAX2 inhibition causes caspase-dependent RCC cell death and 
enhances in vitro the potential of cisplatin to reduce renal cancer cell survival. Our 
findings suggest that strategies inactivating aberrant PAX2 expression in renal tumor 
tissue might be used in combination with classic chemotherapy protocol to enhance the 
response to therapy. 
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4.1.4 Suppression of PAX2 enhances in vivo response of renal tumor to cisplatin 
The second major objective of my research project was to develop an in vivo model of 
renal tumors that allows us to test the therapeutic potential of PAX2 inhibition in 
combination with cisplatin treatment. Subcutaneous injection (s.c) of human cancer cells 
in nude mice forms xenografts and has been used as a standard tumor model for testing 
drugs in a pre-clinical setting. By injecting ACHN cells under the skin of nude mice, we 
generated an in vivo model to test the effect of PAX2 inhibition on cisplatin response. 
Although synthetic PAX2 siRNAs were useful to establish proof of principle in vitro, in 
vivo delivery of siRNAs remain highly challenging and are extremely costly. For these 
reasons, we decided to establish proof-of-principle in vivo, by using a plasmid-based 
expression system that allows a stable expression of siRNAs in the RCC cells. 
Transfection of cells with shRNA-producing plasmids has the advantage of a more 
pronounced and long-lived knockdown compared to transient transfection with siRNA 
(Yu etal, 2002). 
Our strategy was to engineer an RCC cell line that constitutively expresses a PAX2 
shRNA to achieve a lasting and efficient knockdown of PAX2 expression in 100% of the 
cells. We constructed various PAX2 shRNA expression vectors and screened them 
individually for PAX2 knockdown in ACHN cell lines. Clones with PAX2 inhibition and 
sensitization to cisplatin in vitro were injected under the skin of nude mice and tumor 
growth was compared to ACHN/empty vector controls. PAX2 inhibition clearly 
enhanced the suppression of tumor growth in response to cisplatin over a five-day 
observation period. 
An interesting observation is that PAX2 knockdown in the absence of cisplatin treatment 
ACHN cells did not affect basal growth of subcutaneous tumor xenografts. Thus, PAX2 
appears to modify susceptibvility to cisplatin but is not required for malignant growth of 
RCC cells. In contrast, Wu et al. observed that PAX2 knockdown in endometrial cancer 
cells results in a significant decrease in tumor xenograft growth (Wu et al, 2005). 
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Conceivably, other genes exert a partially redundant function for PAX2 in RCC. 
Interestingly, PAX8 has is expressed in ACHN cells and has been shown by Bouchard to 
have overlapping function with PAX2 during normal kidney development. 
Following the discovery of the RNA interference (RNAi) pathway (Fire et al, 1998), it 
was demonstrated that small-interfering RNAs (siRNA) could be exploited for gene 
silencing in mammalian cells (Elbashir et al, 2001). VEGF siRNA has recently been 
shown to be safe and well tolerated in clinical phase I trials as treatment for age-related 
macular degeneration (AMD) (Kim & Rossi, 2007). Our observations establish proof-of-
principle that PAX2 siRNA knockdown might have potential as adjunctive therapy in 
renal cell carcinoma. 
Despite the promising results in terms of the safety of RNAi based therapeutics, the 
principal challenge is the actual delivery of these agents (de Fougerolles et al, 2007). 
Providentially, the kidney appears to be an organ where siRNA tends to accumulate 
spontaneously following systemic injection (van de Water et al, 2006). Therefore renal 
cancer might be a reasonable candidate for the use of RNAi-based therapeutics (van de 
Water et al, 2006). Van de Water and colleagues demonstrated that siRNA accumulates 
spontaneously in the kidney after i.v. injection, where it selectively suppresses gene 
function in the proximal tubules (van de Water et al, 2006). Interestingly, clear cell 
RCC, the major subtype of renal cancer, is thought to arise from a proximat tubule cell. 
Conceivably, PAX2 constitute a therapeutic target in other forms of cancer as well. For 
example, both prostate (Khoubehi et al, 2001) and breast cancer (Silberstein et al, 
2002), the two most common cancers amongst men and women respectively, express 
aberrant PAX2. 
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4.1.5 Other PAX genes in cancer 
The reappearance of embryonic genes expression in tumors suggests that the transformed 
cells can be understood by reference to the properties of normal embryonic cells (Monk 
& Holding, 2001). Our finding also illustrates how developmental biology studies can 
lead to the identification of essential genes function in tumors and can help to identify 
novel candidate genes for therapeutic strategies. Developmental genetic programs are 
typically active during embryogenesis and are shut off once organogenesis is completed. 
The latter aspect (i.e. developmental genes are usually expressed at low level in adult 
tissues), predicts that therapies targeted against these genes will have a limited toxicity in 
patients and thereby may offer greater potential for specific tumor targeting in cancer 
treatment. 
Recendy, a report by Englenka from the J. Epstein group mentioned an indirect 
observation that a PAX3 gene regulatory region was transcriptionally active within the 
urogenital derivative. This prompted us to examine whether PAX3 was also expressed 
during renal development (Engleka et al., 2005). If so, we reasoned that PAX3 might also 
be expressed in renal neoplasia. PAX3 is expressed in melanoma and alveolar 
rhabdomyosarcoma and has been suggested as a therapeutic target in both (Bernasconi et 
al., 1996; Scholl et al., 2001). Thus, PAX3 might have a novel role in the pathogenesis of 
renal cancer and perhaps serve as a potential target for renal cancer therapy. 
4.1.6 PAX3 is expressed in the developing kidney 
For the first time, we demonstrate that the PAX3 gene mRNA and protein are expressed 
in the developing kidney. Until recently, PAX2 and PAX8 were the only PAX gene 
family members thought to be involved in the renal development (Dziarmaga et al. 2006). 
We demonstrate PAX3 immunostaining in the mesenchymal and stromal compartment of 
the kidney. This is consistent with the observation of PAX3 expression in MK4 cells 
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derived from the metanephric mesenchyme in contrast with the absence of PAX3 in the 
epithelial cell line EVICD derived from the collecting duct. 
During normal kidney development multipotent blastmal cells residing in the 
metanephric mesenchyme can differentiate along two main distinct cell lineages: 
nephrogenic vs stromal. Signals from the invading ureteric bud induce the metanephric 
mesenchyme to cluster into a cap that is composed of cells committed towards the 
nephrogenic lineages. 
In contrast, the metanephric cells that are located further from the UB tip are directed 
toward the stromal cell lineage. Stromal progenitor cells expresse specific transcription 
factors including RAR-beta, FoxD (BF-2) and Pod-1 (Hatini et al, 1996; Quaggin et al, 
1999). These stromal cells further differentiate and migrate in peritubular position to 
form the interstitial cells of the cortex and medulla. It is thought that they may also give 
rise to glomerular mesengial cells in response to VEGF signals from podocytes (Cullen-
McEwen etal, 2005). 
Our observations indicate that PAX3 is a novel marker of the stromal lineage in the 
developing kidney. Interestingly kidney-targeted knockout of mesenchymal markers, 
such as FoxDl or retinoic acid receptor-beta, typically leads to renal hypoplasia and 
fewer nephrons. This renal hypoplastic phenotype has been associated with a reduction of 
the pool of progenitor metanephric blastemal cells available to undergo MET to form the 
nephrons (Hatini et al, 1996; Mendelsohn et al, 1999; Schmidt-Ott et al, 2006). 
The Pax3-/- knockout mouse undergoes early embryonic death due to cardiac 
malformation and the Pax3+/- heterozygous mouse has a relatively mild phenotype. Thus 
a possible role for PAX3 in kidney development has not been explored. If we assume that 
Pax3 is important for renal progenitor cells, it is conceivable that Pax3 knockdown 
targeted in the renal tissue will result in renal hypoplasia or reduced nephrogenesis. 
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In conclusion, PAX3 is for the first time directly characterized in the developing kidney. 
PAX3 expression defines the renal mesenchymal and the stromal compartment 
suggesting that PAX3 has a specific function during kidney development. 
4.1.7 PAX3 expression is identified in myogenic Wilms tumors 
Wilms tumor is thought to arise from progenitor cells residing in the metanephric 
mesenchyme. Accordingly, genes expressed during kidney development in the 
metanephric mesenchyme are often expressed in Wilms tumors and might play a role in 
tumorigenesis or contribute to the tumor phenotype (Davies et al, 1999; Jones et al, 
2007; Li et al, 2002). Reflecting its progenitor cells origin, Wilms tumor recapitulates 
all the cellular lineages of the embryonic kidney including blastemal, stromal and 
epithelial components. In addition, 10-15% of Wilms tumors exhibit a myogenic 
differentiation (Fukuzawa et al, 2007). 
Although PAX3 is a transcription factor well-characterized in muscle development and 
rhabdomyosarcomas, we are the first to identify PAX3 expression in Wilms tumor. Our 
finding designates PAX3 as the missing piece of the puzzle that accounts for the potential 
of renal cells to differentiate into skeletal muscle in Wilms tumor. Indeed PAX3 was 
observed in 13/13 Wilms tumors that contain myogenic elements; PAX3 was not 
expressed in Wilms tumors lacking myogenesis (7/7). Interestingly we did not find PAX3 
expression in RCC cells (ACHN and CAKI-1) that are assumed to have derived from the 
renal proximal tubules epithelium. 
Aberrant PAX3 expression has been observed in a variety of cancers including melanoma 
and rhabdomyosarcoma (Barr et al, 1993; Scholl et al, 2001). Alveolar 
rhabdomyosarcoma (RMS), an aggressive skeletal muscle cancer, carries a unique t(2;13) 
chromosomal translocation resulting in the formation of a chimeric transcription factor 
PAX3-FKHR. This fusion protein contains the intact DNA-binding domains (PD: paired 
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box binding domain; HD: paired-type homeodomain) of Pax3 fused to the activation 
domain of FKHR (Zhang & Wang, 2007). The expression of the resulting fused 
oncoprotein PAX3-FKH is associated with increased metastasis and myogenic 
differentiation of the tumor (Sorensen et al, 2002; Zhang and Wang, 2007). 
4.1.8 PAX3 is regulated by WT1 during renal development 
Our results suggest an association between WT1 loss and the presence of PAX3 
expression in Wilms tumors. In addition, we provide evidence in vitro for WT1 as a 
potential regulator of PAX3 expression in the renal context of HEK293 cells. 
Interestingly, the association of WT1 loss and ectopic myogenesis in Wilms tumor has 
already been established by Hastie et al.(Fukuzawa et al, 2004; Miyagawa et al, 1998). 
Our observation that WT1 is able to regulate PAX3 expression fits perfectly in this 
model. The effect of WT1 on PAX3 is relatively modest, however. Thus, WT1 may 
affect PAX3 expression indirectly, for example by influencing the process of stromal cell 
commitment. 
4.1.9 PAX3 function 
Aberrant PAX3 expression in melanoma contributes to cell survival and migratory ability 
(Scholl et al, 2001). Similarly, in normal myoblasts, PAX3 is required for proper cell 
migration from the neural tube to the limb bud (Buckingham & Relaix, 2007). By 
overexpressing and knocking down endogenous PAX3 in human embryonic kidney 
HEK293 cells, we show that PAX3 can influence cellular proliferation and cellular 
migration potential. By inference, PAX3 may function during in kidney development to 
enhance the migratory ability of the stromal progenitor cells. Similarly we can 
hypothesize that PAX3 expression in Wilms tumor may contribute to metastasis. 
Although stromal-predominant myogenic tumors generally have a good prognosis they 
respond poorly to chemotherapy (Maes et al, 1999). Since we previously showed that 
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PAX2 contributes to chemotherapy resistance of RCC, we also examined the effect of 
PAX3 aberrant expression on apoptosis susceptibility. However PAX3 expression had 
no significant effect on cisplatin-induced apoptosis in HEK293 cells. 
Our work demonstrates PAX3 expression in a subset of Wilms tumors and suggests 
PAX3 as a marker of Wilms tumor with myogenic differentiation. 
4.1.10 A novel WTl(-) primary Wilms tumor cell line 
We isolated a novel WTl(-) Wilms tumor cell line (WiTP3) derived from the stromal 
portion of a triphasic Wilms tumor. WiTP3 cells were shown to express abundant PAX3 
protein but very low levels of PAX2. In addition, WiTP3 cells were shown to harbor a de 
novo genomic WT1 deletion. 
In contrast the WT1(+) WiT49 cell line derived from the epithelial compartment of a 
Wilms tumor (Alami et al, 2003) expresses high levels of WT1 and PAX2. Other 
investigators have noticed PAX2 expression in Wilms tumors but did not associate this 
with a specific tumor subtype (Dressier and Douglass, 1992; Eccles et al, 1992). Our 
observations suggest that PAX2 expression marks progression toward an epithelial 
lineage (MET) (Rothenpieler & Dressier, 1993) and is characteristic of the epithelial 
component of triphasic Wilms tumors. In contrast, the expression of Pax3 in WTl(-) cells 
allow us to propose a dichotomy between cell fates marked by PAX3 vs PAX2 in stromal 
vs epithelial Wilms tumors. 
4.1.11 A novel model of renal development and Wilms tumor 
Our finding of PAX3 expression in the stromal compartment of the developing kidney 
and our observation that PAX3 expression is suppressed by WT1 prompt us to propose a 
novel model of kidney development. We suggest that WT1 participates in the control of 
MET which leads to PAX2 expression in the nephrogenic lineage. Conversely, cells 
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directed toward the stromal lineage lose WT1 and express alternative transcription 
factors, including PAX3. These cells retain a non-polarized mesenchymal phenotype and 
migrating inwardly between emerging tubules to form the stromal component of the renal 
medulla. We hypothesize that PAX3 is implicated in this process. 
In Wilms tumors associated with loss of WT1, cells fail to undergo EMT and are pushed 
toward the stromal cell fate. Expression of PAX3 contributes to the potential for 
myogenic differentiation. However, loss of WT1 and expression of PAX3 do not appear 
to be sufficient for malignant transformation, since most WTl(-) tumors acquire 
activating mutations of CTNNB1. 
In other forms of Wilms tumors where WT1 is intact, metanephric progenitor cells can 
undergo EMT, express CTNNB1 and PAX2. These cells are partially committed and 
may differentiate into epithelial lineages even after transforming events such as loss of 
WTX or loss of IGF2 inhibition. This subset of Wilms tumors exhibits triphasic 
histology. While some cells can undergo epithelial differentiation, the majority appears as 
undifferentiated blastemal cells; neither expresses PAX3. Presumably, a small fraction of 
the partially committed blastemal cells can revert (EMT) toward the PAX3(+) stromal 
component. 
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4.2 SUMMARY 
1) PAX2 contributes to the resistance of Renal Cell Carcinoma cells to apoptosis in vitro. 
SiRNA inhibiton of endogenous PAX2 sensitizes cultured RCC cells to cisplatin-induced 
cell death. 
2) In vivo observations provide proof-of-principle for the hypothesis that PAX2 may be a 
potential therapeutic target in renal cancer. Growth of subcutaneous RCC tumor 
xenografts in nude mice is relatively resistant to intraperitoneal cisplatin administration. 
However, growth of tumors from RCC cells stably transfected with PAX2 shRNA ceases 
after cisplatin treatment. 
3) PAX3 is expressed in the stromal compartment in the developing kidney but is 
downregulated postnatally. Specific embryonic Pax3 transcripts are identified from El 5-
E18. 
4) PAX3 is expressed in a subset of Wilms tumors with mutations of WT1, absence of 
PAX2 expression and evidence of myogenic differentiation. This suggests that a novel 
approach to classification of Wilms tumors. 
5) WT1 suppresses PAX3 in vitro. Taken together with observations in a novel WTl(-), 
Pax3(+) primary cell line, we suggest that WT1 participates in the mesenchyme-to-
epithelium transition during normal kidney development and that loss of WT1 accounts 
for the migratory stromal phenotype of some Wilms tumors. 
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4.3 FUTURE DIRECTIONS 
As previously mentioned, PAX2 RNAi based therapeutics should be developed and 
tested in an in vivo model of renal cancer. Orthotopic injection of RCC xenograft cells in 
the renal capsule of nude mice could provide such a model to test the efficacy and the 
delivery of the RNAi therapeutics to the renal tumor site. Alternatively, it may be 
possible to develop small molecule inhibitors which either block PAX2 expression or 
activation of PAX2 gene targets. 
The Angiotensin II receptor activation has been shown to have an effect on PAX2 mRNA 
and protein in the embryonic kidney (Zhang et al, 2004a; Zhang et al, 2004b). Similarly, 
Angiotensin II stimulates PAX2 in rat kidney proximal tubular cells (Zhang et al, 2004a; 
Zhang et al, 2004b). Since, RCC is thought to arise from proximal tubule cells, it would 
be of interest to examine the effects of angiotensin receptor blockers (routinely used for 
the treatment of hypertension) for effects on PAX2 expression in renal cancer cells. 
Conceivably, these agents might sensitize RCC to chemotherapeutic agents as did Pax2 
knockdown in our studies. 
Small peptides could be synthesized and tested for their potential interaction with PAX2 
and disruption of its function. The protein Grg4 of the Groucho/TLE family has been 
described as a normal endogenous inhibitor of PAX2 transcriptional activity and its 
interaction with PAX2 prevents its phosphorylation by c-Jun N-terminal kinase (JNK) 
and thereby inhibits PAX2 transcriptional activity (Cai et al, 2003; Cai et al, 2002). 
Therefore molecules with an analogue structure to Groucho may have potential as a 
protein PAX2 inhibitor. 
In addition, the expression of specific embryonic PAX3 isoforms in the kidney remains to 
be clarified. Furthermore, it would be interesting to determine whether targeted renal 
Pax3 knockout further reveals PAX3 function during renal development. A targeted Cre-
loxP system, inactivating Pax3 in embryonic mesenchymal cells, would be an appropriate 
tool to examine these issues. 
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It would be interesting to know whether PAX3 inhibition has a significant effect on the 
PAX3+ Wilms tumor phenotype. Also the precise frequency of PAX3 expression and its 
association with tumor histology should be confirmed in a large panel of tumor samples. 
From a clinical perspective, myogenic tumors are resistant to chemotherapy and therefore 
PAX3 could constitute a reliable histological marker that will identify such tumors. 
Other approaches should not be ignored. Recently, a "PAX3" experimental vaccine has 
been developed. Although PAX3 acts as a nuclear transcription factor, PAX3 cleavage 
products are expressed at the cell surface in conjunction with HLA class I peptides and 
can serve as epitopes which trigger specific cytotoxic T-cell recognition. Rodeneberg and 
colleagues successfully synthesized an immunogenic PAX3 peptide that induced specific 
CTL recognition of PAX3-containing tumors (Rodeberg et al, 2006). Intravenous 
administration of anti-PAX3 T-cells caused regression of established PAX3+ tumors in 
mice, indicating a promising clinical application for anti-PAX3 immunotherapy 
(Himoudi^aZ.,2007). 
Concluding remarks 
Our work illustrates how the study of kidney embryogenesis can provide insight into the 
molecular pathogenesis of renal cancer. We are now witnessing the emergence of the first 
generation of targeted molecular therapies for cancer. Along with this comes a great 
optimism that through the understanding of the basic molecular biology of the tumor, we 
are indeed on the road towards developing successful therapies for the treatment of 
cancer. 
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4.4 ORIGINAL CONTRIBUTIONS 
1. I showed that the PAX2 expression confers resistance to cisplatin-apoptosis in 
HEK293 cells in vitro. 
2. Treatment of ACHN and CAKI-1 with PAX2 siRNA results in a significant 
reduction of PAX2 protein expression and a concomitant increase of basal cellular 
apoptosis. 
3. I showed that PAX2 inhibition in ACHN and CAKI-1 cells sensitizes RCC cells 
to cisplatin-induced apoptosis. 
4. I showed that ACHN cells injected subcutaneously can serve as an in vivo model 
of renal tumors. 
5. I showed that Aa2-shRNAs are able to successfully inhibit PAX2 in ACHN 
cells. 
6. I demonstrated that ACHN-shPAX2 tumors were more responsive to caspase-3 
induced cisplain in vitro and to the growth inhibition caused by cisplatin treatment 
in vivo. 
7. I showed that PAX3 is expressed in the murine developing kidney where it marks 
the stromal and mesenchymal compartment. 
8. I showed that the PAX3 level is regulated by WT1 in HEK293 cells. 
9. I showed that HEK293 cells overexpressing PAX3 have enhanced cell 
proliferation and migration in vitro. 
10.1 showed that the WiTP3 WTl(-) cell line expresses high levels of PAX3, low 
levels of PAX2 and no WT1. 
11.1 proposed a novel model of renal development and Wilms tumorigeneis based on 
PAX2 vs. PAX3 expression dichotomy. 
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Iglesias DM, Hueber P-A, Chu LL, Campbell R, Patenaude 
A-M, Dziarmaga AJ, Quintan J, Mohamed O, Dufort D, Goodyer 
PR. Canonical WNT signaling during kidney development. Am J 
Physiol Renal Physiol 293: F494-F500, 2007. First published May 9, 
2007: doi:l().ll52/ajprenal.00416.2006.—The canonical WNT sig-
naling pathway plays a crucial role in patterning of the embryo during 
development, but little is known about the specific developmental 
events which are under WNT control. To understand more about how 
the WNT pathway orchestrates mammalian organogenesis, we studied 
the canonical p-catenin-mediated WNT signaling pathway in kidneys 
of mice bearing a p-catenin-responsive TCF/jiGal reporter transgene. 
In rnetanephric kidney, intense canonical WNT signaling was evident 
in epithelia of the branching ureteric bud and in nephrogenic mesen-
chyme during its transition into renal tubules. WNT signaling activity 
is rapidly downregulated in maturing nephrons and becomes unde-
tectable in postnatal kidney. Sites of TCF/jiGal activity are in prox-
imity to the known sites of renal WNT2b and WNT4 expression, and 
these WNTs stimulate TCF reporter activity in kidney cell lines 
derived from ureteric bud and rnetanephric mesenchyme lineages. 
When fetal kidney explants from HoxB7/GFP mice were exposed to 
the canonical WNT signaling pathway inhibitor, Dickkopf-1, ar-
borization of the ureteric bud was significantly reduced. We conclude 
that restricted zones of intense canonical WNT signaling drive 
branching nephrogenesis in fetal kidney. 
nephrogenesis; p-catenin; branching morphogenesis 
THE WNT FAMILY is comprised of 19 secreted glycoproteins 
which act as short-range intercellular signaling molecules, 
recognizing one of the 10 frizzled receptors expressed at the 
surface of nearby target cells. The canonical signaling pathway 
is activated by WNTs which bind to cognate frizzled receptors 
heterodimerized with LRP5 or LRP6 coreceptors (2). Acti-
vated receptors recruit dishevelled protein (Dvl) and inhibit 
degradation of cytoplasmic (3-catenin via the GSK3f3-axin-
APC complex (11). When its degradation is blocked, cytoplas-
mic f3-catenin is available to translocate to the nucleus, dimer-
ize with partners belonging to the T-cell factor (TCF) family, 
and activate target genes. TCF recognition motifs have been 
well-studied, allowing design of vectors (e.g., TOPFIash) 
which drive transcription of reporter genes in response to 
canonical WNT signaling activity (32). In general, canonical 
p-catenin/TCF signaling is thought to activate gene targets 
(e.g., c-myc) involved in cell proliferation (3, 27). 
More than 35 years ago, Unsworth and Grobstein (33) 
reported that tissue from spinal cord could induce formation of 
renal tubules when cocultured with isolated rnetanephric mes-
Address for reprint requests and other correspondence: P. Goodyer. Mon-
treal Children's Hospital Research Institute, 4060 St. Catherine West. Mon-
treal, QC, Canada H3Z 2Z3 (e-mail: Paul.Goodyer@mcgill.ca). 
enchyme. In 1994, Herzlinger et al. (12) found that WNT1-
expressing NIH3T3 cells were also able to induce tubule 
formation in the coculture assay, suggesting that the canonical 
((3-catenin-mediated) WNT signaling pathway is essential for 
mammalian nephrogenesis. However, the precise function of 
canonical WNT signaling in renal development is unknown. 
Surprisingly, WNT1 is not present in the developing kidney, 
but numerous other WNTs are transiently expressed in specific 
cell lineages (34). Several of these are able to activate the 
canonical signaling pathway in other contexts; these include 
WNT4 (19), WNT2b (15), and WNT7b (35). Additional 
WNTs (WNT6, WNT9, and WNTU) are expressed in fetal 
kidney (4, 13, 16) but have not been shown to activate the 
canonical signaling pathway. Little is known about the expres-
sion patterns of the many FRZ and LRP5/6 receptors in fetal 
kidney. Thus it has been difficult to decipher the function of 
canonical Wnt and/or Fz genes during renal development. 
Furthermore, there is insufficient information about the specific 
sites of canonical signaling activity to predict the precise role 
of this pathway in nephrogenesis. 
In this study, we report the detailed spatio-temporal pattern 
of canonical WNT signaling activity in developing kidney 
from a (3-catenin-responsive TCF/jiGal transgenic reporter 
mouse. We found that the renal TCF signal is initially evident 
throughout the nephric duct and ureteric bud (UB) but becomes 
progressively focused at two sites: branching ureteric bud tips 
and in distal portions of the S-shaped body. In the perinatal 
period, it is sharply downregulated as nephrogenesis comes to 
an end. Several WNTs expressed in close proximity to the sites 
of canonical j3-catenin/TCF pathway activity were found to 
activate the canonical pathway in cultured MK4 (derived from 
nephrogenic mesenchyme) cells and inner medullary collecting 
duct (IMCD, derived from renal collecting duct epithelium) cells. 
We also show that when fetal kidney explants are exposed to the 
canonical pathway inhibitor, Dickkopf-1, branching morphogen-
esis of the UB is significantly suppressed. 
MATERIALS AND METHODS 
Cell culture. MK4 cells (kindly provided by Dr. S. Potter) and 
IMCD-3 (mouse collecting duct) cells (ATCC number CRL-2123) 
were all cultured in DMEM (Invitrogen, Carlsbad, CA) supplemented 
with 10% FBS and 1% penicillin-streptomycin. 
Transient transfection assays. Expression plasmids used for tran-
sient transfection assays include: empty expression plasmid 
pCDNA3.1 (as a control), full-length human DKK1 cDNA (kindly 
provided Dr. X. He), mouse WNT4 cDNA (Upstate Biotech, Char-
The costs of publication of this article were defrayed in part by the payment 
of page charges. The article must therefore be hereby marked "advertisement" 
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 
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lottesville, VI), mouse WNT7b cDNA (kindly provided by E. Mor-
risey), mouse WNT2b cDNA (kindly provided by I. Drummond), 
TOPFLASH and FOPFLASH reporter vectors (Upstate Biotech), and 
pGL2 basic (Promega, Madison, Wl; as a control). All transfections 
included the renilla lucif'erase expression vector, pRL-SV40 (Pro-
mega), as a control for sample-to-sample variation in transfection. 
Transfections were performed in triplicate in 24-well plates; each 
experiment was performed three times. At 60% confluency, cells were 
transfected with 200 ng of the various plasmids using FuGENE 6 
Transfection Reagent (Roche, Penzberg, Germany) according to the 
protocol recommended by the manufacturer. Firefly luciferase and 
renilla luciferase reporter activities were determined using Dual 
Luciferase Assay System reagents (Promega) and quantified in a 
Microlumat Plus Luminometer (EG&G Berthold). Reporter activity 
was expressed as the ratio of luciferase to renilla values. Statistical 
analysis was performed using Student's Mest. 
For study of the canonical signaling inhibitor, DKK1, cells were 
plated at 60% confluency in a 24-well plate; recombinant mouse 
DKKI protein (R&D Systems, Minneapolis, MN) was added (0 or 
500 ng/ml) to the wells. After 24 h, the cells were transfected with 
either TOPFLASH or control vector and pRL-SV40 renilla as a 
transfection efficency control. Fresh DKKI was added to the media 
1 h after the transfection was performed. Firefly luciferase and renilla 
luciferase reporter activities were determined after 24 h. The experi-
ment was performed two times in triplicate. 
Reporter mice. Animal procedures followed the guidelines estab-
lished by the Canadian Council of Animal Care and were approved by 
the Animal Care Committee from McGill University. CD1 mice 
bearing a (3-catenin-responsive lacZ reporter gene have been previ-
ously described (22). Briefly, this transgene contains six TCF/LEF 
response elements cloned upstream of a minimal Hsp68 promoter 
driving the lacZ reporter gene. C3H mice (provided by F. Costantini) 
bearing a GFP transgene under the control of the HoxB7 promoter 
have been described elsewhere (30). 
Inimunohistochemistry. Paraffin-embedded sections (7 p,m) of em-
bryonic kidneys were incubated in 5% H202 to quench endogenous 
peroxidase activity, followed by a 30-rnin incubation with normal 
horse serum. Tissue sections were then incubated with anti-nonphos-
phorylated 8-catenin antibody (Upstate, Lake Placid, NY), washed, 
and incubated with a universal biotinylated secondary antibody (Vec-
tor Laboratory, Burlingame, CA). Staining was developed using DAB 
(Vector Laboratory) and counterstained with Gill's hematoxylin. 
Analysis of LacZ activity in transgenic mice. The protocol for 
|3-galactosidase staining has been described elsewhere (23). Kidneys 
from mice bearing the TCF-lacZ transgene and wild-type mice were 
removed and fixed in PBS containing 2 mM MgCl2, 0.02% NP-40, 
0.01% deoxycholate, 1% formaldehyde, and 0.2% glutaraldehyde, 
rinsed in washing buffer (PBS with 2 mM MgCl2, 0.02%. NP-40, 
0.01% deoxycholate), and stained in the dark overnight in washing 
buffer supplemented with 1 mg/rnl X-gal, 5 mM potassium ferricya-
nide, and 5 mM potassium ferrocyanide. After being stained, kidneys 
were washed in PBS and visualized directly or embedded in paraffin 
for sectioning and standard counterstaining with hematoxylin and 
eosin. 
Immunofluorescent microscopy. Frozen sections of embryonic kid-
neys (10 p.m) from transgenic mice were blocked in normal serum and 
incubated with rabbit anti-B-galaetosidase antibody (1 -.250, Chemicon 
International. Temecula, CA). Sections were washed and incubated 
with rhodamine-tagged secondary anti-rabbit IgG antibody (1:50, 
Chemicon International), washed, and incubated with lluorescein-
tagged dolichos biflorus lectin (1:200, Vector Laboratory) before 
microscopic examination under fluorescent light. 
For WTI staining of GFP explants, kidneys were fixed for 10 min 
in methanol, washed in PBS 0.1% Tween 20 (P.BST), and incubated 
overnight at 4°C with rabbit polyclonal anti WTI antibody (C19, 
Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in 
PBST/2%. BSA. After washes in PBST, kidneys were incubated with 
AJP-Renal Physiol • vol. 293 • i> 
anti-rabbit Alexa Fluor 594 (Invitrogen) 1:400 at 22°C for dual 
immunofluorescent microscopy. 
Kidney explain culture. Kidneys from HoxB7/GFP mice were 
dissected from embryonic day 13.5 (£73.5) embryos and placed on a 
filter in six-well plates in DMEM with 10% BSA (control) or medium 
containing 2 u,g/ml recombinant mouse DKKI protein (R&D Sys-
tems). The explants were cultured in a humidified 37°C incubator 
under 5% C02. Kidneys were supplemented every 24 h with fresh 
medium (control) or medium containing DKKI. Pictures were taken 
every 24 h under fluorescent light. UB tips were counted using Image 
J software. Statistical analysis was performed using Student's (-test. 
RESULTS 
Canonical fi-catenin signaling activity is progressively re-
stricted to UB tips and newly formed S-shoped bodies in 
developing kidney. To examine the pattern of canonical (3-cate-
nin pathway signaling activity, Ell.5 embryos (Ell.5) or 
microdissected kidneys (E14-P2I) from TCF/fi-galactosidase 
mice were assessed for transgene activity. The TCF signal is 
first seen in the nephric duct at El 1.5 (Fig. 1, A and 7?). By 
E13-E15, the TCF reporter signal is seen throughout the 
arborizing UB but is somewhat stronger in UB tips than in its 
trunk (Fig. 1, C, D, E). By £76.5 the TCF signal is highly 
restricted to the UB tips and distal S-shaped body but is 
suppressed in UB trunks (Fig. IF). 
To confirm that transgene expression reflects endogenous 
canonical WNT signaling activity, sections from X-gal-stained 
E15 transgenic kidney (Fig. 2A) were compared with sections 
from E15 wild-types stained with an antibody against active 
(nonphosphorylated) (3-catenin (Fig. 273). Active (3-calenin 
staining is, like the TCF signal, intense at the tips of the UB 
and in distal portions of the S-shaped body. To confirm that 
canonical WNT signaling becomes restricted to the tips (vs. 
trunks) of the UB, cryosections of El6.5 kidney were costained 
with antibody for fi-galactosidase (red) and a UB marker 
dolichos biflorus agglutinin (green). At this stage, the fused 
image shows restricted TCF signaling at UB tip but is disap-
pearing in the UB trunk (Fig. 2, C—E). 
As kidney development proceeds, the TCF signal is sus-
tained only in the nephrogenic zone (Fig. 3, A and 73). All 
canonical signaling activity is extinguished as nephrogenesis 
comes to an end in the early postnatal period (Fig. 3, C and D). 
WNT2b, WNT4, and WNT7b stimulate canonical ji-catenin 
signaling. Since our observations in the TCF/LacZ mouse 
indicate intense activity of the canonical WNT pathway at the 
UB tips and in the distal S-shaped bodies, we used cell lines 
derived from these two lineages, MK4 (murine nephrogenic 
mesenchyme) and IMCD (murine collecting duct), to screen 
various WNTs for canonical activity. Six WNTs have been 
reported in developing kidney, but only four of these (WNT2b, 
WNT4, WNT7b, and WNT 11) are expressed in sustained 
fashion near the branching UB tips and emerging S-shaped 
bodies. Cells were grown to 60% confluence and transiently 
transfected with pcDNA expression vectors containing various 
full-length murine WNT cDNAs (or empty vector) in the 
presence of either TOPFLASH or FOPFLASH (mutant) re-
porter vectors. Cotransfection with SV40/renilla vector was 
used as a control for transfection efficiency, in the absence of 
any WNT vectors, TOPFLASH had significant basal activity 
above a promoterless luciferase vector in both cell lines. 
TOPFLASH activity reflects (3-catenin/TCF signaling in these 
JGUST 2007 • www.ajprenal.org 
F496 CANONICAL WNT SIGNALING IN KIDNEY DEVELOPMENT 
Fig. 1. Ontogeny of (3-catenin signaling during 
early development in TCF/lac'Z reporter trans-
genic mouse kidney. Mouse embryonic (A and B) 
and kidney (C, D, E) sections were stained for 
fi-galactosidase activity. At embryonic day 11.5 
(Ell.5), B-galactosidase is seen in the nephrie 
duct (arrows; A and B). At EI3, strong signal is 
observed throughout the arborizing ureteric bud 
(UB; Q. At EI4.5, strong staining is seen in the 
branching UB. particularly at its tips, and in distal 
segments of S-shaped bodies (arrows; D). Low-
power view of EI5.5 kidney shows strong fi-
galactosidase staining in UBs, whereas maturing 
collecting ducts show reduced staining (£). At 
E16.5, the B-galactosidase signal is restricted to 
the tips of the branching UBs (F). Scale bar = 
100 u,m for A. B, D, E, and /;' and 1 mm for C. 
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cells, since mutation of one of the three sense TCF response 
elements (FOPFLASH) reduced activity by 40%. TOPFLASH 
activity was unaffected by cotransfection with a (noncanonical) 
WNT11 expression vector (data not shown). In the presence of 
WNT2b, basal TOPFLASH activity was stimulated 5.6-fold in 
MK4 cells (P = 0.03) and 6.6-fold (P < 0.05) in IMCD cells 
above the empty expression vector controls (Fig. 4, A and B). 
WNT7b stimulated TOPFLASH 7.4-fold (P = 0.09) and 4.3-
Bl 
Fig. 2. B-Catenin signaling is restricted to the 
UB tips at later stages in development. Higher-
power view of £75 kidney shows p-galactosi-
dase staining at the tips of the UB and in the 
distal portion of S-shaped bodies (arrow); there 
is reduced fj-galactosidase staining in the matur-
ing trunk of the collecting duct (A). EJ5 wild-
type mouse kidney probed with anti-unphospho-
rylated fi-eatenin antibody shows active S-cate-
nin (arrows) at the tips of the branching UB and 
in the S-shaped bodies (B). Cryosections from 
E16.5 kidneys were stained with the fluorescent 
UB marker dolichos hiflorus agglutinin (green: 
O and a rhodamine-labeled antibody raised 
against p-galactosidase (red; D); the merged 
image demonstrates colocalization at the UB tip 
(£). Scale bar = 100 p,m. 
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Fig. 3. pi-Catenin signaling disappears after kid-
ney development is completed. From EI8.5 
through 3 wk of age. the (i-galactosidase signal 
fades progressively: PI [whole kidney (A), kid-
ney section (fl)], 1 wk (C), 3 wk (£>). Scale 
bar = 100 |xm. 
fold (P < 0.01). in the two cell lines, respectively. Although 
WNT4 had no effect on MK4 cells, it stimulated TOPFLASH 
2.7-fold (P < 0.01) in IMCD cells (Fig. 4, A and B). 
DKK1 inhibition of the canonical fi-catenin pathway sup-
presses branching nephrogenesis. Since p-catenin/TCF signal-
ing was associated with UB tips, we considered the possibility 
that the canonical WNT pathway might be involved in branch-
ing nephrogenesis. To first confirm that DKK1 inhibits the 
canonical WNT signaling pathway in cells derived from the 
UB, as it does in other cell types (1), we transiently cotrans-
fected IMCD cells with TOPFLASH and an expression vector 
containing the full-length murine DKK1 cDNA or an empty 
vector control. Cells were harvested after 48 h and assayed for 
luciferase activity. Luciferase activity was reduced to 23% of 
control in the presence of DKK1 plasmid (P < 0.05; Fig. 5A). 
IMCD cells were also exposed to recombinant murine DKK1 
protein (0 or 500 ng/ml) for 24 h and then transiently trans-
fected with TOPFLASH reporter vector. Fresh DKK1 was 
added 1 h after transfection and luciferase was measured 24 h 
later. As seen in Fig. 5B, recombinant DK.K1 suppressed 
TOPFLASH activity by -40% (P < 0.01). 
To examine the effect of DKK1 on branching morphogen-
esis, El3.5 kidneys were isolated from HoxB7/GFP mice and 
placed in explant culture for 24-48 h. From each embryo (n = 
4), one kidney was cultured in the presence of recombinant 
DKK1 protein (2 |xg/ml) to inhibit the canonical pathway, 
while the contralateral kidney served as a control. At 0, 24, and 
48 h, explants were photographed under fluorescent light to 
assess the number of terminal UB tips; the extent of arboriza-
tion was expressed as the percent increase in UB tip number 
compared with baseline for each kidney. At 24 h, UB tip 
number increased by 40% in controls but by only 18% in 
kidneys exposed to DK.K1 (P < 0.005; Fig. 6, A and B). At 
48 h, UB tip number had increased by 70% of baseline in 
controls vs. 40% of baseline in the presence of DKK1 
(P < 0.01; Fig. 6, A and B). 
To ascertain whether DKK1 blockade of canonical signaling 
affects structure of individual nephrons derived from induced 
mesenchyme, we visualized the expression pattern of Wilms 
Tumour protein (WT1) in E13 kidney explants isolated from 
HoxB7/GFP mice after 24-h exposure to DKK1. In normal 
explants, WT1 protein is seen in condensing mesenchyme 
capping UB tips and in podocyte layers of emerging glomeruli; 
this pattern is well-preserved in DKK1-treated explants 
(Fig. 6 0 . 
DISCUSSION 
In this study, fJ-catenin/TCF signaling activity was first 
noted at El 1.5 in cells of the nephric duct cells during its 
caudal descent. This was also noted by Maretto et al. (20) in 
EI3.5 kidney of a similar (3-catenin/TCF reporter mouse. The 
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Fig. 4. Effect of WNTs on canonical signaling activity. MK4 (murine mes-
enchyme; A) and IMCD (murine collecting duct; B) cell lines were transfected 
with WNT2b, WNT4, WNT7b expression vectors, or empty vector to test 
their effect on the cotransfected canonical WNT pathway reporter vector, 
TOPFLASH. In both celt lines, WNT2b activated TOPFLASH (**P < 0.05) 
compared with empty vector controls. WNT4 had no effect on TOPFLASH in 
MK4 cells but had a significant effect in IMCD cells (P < 0.01). WNT7b also 
had a significant stimulatory effect in IMCD cells (**P < 0.01). 
nephric duct lineage expresses a unique panel of genes such as 
Lim-1, c-Ret, Pax2, Pax8, and Gata3. Conceivably, canonical 
WNT signaling may specify nephric duct cell fate as it does in 
a variety of other developmental settings. In zebrafish, the 
canonical effects of WNT2b in lateral plate mesoderm are 
required for liver specification; liver organogenesis fails in 
prl(—/—) mutants bearing Wnt2b null alleles (25). Canonical 
WNT signals propel differentiation of bone cell precursors 
along the osteoblast pathway (10). In the inner ear, canonical 
WNT signals drive precursor cells toward the otic placode fate 
(26). Canonical WNT signaling is important for organogenesis 
of lung, pancreas, and mammary gland as well (5, 7, 24). 
In developing metanephric kidney, we noted that p-catenin 
signaling activity becomes progressively focused at the tips of 
UB branches and gradually disappears from maturing UB 
trunks. Costantini has shown that UB tip cells express a unique 
panel of genes such as Ret and Wntll, distinguishing them 
from sister cells which comprise the UB trunk (28). Davies and 
Michael (21) have also drawn attention to the fact that cell 
division at UB tips is especially intense at UB tips compared 
with the UB trunk. The P-catenin/TCF pathway activates 
transcription of specific gene targets including Myc and cyclin 
Dl (9) and can negatively regulate transcription of the potent 
cell cycle inhibitor, p21, in HEK293 cells (14). It seems 
plausible therefore that the (3-catenin pathway could be in-
volved in cell fate specification and proliferation of UB tip 
cells. 
Strong B-catenin/TCF signaling activity was observed in the 
mesenchymal clusters capping each UB tip. As mesenchymal 
condensates progressed to the S-shaped body stage, (3-catenin/ 
TCF signaling was restricted to the distal portion of the 
structure, comprising the anlage of renal proximal and distal 
tubules; WNT signaling was conspicuously absent in the 
emerging glomerulus. This could suggest an additional role for 
canonical WNT signaling in cell fate specification and rapid 
growth of the nephron's tubular segments derived from mes-
enchyme. Interestingly, mice with a conditional knockout of 
(3-catenin in lung epithelial cells exhibit fairly normal proximal 
airways but lack the distal portions of the pulmonary tree (24). 
Since (3-catenin/TCF signaling was especially intense in the 
nephrogenic zone of developing kidney, we considered the 
possibility that the pathway might be required for branching 
morphogenesis. To test this hypothesis, we blocked the canon-
ical WNT signaling in kidney explants using recombinant 
DKK1. DKKI specifically blocks the canonical pathway by 
binding to the frizzled coreceptor, LRP5/6, and interfering with 
WNT ligand binding (1). When EI3.5 kidney explants from 
HoxB7/GFP fetal mice were exposed to DKKI, we found that 
the number of UB branch tips was significantly reduced (40% 
of controls) within 24 h. If we take into account that UB 
branching is reiterated many times before nephrogenesis comes 
to an end, the impact of a moderate inhibition of branching is 
amplified many times over. The effect of DKK1 is comparable 
to the effect of Pax2 haploinsufficiency which produces renal 
insufficiency in mutant mice (8). This is the first demonstration 
DKKI 500 ng/ml DKKI 
Fig. 5. DKKI suppresses canonical WNT signaling activity in cell culture. 
Inner medullary collecting duct (IMCD) cells were transiently cotransfected 
with TOPFLASH and an expression vector containing full-length DKKI 
cDNA or empty vector control (A). After 48 h, luciferase activity was 
significantly reduced (23% of control, **/» < 0.05) by DKKI. To test the 
ability of recombinant mouse DKKI protein to inhibit canonical signaling, 
IMCD cells were transiently cotransfected with TOPFLASH and a control 
vector in the presence (500 ng/ml) or absence (0 ng/ml) of DKKI protein (8). 
After 24 h, luciferase activity was reduced to 40% of the control (**/* < 0.01). 
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Fig. 6. DKK1 reduces UB branching in El3.5 mouse kidney explants. El3.5 
kidneys from Hoxb7/GFP mice were cultured in the presence or absence of 
recombinant murine DKK1 protein. UB tip number was counted under fluo-
rescent light at 0. 24, and 48 h and expressed as the percent increase above 
baseline (A). After 24 h, control kidney UB tips had increased by 40%, while 
kidneys exposed to DKK1 inhibitor showed an increase of only 18% in UB tip 
number (**P < 0.005). After 48 h, control kidney UB tip number had 
increased to 70% of baseline, whereas UB tip number had increased to only 
40% of baseline in kidneys exposed to DKK I (**P = 0.01). Representative 
images (8) of control and DKK.1 explants at 48 h (X40) demonstrate the 
decrease in UB branching. Immunofluorescent staining of WT1 in El3 HoxB7/ 
GFP kidney explants shows similar WT1 expression pattern in induced 
mesenchyme (tm) and podocyte layers of emerging glomeruli (g) in both 
control and DKK 1-treated tissue (C). 
that canonical WNT signaling is required for branching mor-
phogenesis in the kidney. De Langhe et al. (6) observed similar 
inhibition of pulmonary branching in murine fetal lung ex-
plants exposed to DKK1. 
Our studies identify the primary sites of canonical (3-catenin/ 
TCF pathway activity during kidney development. This begs 
the question as to which WNT ligands might be driving this 
focused pathway activity. Several canonical WNTs (WNT7b, 
WNT6, and WNT9b) are expressed in the nephric duct and the 
early UB. However, WNT7b is evident in the UB stalk by 
El3.5 (16) but is not evident at UB tips or in S-shaped bodies. 
WNT6 is expressed in the UB at early stages but is downregu-
lated after E14.5 (13). WNT6 can induce tubulogenesis in 
tissue culture assays but was unable to support UB branching 
in vitro. Similarly, WNT9b is expressed in the nephric duct and 
UB stalk from E9.5 to £74.5, but is downregulated thereafter 
(4). While each of these three WNTs could contribute to 
canonical signaling in early stages, none could account for the 
intense TCF signaling activity associated with UB tips or 
S-shaped bodies during later stages of nephrogenesis. 
WNT 11, WNT2b, and WNT4 are all expressed at sites that 
might account for the observed TCF signaling activity. How-
ever, WNT11 has been consistently associated with noncanoni-
cal signaling pathway activity in other reports and had no effect 
on TOPFLASH in our assays. On the other hand, WNT2b is 
expressed as early as El 1.5 in metanephric mesenchyme (18) 
and has been shown to activate the |J-catenin pathway in other 
settings (17). Lin et al. (30) showed that WNT2b supported 
growth of isolated mouse UB. In our studies, WNT2b activated 
the canonical pathway in both MK4 (mesenchymal) and IMCD 
(UB lineage) cells. 
WNT4 is expressed in the condensing mesenchyme and in 
the S-shaped bodies as they differentiate (31) and can activate 
the canonical pathway in Madin-Darby canine kidney cells 
derived from the renal collecting duct (19). Similarly, in our 
assays, WNT4 activated the canonical TOPFLASH reporter in 
IMCD cells. However, there was no apparent effect on mes-
enchymally derived MK4 cells. Furthermore, we found no 
apparent effect of DKK 1 on WT1 expression in glomeruli of 
fetal kidney explants. Thus the restricted canonical signaling 
activity at the distal end of the S-shaped body may reflect 
stimulation by mesenchymal WNT2b. WNT4 derived from the 
condensing mesenchyme might contribute to other canonical 
ligands affecting the UB tip, but the profound effects of WNT4 
on progression of condensing mesenchyme to the S-shaped 
body stage must involve its capacity to activate noncanonical 
signaling pathways (19). 
As murine kidney development progresses, canonical WNT 
signaling activity disappears from maturing segments of the 
nephron and is restricted to the nephrogenic zone. In the 
perinatal period, as nephrogenesis comes to an end, WNT 
signaling activity is completely extinguished. The inhibitory 
mechanism is not entirely clear, but Simons et al. (29) pro-
posed that onset of tubular flow through mature nephron 
segments induces signals from luminal cilia which may sup-
press the canonical WNT pathway. When IMCD cells were 
exposed to laminar flow in vitro, expression of the cilial 
protein, inversin, increased and cytoplasmic levels of (i-catenin 
fell. Inversin appears to suppress TOPFLASH activity by 
inducing degradation of the key signal transduction pathway 
molecule, dishevelled. 
In summary, intense canonical WNT signaling pathway 
activity is evident throughout the nephric duct and early UB, 
where it is required for normal branching morphogenesis. 
When canonical WNT activity is blocked by exogenous 
Dickkopf-1 protein, arborisation of the UB is diminshed. As 
development proceeds, WNT signaling is progressively re-
stricted to UB tips and distal portions of the S-shaped body but 
is suppressed in the emerging glomerulus and in maturing 
trunks of the UB and is globally downregulated as nephrogen-
esis comes to an end. We hypothesize that suboptimal WNT 
signaling could result in renal hypoplasia, whereas failure of 
mechanisms that normally suppress WNT signaling might 
contribute to aberrant budding growth of tubular cells in 
polycystic kidney disease. 
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Dziarmaga, Alison, Pierre-Alain Hueber, Diana Iglesias, Nancy 
Hache, Aaron Jeffs, Nathalie Gendron, Alex MacKenzie, Michael 
Eccles, and Paul Goodyer. Neuronal apoptosis inhibitory protein is 
expressed in developing kidney and is regulated by PAX2. Am J 
Physiol Renal Physiol 29\: F913 F920.2006. First published May 30, 
2006; doi:10.1152/ajprenal.00004.2006.—During fetal kidney devel-
opment, the extent of ureteric bud (UB) branching will determine final 
nephron endowment for life. Nephron number varies widely among 
normal humans and those who are born at the low end of the nephron 
number spectrum may be at risk for essential hypertension in adult-
hood. Little is known about how nephron number is set. However, we 
previously showed that the transcription factor, Pax2, suppresses 
apoptosis in UB cells during kidney development and optimizes 
branching morphogenesis. Here, we report that PAX2 directly binds 
to a specific recognition motif in the human neuronal apoptosis 
inhibitory protein (NAIP) gene promoter. NAfP is an endogenous 
inhibitor of apoptosis, inactivating caspase-3 and caspase-7 in neuro-
nal tissues. PAX2 activates NAIP gene transcription (7-fold) in vitro 
and NAIP transcript level is increased fourfold in HEK293 cells stably 
transfected with PAX2. We show that Naip is expressed in embryonic 
day 15 (£75) fetal kidney tissue (RT-PCR) and NAIP protein is 
demonstrated by immunohistochemistry in EI5 mouse kidney collect-
ing ducts and PI proximal tubules. Naip mRNA is significantly 
reduced (50%) in heterozygous Pax2 mutant mice. Finally, we show 
that an antisense Naipl cDNA transfected into murine collecting duct 
cells doubles caspase-3/7 activity induced by Baxa. These observa-
tions suggest that the powerful effects of PAX2 on renal branching 
morphogenesis and final nephron number may be mediated by acti-
vation of Naip which then suppresses apoptosis in UB cells. 
Naip {Bird): kidney development; renal hypoplasia 
DEVELOPMENT OF THE METANEPiiRic kidneys begins when the 
ureteric bud (UB) emerges from the wall of the nephric duct 
and grows laterally into the adjacent mesenchyme and begins 
to arborize. Signals from the tip of each UB branch induce 
formation of individual nephrons. When nephrogenesis finally 
conies to an end (••--] mo before birth in humans), the number 
of UB branching events by that time will determine nephron 
number for life. Although there are multiple genes required for 
branching morphogenesis, the molecular mechanism by which 
nephron number is set remains unknown. 
When congenital nephron number is severely reduced, renal 
functional capacity is insufficient for postnatal life and children 
Address for reprint requests and other correspondence: P. Goodyer, Mon-
treal Children's Hospital Research Institute, 4060 Ste-Catherine St. West, 
#413-1, Montreal, Quebec. Canada H3Z 2Z3 fe-mail: Paul.Goodyer 
@muhc.mcgill.ca). 
develop progressive renal failure as they grow. About 40% of 
pediatric end-stage renal disease is due to some form of 
congenital hypoplasia (2). Even in the "normal" population, 
however, nephron number varies widely, ranging from 300,000 
to over one million per kidney (7). This was once dismissed as 
a benign reflection of human diversity but recent evidence 
suggests that subtle renal hypoplasia may be of considerable 
clinical importance. Mice with heterozygous Gdnf mutations 
have a significant decrease (30%) in total nephron number. 
These mice develop glomerular hypertrophy and hypertension 
as adults (9). This observation is remarkably similar to the 
report of Keller et al. (22) who found that patients with 
essential hypertension have roughly 50% fewer nephrons than 
age-matched controls. 
In 1995, Sanyanusin et al. (42, 43) reported that a rare form 
of autosomal dominant renal hypoplasia, Renal-Coloboma 
Syndrome (RCS), is caused by mutations of the developmental 
transcription factor, PAX2. In this syndrome, renal hypoplasia 
is associated with defects of the optic nerve (36). Some patients 
lacking obvious eye findings were initially assigned the diag-
nosis of "oligomeganephronia," based on renal biopsies show-
ing an absolute reduction in nephron number associated with 
striking hypertrophy of glomeruli (40). Subsequently, the pa-
tients were also found to have heterozygous PAX2 mutations 
(40), suggesting that PAX2 is centrally involved in setting 
nephron number. 
PAX2 is one of the nine members of the "paired-box" family 
of transcription factor genes and is normally expressed in fetal 
midbrain-hindbrain region, the eye, the ear, and the kidney 
(11). During kidney development, Pax2 is first expressed in the 
nephric duct during its caudal descent and then in the branch-
ing UB (4, 11). Fetal mice with heterozygous Pax2 mutations 
exhibit a striking increase in apoptosis of UB cells (36). Pax2 
inactivation also enhances apoptosis in mIMCD-3 cells derived 
from murine collecting duct (46). Targeted expression of a 
proapoptotic gene (Baxa) to the fetal UB increases apoptosis 
and reduces the number of branching events by embryonic day 
15 (El5.5), mimicking RCS (12). Furthermore, the renal 
branching deficit in Pax2 mutants can be reversed in vitro and 
in vivo by the caspase inhibitor z-VAD-fmk (8). Thus PAX2 
appears to suppress programmed cell death in the UB lineage 
during branching morphogenesis of the kidney. This effect is 
critical to achieve optimal nephron number at birth (12). 
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F914 NAIP IS EXPRESSED IN KIDNEY AND IS REGULATED BY PAX2 
The mechanism by which PAX2 suppresses the pathways of 
programmed cell death is unknown. We examined expression 
of apoptosis-related genes in HEK293 cells stably transfected 
with PAX2. This focused our attention on the neuronal apop-
tosis inhibitory protein (NAIP) gene, also known as BIRCL 
encoding an endogenous caspase inhibitor. Although NAIP 
was initially discovered during positional cloning of the spinal 
muscular atrophy gene and NAIP protein was subsequently 
shown to inhibit caspases-3 and -7 in neural tissue (27), we 
show that NAIP is also expressed in fetal kidney UB. PAX2 
directly binds to a motif in the NAIP promoter and stimulates 
transcriptional activity in vitro. Naip transcript levels are de-
creased in Pax21Neu mutant mice. Unlike humans who have a 
single functional NAIP gene, mice have multiple copies. How-
ever, we show that the Naipl transcript is abundant in fetal 
kidney and an anti-sense Naipl cDNA enhances apoptosis in 
cultured murine kidney collecting duct cells. 
MATERIALS AND METHODS 
RNA isolation. Total RNA was isolated from mouse kidneys at fetal 
stages £75.5 and E18.5, at postnatal day 1, and adult kidney of 
wild-type and Pax2INeu mice. Briefly, tissues were microdissected and 
placed in RNAlater (Ambion, Austin, TX) at 4°C. Each kidney was 
homogenized in TRIzol (lnvitrogen, Carlsbad, CA) for 5 min and then 
mixed with 0.2 volumes of chloroform and incubated at room tem-
perature for 10 min. Samples were centrifuged at 12,000 rpm for 15 
min at 4°C. The aqueous layer was removed and equal volume of 70% 
ethanol was added. Samples were then processed with the RNeasy kit 
(Qiagen. Valencia, CA) as per manufacturer's recommendations and 
total RNA was eluted in 30 JJLI of RNase-free water. Total RNA was 
also isolated from cultured cells with TRIzol (lnvitrogen) as above or 
with phenol/chloroform extraction followed by DNasel treatment 
(Promega, Madison, WI). 
Real-time RT-PCR of lAPs. Human fetal kidney (HEK293) cells 
were stably cotransfected with a hygromycin resistance vector and a 
pUHD mammalian expression vector containing a CMV-driven full 
length human PAX2b cDNA or an empty vector control (46). Trans-
fectants were selected in hygromycin and cloned. PAX2 expression 
was confirmed by Western immunoblotting. RNA samples from 
cells ± PAX2 were analyzed for the following inhibitors of apoptosis 
(lAPs): XIAP, NAIP, HIAPI, HIAP2, and Survivin, by real-time 
RT-PCR (with GAPDH as internal standard) as previously described 
(30). The comparative CT method was used for relative quantification 
between HEK293/P/«2(+) and HEK293/ft4X2( - ) cells (26). 
RT-PCR of total Naip transcripts in mIMCD-3 cells. Total RNA 
(200 ng or 1 |xg) was reverse transcribed by using a one-step RT-PCR 
kit (Qiagen) with gene-specific primers as per manufacturer's recom-
mendations. Mouse Naip primers were designed for a 487-bp frag-
ment of the coding region spanning exons 2-9. The primers contained 
conserved sequences common to all mouse Naip isoforms (21). Naip 
forward: 5'-GGGACATCACCACGTGTACTC-3'; Naip reverse: 5'-
TTGTTGTGCTCTTGTATTGGG-3'; Gapdh forward: 5'-AAG-
GGCTCATGACCACAGTC-3'; and Gapdh reverse: 5'-CATACTT-
GGCAGGTTTCTCCA-3'. RT-PCR conditions were as follows; a 
30-min reverse transcription step at 50°C proceeded by an incubation 
at 95°C for 15 min. A total of 35 cycles were performed at 94°C for 
1 min, 58°C for 1 min, 72°C for 1 min, followed by 72°C for 10 min. 
Samples were run on a 1 % agarose gel. The product sizes for Naip and 
Gapdh were 487 and 252 bp, respectively. 
Real-time RT-PCR assay of total Naip transcripts in Pax21N''" 
(+/—) mutant mice. cDNA was synthesized from 500 ng of mouse 
kidney total RNA using random hexamer primers (Promega) and 
Superscript III (lnvitrogen) as per the manufacturer's recommenda-
tion. One microliter of cDNA was used for Sybr Green-based quan-
titative real-time RT-PCR by using a Prism 7000 Sequence Detection 
System (ABI). PCR conditions were as follows: 2-rnin incubation at 
95°C, followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C 
for 30 s. Results were standardized with a housekeeping gene, beta 2 
microglobulin (B2m), and the comparative CT method was used for 
relative quantification (3, 26). Duplicate samples from four different 
litters of £75.5 fetuses (wild-type, n = 12 and Pax2,Neu, n = 16) and 
two different litters of postnatal day I animals (wild-type, n — 13 and 
Pax21Nl'", n — 5) were studied. Intron-spanning primers were de-
signed for mouse Naip and B2m as follows: Naip forward primer: 
5'-GCCAGGTACCATGAAGAGGA-3'; Naip reverse primer: 5'-
CCACAGGAAAAACACTGCAC-3'; B2m forward primer: 5'-TG-
CAGAGTTAAGCATGCCAGTATGG-3'; and B2m reverse primer: 
5'-TGATGCTTGATCACATGTCTCG-3'. Amplicons for Naip and 
B2m were 143 and 75 bp, respectively. 
Real-time RT-PCR of Naipl transcript in mouse kidney. For real-
time quantitative RT-PCR of Naipl, 100 ng of total RNA for each 
sample were assayed in triplicate for expression of Naipl RNA 
simultaneously with mouse Gapdh rnRNA. RT-PCR reactions were 
performed in the ABI Prism 7700 Sequence Detection System (Perk in 
Elmer Applied Biosystems, Foster City, CA) with the TaqMm EZ 
RT-PCR kit (Perkin Elmer Applied Biosystems) and TaqMm Rodent 
Gapdh control reagent (Perkin Elmer Applied Biosystems). Reactions 
were performed according to manufacturer's recommendations. 
Briefly, 25-ud RT-PCR reactions contained: 1X Ta^Man EZ Buffer, 
3 mM Mn(OAc), 300 p.M deoxy-ATP, -CTP, -GTP, 600 |xM de-
oxyUTP, 100 nM rodent Gapdh primers and probe, 600 nM mouse 
Naipl primers, 200 nM mouse Naipl probe, 0.25 u.1 AmpErase UNG, 
and 2.5 U rTth DNA Polymerase. RT-PCR conditions were: 2 min at 
50°C, 30 min at 60°C, 5 min at 95°C, followed by 40 cycles of 15 s 
at 94°C and 1 min at 60°C. Samples were normalized for Gapdh 
rnRNA content and expressed as fold induction. Primers and probes 
use for Naipl were: forward primer: 5'-TTCCTGTGGCGGA-
AGCTT-3'; reverse primer: 5'-TGGGCAATTTCCTCTGAAGATT-
3'; and probe: 5'-AGCATGCCAAGTGGTTCCCCAAATG-3'. 
Western immunoblotting. Stably transfected HEK293 cells (47— 
PAX2) were incubated on ice for 15 min in 10 mM HEPES, pH 7.9, 
10 mM KC1, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 
mM PMSF, and proteinase inhibitory cocktail (Roche Diagnostics, 
Mannheim, Germany). NP-40 was then added (0.3%) and the mix was 
vortexed, incubated on ice for 1 min, and centrifuged at 13,000 rpm 
for 5 min. The supernatant was discarded and the pellet was resus-
pended in lysis buffer containing 20 mM HEPES, pH 7.9, 400 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM PMSF, 
proteinase inhibitory cocktail (Roche Diagnostics) and glycerol 
(25%). Following a 1-h incubation on ice, the lysate was centrifuged 
at 13,000 rpm for 5 min and the supernatant was removed and stored 
at —70°C until ready to use. 
Cytoplasmic protein was extracted from whole postnatal day — 1 
mouse kidnev tissue. Briefly, kidnevs were homogenized in 500 p.1 of 
RIPA buffer'(50 mM Tris-HCl, pll'7.4, 150 mM NaCl, 1 mM PMSF, 
1 mM EDTA, 5 u,g/ml aprotinin, 5 jxg/ml leupeptin, 1 % Triton X-100, 
1% Na Deoxycholate, 0.1% SDS), incubated on ice for 20 min, 
centrifuged at 13,500 rmp for 25 min at 4°C, and the supernatant was 
removed and stored at —70°C until ready to use. 
Extracts containing 30 p,g of protein (Pierce Biotechnology, Rock-
ford, IL) were resolved on a 10% SDS-polyacrylamide gel and 
transferred to a nitrocellulose membrane (Bio-Rad, Mississauga, On-
tario). Blots were probed with a 1:200 dilution of polyclonal anti-
hNAIP antibody (AbCam) or a 1:250 dilution of polyclonal anti-
mPAX2 antibod'y (Zymed, San Francisco, CA) followed by a 1:1,000 
dilution of anti-rabbit IgG secondary antibody (Perkin Elmer Life 
Sciences, Boston, MA), detected with an enhanced chemilumines-
cence detection system (Amersharn, Picataway, NJ) and exposed to 
autoradiography film (Kodak Biomax MR Film). Membranes probed 
for PAX2 were, reprobed for B-actin (Oncogene Research Products, 
San Diego, CA) to normalize for loading differences. 
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ImmunojUiorescent staining. Kidneys from wild-type CD1 animals 
were mierodissected at fetal age day 1S.S and postnatal day J and 
fixed in 4% paraformaldehyde (Sigma, St. Louis, MO) for 4 h at 4°C. 
Kidneys were rinsed briefly and then kept overnight in cold PBS. 
Tissues were placed in 15% sucrose/PBS until they sank, followed by 
30% sucrose/PBS incubation and then placed in Tissue-Tek OCT 
(Sakura, Torrance, CA) at room temperature for 2 h before freezing on 
dry ice. Fourteen-micrometer sections were washed in PBS for 5 10 
min, dried at room temperature for 10 min, and fixed in cold acetone 
for 10 min at room temperature. Sections were incubated in universal 
blocking horse serum in PBS for 1 h at room temperature, followed by 
an overnight incubation at 4°C with a 1:25 dilution of a polyclonal 
IgG rabbit anti-hNAIP antibody (Abeam, Cambridge, MA). Sections 
were then incubated with a 1:200 dilution of goat IgG anti-rabbit 
Texas Red (Vector Laboratories, Burlingame, CA) in a 0.1 M sodium 
bicarbonate, 0.15 M sodium chloride buffer, pH 8.5, for 1 h at room 
temperature in the dark. For double labeling, sections were also 
incubated overnight at 4°C with fluoiescein-labeled lectins, Dolichos 
Biflorus Agglutinin (DBA), to identify collecting duct tubules and 
Lotus Tetragonolobus Lectin (LTL) to identify proximal tubules 
(Vector Laboratories), mounted with fluoromount (Sigma), and visu-
alized with a Zeiss microscope. This antibody did not work on 
paraffin-embedded sections. 
Vector construction and assay of promoter activity in vitro. A 
780-bp Snial and an end-filled Agel fragment containing the 5' 
flanking sequence of the human NAIP gene (—780 to +1) was ligated 
into pGL2-basic upstream of the luciferase reporter using Smal sites. 
NIH3T3 cells were cultured in monolayer and transiently transfected 
with the reporter vector using FuGene (Roche, Laval, QC) in the 
presence and absence of a full-length human PAX2b cDNA in 
pcDNA3. Cells at 60 70% confluency were transfected with 0.5 pg 
of human NAIP-Luciferase, 0.5 (xg of human PAX2b cDNA or empty 
vector control, and 5 ng of renilla luciferase as a standard control. 
Cells were harvested after 48 h posttransfection and lysed in a 1X 
passive lysis buffer (Promega) and assayed for firefly and renilla 
luciferase using the Dual Luciferase Kit (Promega) as per the mau-
facturer's recommendations. Transfections were performed (6 repli-
cates) on three separate occasions. 
EMSA. Initial screening of the 780-bp human NAIP promoter 
sequence was done by Matlnspector software. Putative PAX2 binding 
sites were identified and 40-bp oligos were synthesized, annealed, and 
labeled with [ot-32P]dCTP via the Klenow fill in reaction. Binding 
reactions containing buffer and purified human PAX2b protein were 
incubated on ice for 15 min, after which hot probe was added, and 
reactions were further incubated on ice for 30 min in a total volume 
of 20 (xl. Samples were resolved at room temperature on a 6% 
nondenaturing polyacrylamide mini gel in 0.25 X TBE at 90 V. Gels 
were then dried at 80°C for 30 min in a vacuum and exposed to film 
at room temperature overnight. To confirm specificity of DN A/protein 
complexes, reactions were also incubated with rabbit anti-PAX2 
antibody (Zymed) or with mutated oligonucleotides. Competitive 
binding assays were performed with cold unlabeled probe at 50 X and 
100X excess. Full-length human PAX2b cDNA cloned into pcDNA3 
was used to synthesize purified protein by a coupled in vitro tran-
scription-translation system (TNT/T7, Promega) as per the manufac-
turer's recommendations and run on a 4% SDS-PAGE gel to confirm 
specificity. NAIP oligo: 5'-TGCCAGTGATTTAGCCAATCATGC-
CTAAGTGATGGCACCT; NAIP mut: 5'-TGCCAGTGATTTAGC-
CAATAATGTCTAAGTGATGGCACCT. 
Naipl knockdown in vitro in cultured cells. To study the effects of 
Naipl knockdown, murine inner medullary collecting duct 
(mJMCD-3) cells were cultured in DMEM medium supplemented 
with 10% fetal bovine serum and with 1 % penicillin/streptomycin in 
six-well plates. Cells that were 5 0 - 6 0 % confluent were transiently 
cotransfected with Box cDNA and mouse Naipl anti-sense cDNA. 
The Naipl anti-sense construct is a 566-bp fragment of the first coding 
exon (exon 2) of the mouse NAIP gene cloned into the pCI plasmid 
(20). One microgram of total DNA (0.5 |o.g of Bax and 0.5 pg of either 
Naip anti-sense or empty pCI control) using FuGene (Roche) reagents 
as per the manufacturer's recommendations. Cells were harvested 
after 48 h of transfection in 1.0 ml of PBS by scraping and eentrifu-
gation at 4,000 rpm for 4 min. After several PBS washes, cell pellets 
were lysed in 1% NP-40, 0.1% SDS lysis buffer in PBS and incubated 
on ice for 20 min, followed by a 20-min centrifugation at 14,000 rpm 
at 4°C. The supernatant was removed and stored at —70°C until ready 
for analysis of caspase-3 activity (Promega). Total protein was mea-
sured (Pierce) and 10 pg were used in a volume of 50 pi and 
combined with 50 pi of caspase 3/7 substrate with buffer and 
incubated at room temperature for 1 h in the dark. Samples were 
assayed for caspase 3/7 activity by measure of firefly luciferase 
activity according to the manufacturer (Promega). Experiments were 
repeated on three separate occasions in duplicate. 
RESULTS 
PAX2 selectively activates endogenous NAIP in HEK293 
cells. The H E K 2 9 3 human embryonic kidney cell line ex-
presses low levels of P A X 2 protein. To determine whether 
P A X 2 has an effect on the transcriptional activation of LAP 
genes, HEK.293 cells were stably transfected with a CMV-
driven expression vector containing the full-length human 
PAX2b cDNA. Stably transfected HEK293 / /MX2 cells exhib-
ited high levels of P A X 2 protein by Western immunoblott ing 
compared with control cells transfected with empty plasmid 
(Fig. 1A). Total R N A was extracted from the cells and ana-
lyzed by real-time RT-PCR for changes in transcript levels of 
various IAP family members (HAIP1, HAIP2, XIAP, Survivin, 
and NAIP). Of these, only NAIP showed a significant increase 
(4-fold ± 0 . 2 0 SE) in transcript level compared with control 
cells transfected with an empty plasmid ( P < 0 .01 ; Fig. IB). 
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Fig. 1. Increased NAIP expression in HEK293 cells transfected with PAX2. 
HEK293 cells transiently transfected with full-length human PAX2 cDNA had 
increased PAX2 protein compared with HEK293 cells transfected with an 
empty plasmid as a control (A). HEK293 cells ± PAK2 were analyzed by 
real-time RT-PCR for changes in inhibitors of apoptosis (IAP) mRNA expres-
sion normalized to GAPDH. In the presence of PAX2, NAIP mRNA was 
increased 4-fold (P < 0.01; B). No other IAP was significantly stimulated by 
PAX2. 
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Naip is expressed in developing mouse kidney. Unlike hu-
mans who bear only one functional copy of the NAIP gene 
(51), mice have undergone gene duplication events resulting in 
six separate but highly homologous Naip genes (13, 52), To 
determine whether one or more Naip genes is expressed in the 
developing mouse kidney, we first assessed total Naip tran-
scripts in RNA from EJ5.5, EJS.5, PI mouse kidney tissues, 
and mIMCD-3 cells (derived from murine collecting duct) by 
qualitative RT-PCR using primers for a completely conserved 
region spanning exons 2- 8. Naip transcripts were evident in all 
samples (Fig. 24), although earlier time points were not ex-
amined. 
To demonstrate NAIP protein expression in the developing 
mouse kidney, we performed Western immunoblotting on 
whole PI kidneys and immunofluorescent microscopy on fro-
zen sections of normal £75.5 mouse kidney, using a rabbit 
polyclonal antibody raised against human NAIP. Earlier time 
points were not studied. NAIP protein was identified as a single 
140-kDa band by Western immunoblotting, confirming speci-
ficity of our antibody (Fig. 2B). As a marker for fetal collecting 
ducts, sections were costained with FITC-labeled DBA. As a 
marker for proximal tubules, the sections were costained with 
LTL. NAIP expression, detected with an anti-hNAIP primary 
Fig. 2. Naip expression in fetal mouse kidney. Naip mRNA was detected in 
RNA from murine mIMCD-3 cells by RT-PCR (A). Naip mRNA was also 
detected in fetal (E15.5, E1S.5) and newborn (PI) mouse kidney tissues (.4). 
NAIP protein is seen as a 140-kDa band in extracts of whole PI kidney (B). In 
frozen sections of E15.5 mouse kidney, collecting duct cells stained by 
FITC-labeled dolichos biflorus agglutinin (DBA; C) also expressed NAIP 
protein (D). Coexpression of NAIP and DBA in collecting ducts is clearly 
demonstrated in the merged image (£). Newborn proximal tubular cells 
staining with lotus tetragonolobus lectin (LTL; F) also expressed NAIP protein 
(G). The coexpression of NAIP in proximal tubule cells is also demonstrated 
in a merged image (//). 
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Fig. 3. Decreased Naip expression in heterozygous Pax2!Nr" mutant mice. 
Real-time RT-PCR was used to assess levels of Naip mRNA (normalized to 
beta 2 microglobulin mRNA) in both fetal (EI5.5) and newborn (PI) mouse 
kidneys. In E15.5 Pax2IN"' heterozygous mutant kidneys, Naip mRNA was 
significantly reduced (50%) compared with wild-type controls (/•> < 0.005). 
Naip mRNA was similarly decreased in newborn Pax2 mutants (P < 0.05). 
antibody and Texas Red-tagged secondary antibody, was 
strong in all collecting duct structures (Fig. 2, C, D, E). By 
postnatal day 1, NAIP staining was also evident in proximal 
tubules (Fig. 2, F, G, H). Subcellular NAIP staining pattern is 
broader than that of DBA or LTL luminal markers (implying 
cytoplasmic and/or basolateral localization) but also seems to 
involve some NAIP protein at the luminal membrane. These 
expression patterns show some overlap with those of PAX2, 
which is strongly expressed in both collecting ducts and prox-
imal tubules of fetal kidney (4, 36). Sections stained with 
secondary antibody alone showed no signal. 
Naip mRNA expression is reduced in fetal kidney of 
Pax2'Ne" (+/-) mutant mice. Total RNA was isolated from 
wild-type and heterozygous Pax2INe" mutant mouse kidney 
tissues at El5.5 and postnatal day —I (PI). Quantitative 
real-time RT-PCR was used to assess Naip mRNA transcript 
levels normalized for beta 2 microglobulin. Kidneys from 
£75.5 Pax2JNeu (+/—) mice showed a significant reduction 
(43 ± 3.4% SE of wild-type littermate controls) in the level of 
Naip transcript (P < 0.005). In PI mutant kidneys, the de-
crease in Naip transcript expression was slightly less prominent 
(66 ± 16% SE of wild-type littermates; P < 0.05; Fig. 3). 
PAX2 activates the NAIP promoter in vitro. Initial screening 
of the 780-bp 5' flanking sequence of the human NAIP gene 
revealed a site homologous to the published core consensus 
sequence for PAX2 recognition motifs (Fig. 44). This motif 
was located 140 bp upstream of the transcriptional start site. To 
determine whether PAX2 activates the human NAIP promoter, 
a 780-bp fragment of the human NAIP 5' flanking sequence 
was cloned into a luciferase reporter vector (Fig. AB). NIH3T3 
cells were transiently cotransfected with the NAIP promoter 
reporter and an expression vector containing the full-length 
PAX2b cDNA. Luciferase activity was increased 6.7-fold 
(±0.05 SD) in the presence of PAX2b compared with empty 
vector controls (1.0 ± 0.17 SD; P < 0.001; Fig. AC). 
PAX2 protein binds directly to the NAIP promoter. EMSA 
were used to demonstrate direct binding of human PAX2 
protein to the human NAIP promoter. PAX2b protein was 
synthesized in vitro; presence of PAX2 protein in the transla-
tion mix was confirmed by Western immunoblotting (Fig. 5A). 
For EMSA, a 40-bp oligonucleotide containing the putative 
PAX2 binding motif was radiolabeled and incubated with 
PAX2b protein. A DNA/protein complex was observed that 
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Fig. 4. Putative PAX2 binding sites in the NAIP promoter. A unique motif was 
identified in the 780-bp 5' flanking sequence of the human NAIP gene which 
was highly homologous to published PAX2 binding sites (A). This putative 
PAX2 recognition motif was in close proximity to the NAIP transcriptional 
start site ([)). To assess the promoter activity of this sequence in vitro, the 
whole 780-bp fragment was cloned into a luciferase reporter vector. The 
rVA/P-luciferase construct was transiently cotransfected into NIH3T3 cells 
with or without a full-length PAX2 expression vector. In the presence of 
PAX2. NAIP promoter activity was significantly increased (6.7-fold) compared 
with an empty vector control (P < 0.001; C). 
Pax2 haploinsufficiency (12). To ascertain whether Naipl 
inactivation affects susceptibility of murine collecting duct 
cells to apoptosis, we transiently transfected mIMCD-3 cells 
with an expression vector containing the full-length murine 
Bax-a cDNA to initiate the caspase cascade (Fig. 7). Cells 
were cotransfected with control (empty pCI. vector) or a Naipl 
antisense cDNA expression vector previously shown to inac-
tivate Naipl expression in neuronal cells (19). This antisense 
vector contains a 566-bp sequence complementary to the first 
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disappeared in the presence of PAX2 antibody (Fig. 5B). To 
confirm the specificity of the putative PAX2 binding motif, we 
performed competitive assays, incubating the protein and hot 
probe with 50 X and 100X excess cold probe. Incubation with 
cold probe resulted in the disappearance of the DNA/protein 
complex (Fig. 5C). Furthermore, we mutated 2 bp in the 
conserved region of the published consensus sequence (Fig. 
5E) and repeated the EMSA. When mutated oligos were 
incubated with PAX2b protein, a band shift was no longer 
observed (Fig. 5D). 
Naipl is expressed in fetal mouse kidney. In preliminary 
experiments using gene-specific primers for quantitative RT-
PCR, we found that multiple Naip isoforms are expressed in 
mouse kidney (data not shown). However, Naipl (the most 
homologous to human NAIP) was a dominant transcript. Naipl 
levels in E15 normal fetal mouse kidney were 7.4-fold higher 
(±1.87 SE) than in adult kidney (1.0 ± 0.138 SE; P < 0.0001; 
Fig. 6). 
Naipl ami sense cDNA enhances apoptosis induced by Baxa 
in 1MCD cells. In previous studies, we showed that mice 
expressing a Baxa transgene in renal collecting ducts caused 
increased apoptosis of those cells, mimicking the effects of 
D 
Mut otigo -
Antibody - - * -
PAX2 - + + + 
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Fig. 5. Direct binding of PAX2 to human NAIP promoter. PAX2 protein was 
synthesized in a cell-free system and confirmed by immunoblotting (.4). In 
EMSA experiments, PAX2 protein formed a high-molecular-weight complex 
with a radiolabeled 40-bp oligonucleotide containing the putative NAIP bind-
ing site (B). The band shift disappeared when the PAX2 protein was first 
incubated with anti-PAX2 antibody (B and C). The band shift was progres-
sively competed out by increasing concentrations of cold NAIP probe (C). 
NAIP oligonucleotides containing mutations of 2 core nucleotides in the 
putative PAX2 recognition motif (E) abrogated PAX2 binding (D). 
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Fig. 6. Naip-1 mRNA expression in fetal (E15) mouse kidney relative to that 
in adult mouse kidney. Naip-I mRNA was quantified by transcript-specific 
RT-PCR (normalized to Gapdh) in total RNA extracted from whole kidney 
isolated from 3 E15 and 5 adult (4 mo) wild-type CD1 mice. Naip-1 mRNA 
level in E15 kidney was 7.4-fold greater than in adult kidney (P < 0.0001). 
coding exon oi Naipl (20). mIMCD-3 cells cotransfected with 
anti-sense Naipl showed a twofold (192 ± 35% SE) increase 
in fiaxa-induced caspase 3/7 activity (P < 0.05). 
DISCUSSION 
Studies of mice and humans with RCS clearly implicate 
PAX2 in the regulation of final nephron number (36, 42, 43). 
During normal branching morphogenesis, UB cells rarely un-
dergo programmed cell death but in mice with heterozygous 
PaxI mutations there is a dramatic increase in the fraction of 
UB cells undergoing apoptosis. This phenomenon was primar-
ily seen in the elongating trunks of the UB rather than at UB 
tips in the nephrogenic zone (36). Our previous studies show 
that there is a direct relationship between the susceptibility of 
UB cells to programmed cell death, the extent of UB branching 
during development, and congenital nephron number (36). 
The effects of PAX2 on programmed cell death have been 
confirmed in a variety of settings. In cancers where PAX2 is 
aberrantly overexpressed, PAX2 inactivation with siRNAs was 
shown to sensitize the cells to apoptosis induced by chemo-
therapeutic agents (29). PAX2 promotes survival of cultured 
HEK293 cells overexpressing caspase genes (46) or renal 
collecting duct cells exposed to high-salt concentrations (6). 
Increased PAX2 expression has also been observed in renal 
cystic epithelium (49). Heterozygosity for a null Pax2 mutation 
increased cyst cell apoptosis and reduced cyst size in the cpk 
mouse (33). 
Although it is now clear that PAX2 suppresses apoptosis 
during organogenesis, the mechanism by which it promotes 
cell survival is currently unknown. Here, we show that PAX2 
directly binds to specific recognition motifs in the human NAIP 
gene promoter and specifically activates its transcription. In 
our studies, addition of polyclonal PAX2 antibody eliminated 
the complex formed by PAX2b protein and an oligonucleotide 
containing the putative PAX2 recognition motif. Presumably, 
this antibody interferes with interactions between the binding 
domain of PAX2b protein and the recognition motif. Numer-
ous other reports show that specific antibodies do not always 
cause a supershift but can often eliminate complex formation 
(15, 37). The sevenfold activation of NAIP transcription by 
PAX2 demonstrated in vitro appears to be physiologically 
relevant as total Naip transcript levels were significantly re-
duced in heterozygous Pax2 mutant mice. 
The NAIP gene encodes a member of a family of endoge-
nous caspase inhibitors called IAPs. Eight human IAPs have 
been identified (24). These show a certain degree of tissue 
specificity and are frequently overexpressed in cancer cells 
(45). Specifically, NAIP inhibits caspases-3 and -7 (27) and has 
been shown to suppress apoptosis in neural tissues (16, 20. 25, 
34, 50). NAIP was initially discovered during positional clon-
ing of the causative gene for spinal muscular atrophy (SMA) 
(39). It was later confirmed that mutation of the survivor motor 
neuron (SMN) gene adjacent to NAIP is responsible for SMA 
(23). However, patients with deletions spanning both genes 
present with a significantly more severe form of SMA (1, 39). 
Although only one functional NAIP has been identified thus 
tar in humans (39, 51), six highly homologous but separate 
Naip genes have been identified in the mouse (16, 52). Thus 
knockout of the murine Naipl homolog did not cause a 
developmental abnormality of the brain, although neurons 
exhibited increased susceptibility to kainic acid-induced injury 
compared with controls (18). Presumably, this reflects the 
functional redundancy of Naip genes in mice, making them 
suboptimal models for study of NAIP function in humans. The 
renal status of humans with SMA and homozygous NAIP 
deletions is unknown, but our observations predict that in-
creased susceptibility to apoptosis during kidney development 
should reduce congenital nephron number (36). It is of interest 
that the Naipl transcript is 7.4-fold higher in fetal than in adult 
kidney. This parallels the ontogeny of PAX2 expression during 
murine kidney development (10, 47). In mouse kidney, the 
effects of PAX2 may reflect its regulation of the Naip] gene. 
However, we cannot rule out similar transcriptional regulation 
of the other murine Naip homologs. 
Developmental pathways regulated by PAX2 in the kidney 
may also be important for brain development. Homozygous 
null Pax2 mutant mice are anephric, but also exhibit a massive 
defect in the fetal midbrain/hindbrain region (14). PAX2 has 
been shown to activate the glial cell-derived neurotrophic 
factor (Gdnf) gene in the kidney (5). In developing kidney, 
60000 
pCl+Bax NAIP-AS+Bax 
Fig. 7. Inhibition of Naip in renal collecting duct cells causes increased 
apoptosis. Mouse mIMCD-3 cells derived from renal collecting duct cells were 
transiently transfected with a Bax expression vector (to stimulate apoptosis) in 
the presence or absence of a Naip antisense cDNA expression vector. After 
48 h, Bax-stimulated caspase-3/7 activity was significantly higher in the cells 
cotransfected with the Naip antisense vector than with an empty vector control 
(P < 0.05). 
AJP-Renal Physiol • VOL 291 • OCTOBER 2006 • www.ajprenal.org 
NAIP IS EXPRESSED IN KIDNEY AND IS REGULATED BY PAX2 F9I9 
GDNF is essential for outgrowth and arborization of the UB 
(28, 35, 41) and promotes survival of UB cells (48). GDNF is 
also expressed in the brain where it is an important trophic 
signal for neural differentiation and neuronal ceil survival (44). 
However, it is unknown whether PAX2 directly activates Gdnf 
in brain as it does in kidney. PAX2 activates fibroblast growth 
factor 8 (Fgf8) at the midbrain-hindbrain boundary, a central 
organizer during neuronal development which is also ex-
pressed in the developing kidney (17, 53). 
Similar to the neuroprotective role of NAIP in brain tissues, 
we show that NAIP also has an anti-apoptotic function in 
kidney cells. Inner medullary collecting ducts cells were more 
sensitive to Bora-induced apoptosis, as measured by caspase 
3/7 activity, when cotransfected with a Naip antisense cDNA. 
Previous in situ hybridization experiments show that Naip 
expression coiocalizes with Pax2 in the midbrain/hindbrain 
region, the otic vesicle, and the retina during fetal mouse 
development (21, 31, 38). Similarly, NAIP is expressed in the 
collecting ducts and emerging proximal tubules, paralleling the 
known expression pattern of Pax2 (4, 47). 
Final nephron number ranges widely in humans (0.3 and 1.3 
million nephrons/kidney) (19, 32). Recent evidence suggests 
that subtle renal hypoplasia may have far-reaching clinical 
implications. Humans born into the lower percentiles of the 
nephron number spectrum have reduced renal reserve and 
appear to be at risk for essential hypertension later in life (22). 
Our previous work suggests that PAX2 is centrally involved in 
regulating final nephron number by suppressing programmed 
cell death in the UB lineage. Here, we show that the powerful 
anti-apoptotic effects of PAX2 may be mediated by activation 
of the endogenous caspase inhibitor, NAIP. We hypothesize 
that NAIP activation by PAX2 transiently confers resistance of 
UB cells to programmed cell death during branching morpho-
genesis in fetal kidney, thereby optimizing final nephron num-
ber. Conceivably, NAIP could also play a role in the phenotype 
of cancer cells and cystic epithelium where PAX2 is inappro-
priately overexpressed. 
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